## Diagnosis of Alzheimer's Disease

Archives of Neurology 42, 1097-1105 DOI: 10.1001/archneur.1985.04060100083029

**Citation Report** 

#	Article	IF	CITATIONS
1	Pathological Diagnosis in Clinically Typical Alzheimer's Disease. New England Journal of Medicine, 1985, 313, 1419-1420.	27.0	22
2	Optic-Nerve Degeneration in Alzheimer's Disease. New England Journal of Medicine, 1986, 315, 485-487.	27.0	643
3	Verbal and nonverbal shortâ€ŧerm memory in patients with Alzheimer's disease and in healthy elderly subjects. Developmental Neuropsychology, 1986, 2, 387-400.	1.4	46
4	Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience, 1986, 19, 1-28.	2.3	697
5	No evidence for aluminum in etiology and pathogenesis of alzheimer's disease. Neurobiology of Aging, 1986, 7, 532-535.	3.1	34
6	Ambiguities in Alzheimer's disease diagnosis: Implications for genetic research. Neurobiology of Aging, 1986, 7, 469-471.	3.1	3
7	Problems and limitations in studying a genetic component of Alzheimer's disease. Neurobiology of Aging, 1986, 7, 477-478.	3.1	0
8	Alzheimer's disease. Postgraduate Medicine, 1986, 80, 99-104.	2.0	2
9	Distribution of altered hippocampal neurons and axons immunoreactive with antisera against neuropeptide Y in Alzheimer's-type dementia. Journal of Comparative Neurology, 1986, 248, 376-394.	1.6	100
10	Genuine memory deficits in ageâ€associated memory impairment. Developmental Neuropsychology, 1986, 2, 287-307.	1.4	33
12	Family Oriented Interventions in Alzheimer's Care. American Journal of Alzheimer S Care and Related Disorders, 1986, 1, 16-21.	0.0	0
13	Comparison of Magnetic Resonance and Roentgen Ray Computed Tomography in Dementia. Archives of Neurology, 1987, 44, 1075-1080.	4.5	72
14	Vacuolar Change in Alzheimer's Disease. Archives of Neurology, 1987, 44, 1225-1228.	4.5	50
15	Perspectives on the Etiology of Alzheimer's Disease. JAMA - Journal of the American Medical Association, 1987, 257, 1503.	7.4	19
16	Cytoskeletal Pathology in Neurodegenerative Diseases. Advances in Experimental Medicine and Biology, 1987, 221, 427-442.	1.6	5
17	Thalamic and Subcortical Gliosis With Dementia. Archives of Neurology, 1987, 44, 510-513.	4.5	35
18	Absence of duplication of chromosome 21 genes in familial and sporadic Alzheimer's disease. Science, 1987, 238, 664-666.	12.6	145
19	Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. Science, 1987, 238, 669-671.	12.6	168

	CITATION R	CITATION REPORT	
#	ARTICLE	IF	CITATIONS
20	Family study of platelet membrane fluidity in Alzheimer's disease. Science, 1987, 238, 539-542.	12.6	115
21	Cholinesterases in Cerebrospinal Fluid. Archives of Neurology, 1987, 44, 403.	4.5	44
22	Focal cerebral hypoperfusion and selective cognitive deficit in dementia of the Alzheimer type Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 1602-1612.	1.9	43
23	ls case-ascertainment of Alzheimer's disease in field surveys practicable?. Psychological Medicine, 1987, 17, 549-555.	4.5	32
24	Cerebral amyloid angiopathy. A critical review Stroke, 1987, 18, 311-324.	2.0	1,034
25	Acute confusional states in the elderly: A radiological evaluation. Acta Psychiatrica Scandinavica, 1987, 76, 726-731.	4.5	16
26	Age at Onset and Rate of Progression of Alzheimer's Disease. Journal of the American Geriatrics Society, 1987, 35, 27-30.	2.6	112
27	Monoclonal antibody identification of subpopulations of cerebral cortical neurons affected in Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 8657-8661.	7.1	18
28	Ferritin: isolation of aluminum-ferritin complex from brain Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 7866-7870.	7.1	155
29	Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 3033-3036.	7.1	586
31	Repeated delirium from homatropine eye-drops. Clinical Neurology and Neurosurgery, 1987, 89, 53-54.	1.4	9
32	Antibodies to the neuronal cytoskeleton are elicited by Alzheimer paired helical filament fractions. Brain Research, 1987, 420, 233-242.	2.2	28
33	Dementia. American Journal of Medicine, 1987, 83, 101-110.	1.5	8
34	Glutamate dysfunction in Alzheimer's disease: an hypothesis. Trends in Neurosciences, 1987, 10, 65-68.	8.6	313
35	Quantitative autoradiography of hippocampal GABAB and GABAA receptor changes in Alzheimer's disease. Neuroscience Letters, 1987, 82, 246-252.	2.1	63
36	Methodological considerations when assessing age related changes. Neurobiology of Aging, 1987, 8, 571-573.	3.1	2
37	β-Amyloid gene is not present in three copies in autopsy-validated Alzheimer's disease. Genomics, 1987, 1, 307-312.	2.9	20
38	The Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21. Science, 1987, 235, 885-890.	12.6	1,161

	C	CITATION REPORT	
#	Article	IF	CITATIONS
39	Loss of hippocampal [3H]TCP binding in Alzheimer's disease. Neuroscience Letters, 1987, 74, 371-3	76. 2.1	94
41	Immunocytochemical properties of Alzheimer straight filaments. Journal of Neuroscience, 1987, 7, 3736-3738.	3.6	68
42	A special type of senile plaque, possibly an initial stage. Acta Neuropathologica, 1987, 74, 133-141.	7.7	124
43	Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/silver intensification on vibratome sections: Coexistence with neuropeptide Y neurons, and effects alzheimer-type dementia. Journal of Comparative Neurology, 1987, 260, 201-223.	1.6	255
44	Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease. Annals of Neurology, 1987, 22, 223-228.	5.3	119
45	Anatomy of cholinesterase inhibition in Alzheimer's disease: Effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Annals of Neurology, 1987, 22, 683-691.	5.3	165
46	Dementia of the Alzheimer's Type: Changes in Hippocampal L-[3H]Glutamate Binding. Journal of Neurochemistry, 1987, 48, 543-551.	3.9	274
47	Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Annals of Neurology, 1988, 23, 138-144.	5.3	1,087
48	Intraneuronal and extracellular neurofibrillary tangles exhibit mutually exclusive cytoskeletal antigens. Annals of Neurology, 1988, 23, 184-189.	5.3	66
49	Influence of neuronal location on antigenic properties of neurofibrillary tangles. Annals of Neurology, 1988, 23, 604-610.	5.3	45
50	Validation of clinical diagnostic criteria for Alzheimer's disease. Annals of Neurology, 1988, 24, 17-22	2. 5.3	366
51	Clinically diagnosed Alzheimer's disease: Autopsy results in 150 cases. Annals of Neurology, 1988, 2 50-56.	4, 5.3	355
52	The neuropathology of aminergic nuclei in Alzheimer's disease. Annals of Neurology, 1988, 24, 233-2	242. 5.3	401
53	Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer's disease. Annals of Neurology, 1988, 24, 384-389.	5.3	155
54	Alz 50 recognizes abnormal filaments in Alzheimer's disease and progressive supranuclear palsy. Annals of Neurology, 1988, 24, 407-413.	5.3	76
55	Acetylcholinesterase-rich pyramidal neurons in the human neocortex and hippocampus: Absence at birth, development during the life span, and dissolution in Alzheimer's disease. Annals of Neurology, 1988, 24, 765-773.	5.3	90
56	Cognition activators. Medicinal Research Reviews, 1988, 8, 353-391.	10.5	5 100
57	Cognitive functions affected by scopolamine in alzheimer's disease and normal aging. Drug Development Research, 1988, 12, 271-278.	2.9	26

#	Article	IF	CITATIONS
58	CSF monoamine metabolites in dementia of the Alzheimer type and controls: Evidence for lower levels of homovanillic acid and 5-hydroxyindoleacetic acid in patients. International Journal of Geriatric Psychiatry, 1988, 3, 281-288.	2.7	2
59	Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyltransferase. Journal of Comparative Neurology, 1988, 275, 216-240.	1.6	478
60	Cholinergic deficit in Alzheimer's disease: A study based on CSF and autopsy data. Neurochemical Research, 1988, 13, 135-146.	3.3	98
61	Laminar distribution of neuritic plaques in normal aging, Alzheimer's disease and Down's syndrome. Acta Neuropathologica, 1988, 77, 21-25.	7.7	30
62	Diagnosis of autism and other pervasive developmental disorders. Neuroscience and Biobehavioral Reviews, 1988, 12, 275-282.	6.1	4
63	Galanin-Like Immunoreactivity Is Unchanged in Alzheimer's Disease and Parkinson's Disease Dementia Cerebral Cortex. Journal of Neurochemistry, 1988, 51, 1935-1941.	3.9	45
64	Neuritic Plaque Amyloid in Alzheimer's Disease Is Highly Racemized. Journal of Neurochemistry, 1988, 50, 69-74.	3.9	175
65	Selective silver impregnation of senile plaques: a method useful for computer imaging. Journal of Neuroscience Methods, 1988, 25, 151-158.	2.5	16
66	Decreased densities of dopamine D1 receptors in the putamen and hippocampus in senile dementia of the Alzheimer type. Brain Research, 1988, 475, 164-167.	2.2	41
67	Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer's disease: an autoradiographic study. Brain Research, 1988, 450, 190-201.	2.2	48
68	Are colloid inclusion bodies diagnostic of Parkinson's disease?. Human Pathology, 1988, 19, 1117-1118.	2.0	0
69	Immunohistochemical study of cerebral amyloid angiopathy: Use of an antiserum to a synthetic 28-amino-acid peptide fragment of the Alzheimer's disease amyloid precursor. Human Pathology, 1988, 19, 214-222.	2.0	41
70	A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. Journal of the Neurological Sciences, 1988, 84, 101-116.	0.6	141
71	Epitopes that span the tau molecule are shared with paired helical filaments. Neuron, 1988, 1, 817-825.	8.1	498
72	Innervation of human hippocampus by noradrenergic systems: Normal anatomy and structural abnormalities in aging and in Alzheimer's disease. Neuroscience, 1988, 25, 401-417.	2.3	50
73	Age-related changes in regional cerebral blood flow and behavior in Sprague-Dawley rats. Neurobiology of Aging, 1988, 9, 691-696.	3.1	36
74	Glutamate transmission and toxicity in alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1988, 12, 421-IN4.	4.8	155
75	Cognitive and brain imaging measures of Alzheimer's disease. Neurobiology of Aging, 1988, 9, 69-86.	3.1	47

#	Article	IF	CITATIONS
76	Accuracy of the clinical diagnosis of vascular dementia: a prospective clinical and post-mortem neuropathological study Journal of Neurology, Neurosurgery and Psychiatry, 1988, 51, 1037-1044.	1.9	207
77	Isolation and chemical characterization of Alzheimer's disease paired helical filament cytoskeletons: differentiation from amyloid plaque core protein Journal of Cell Biology, 1988, 107, 2703-2716.	5.2	46
78	Single Photon Emission Computed Tomography in Alzheimer's Disease. Archives of Neurology, 1988, 45, 392.	4.5	82
79	Alzheimer's Disease. Archives of Neurology, 1988, 45, 994.	4.5	45
80	Correlation of Phosphorus-31 Magnetic Resonance Spectroscopy and Morphologic Findings in Alzheimer's Disease. Archives of Neurology, 1988, 45, 1093-1096.	4.5	143
81	Early Alzheimer's Disease. Archives of Neurology, 1988, 45, 345.	4.5	56
82	Familial Alzheimer's Disease With Myoclonus and 'Spongy Change'. Archives of Neurology, 1988, 45, 1097-1100.	4.5	16
83	Absence of linkage of chromosome 21q21 markers to familial Alzheimer's disease. Science, 1988, 241, 1507-1510.	12.6	241
84	Amyloid Protein Precursor Messenger RNAs: Differential Expression in Alzheimer's Disease. Science, 1988, 241, 1080-1084.	12.6	257
85	Major Depression in Primary Dementia. Archives of Neurology, 1988, 45, 1182.	4.5	238
86	REMOTE MEMORY FUNCTION IN ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE. Brain, 1988, 111, 185-206.	7.6	209
87	Bilateral Symmetry of Cholinergic Deficits in Alzheimer's Disease. Archives of Neurology, 1988, 45, 255-259.	4.5	31
88	Bilateral Symmetry of Morphologic Lesions in Alzheimer's Disease. Archives of Neurology, 1988, 45, 251-254.	4.5	84
89	Cerebral Degenerations Producing Dementia: Importance of Neuropathologic Confirmation of Clinical Diagnoses. Topics in Geriatrics, 1988, 1, 187-198.	0.8	5
91	TEMPORAL ORDERING AND SHORT-TERM MEMORY DEFICITS IN PARKINSON'S DISEASE. Brain, 1988, 111, 525-539.	7.6	188
93	Alzheimer disease tangles share immunological similarities with multiphosphorylation repeats in the two large neurofilament proteins Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 7384-7388.	7.1	125
94	What Is a Complete Work-up for Dementia?. Clinics in Geriatric Medicine, 1988, 4, 163-180.	2.6	1
95	Ascertainment of Informative Alzheimer Disease Families from the IMAGE Project Registry for Genetic Linkage Analysis Studies, Canadian Journal of Neurological Sciences, 1989, 16, 468-472.	0.5	1

#	Article	IF	CITATIONS
96	Dementia and Parkinson's Disease. British Journal of Psychiatry, 1989, 154, 596-614.	2.8	81
97	Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 8284-8288.	7.1	135
98	Geographical Knowledge in Patients With Alzheimer's Disease. Topics in Geriatrics, 1989, 2, 76-82.	0.8	13
99	Autopsy Services for Dementia Patients. Gerontologist, The, 1989, 29, 120-123.	3.9	6
100	Endoplasmic Reticulum Abnormality in Alzheimer's Disease: Selective Alteration in Platelet NADH-Cytochrome C Reductase Activity. Topics in Geriatrics, 1989, 2, 3-10.	0.8	28
101	A Brain Regional Analysis of Morphologic and Cholinergic Abnormalities in Alzheimer's Disease. Archives of Neurology, 1989, 46, 634-638.	4.5	60
102	Aging and Alzheimer's Disease. Archives of Neurology, 1989, 46, 138.	4.5	47
103	Ouabain Binding in the Human Brain. Archives of Neurology, 1989, 46, 951.	4.5	33
104	Lateralization of Brain Morphologic and Cholinergic Abnormalities in Alzheimer's Disease. Archives of Neurology, 1989, 46, 639-642.	4.5	36
105	Neuronal RNA in Pick's and Alzheimer's Diseases. Archives of Neurology, 1989, 46, 134.	4.5	11
106	Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 1236-1247.	1.9	169
107	Different cognitive profiles on standard behavioral tests in Parkinson's disease and Alzheimer's disease. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1989, 11, 799-820.	1.1	62
108	Modification of an Impregnation Technique for Use With Glycol Methacrylate. Laboratory Medicine, 1989, 20, 113-115.	1.2	3
109	MINIREVIEW: Amyloid Protein in Alzheimer's Disease. Journal of Gerontology, 1989, 44, B77-B82.	1.9	15
110	Brain quinolinic acid in Alzheimer's dementia. European Archives of Psychiatry and Neurological Sciences, 1989, 239, 177-179.	0.9	15
111	Senile dementia of the Alzheimer type (SDAT): Cholinergic and monoaminergic neuromediator profils in postmortem cortex cerebri. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1989, 1, 105-106.	1.2	4
112	The long ascending monoaminergic neuromediator systems in senile dementia of the Alzheimer type (SDAT): Neuropathological and neurochemical findings. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1989, 1, 107-108.	1.2	0
113	Mamillary bodies in Alzheimer's disease. Acta Neurologica Scandinavica, 1989, 80, 41-45.	2.1	26

#	Article	IF	CITATIONS
114	SECOND DOROTHY S. RUSSELL MEMORIAL LECTURE THE NEUROPATHOLOGY OF ALZHEIMER'S DISEASE–ISSUES IN NEED OF RESOLUTION*. Neuropathology and Applied Neurobiology, 1989, 15, 491-512.	3.2	24
115	COMPARISON OF SEVEN STAINING METHODS FOR SENILE PLAQUES AND NEUROFIBRILLARY TANGLES IN A PROSPECTIVE SERIES OF 15 ELDERLY PATIENTS. Neuropathology and Applied Neurobiology, 1989, 15, 563-578.	3.2	75
116	Phenotypic heterogeneity in familial alzheimer's disease: A study of 24 kindreds. Annals of Neurology, 1989, 25, 12-25.	5.3	154
117	Quantitation of cerebral atrophy in preclinical and end-stage alzheimer's disease. Annals of Neurology, 1989, 25, 450-459.	5.3	227
118	Assessment of genetic risk for alzheimer's disease among firstâ€degree relatives. Annals of Neurology, 1989, 25, 485-493.	5.3	145
119	Aberrant guanosine triphosphate-beta-tubulin interaction in Alzheimer's disease. Annals of Neurology, 1989, 26, 210-215.	5.3	22
120	Abnormal pattern electroretinograms in patients with senile dementia of the alzheimer type. Annals of Neurology, 1989, 26, 226-231.	5.3	140
121	Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease. Annals of Neurology, 1989, 26, 309-320.	5.3	94
122	Tau in situ hybridization in normal and alzheimer brain: Localization in the somatodendritic compartment. Annals of Neurology, 1989, 26, 352-361.	5.3	84
123	Protease nexin I immunostaining in alzheimer's disease. Annals of Neurology, 1989, 26, 628-634.	5.3	51
124	Microtubular reorganization and dendritic growth response in alzheimer's disease. Annals of Neurology, 1989, 26, 652-659.	5.3	163
125	The widespread alteration of neurites in Alzheimer's disease may be unrelated to amyloid deposition. Annals of Neurology, 1989, 26, 771-778.	5.3	89
126	Nicotinic binding sites in cerebral cortex and hippocampus in alzheimer's dementia. Neurochemical Research, 1989, 14, 745-750.	3.3	94
127	Alzheimer's disease: areal and laminar pathology in the occipital isocortex. Acta Neuropathologica, 1989, 77, 494-506.	7.7	138
128	Senile plaque neurites fail to demonstrate anti-paired helical filament and anti-microtubule-associated protein-tau immunoreactive proteins in the absence of neurofibrillary tangles in the neocortex. Acta Neuropathologica, 1989, 77, 430-436.	7.7	65
129	Comparison of four staining methods on the detection of neuritic plaques. Acta Neuropathologica, 1989, 78, 22-27.	7.7	120
130	Immunodetection of the amyloid P component in Alzheimer's disease. Acta Neuropathologica, 1989, 78, 429-437.	7.7	108
131	A neuropathological subset of Alzheimer's disease with concomitant Lewy body disease and spongiform change. Acta Neuropathologica, 1989, 78, 194-201.	7.7	118

#	Article	IF	CITATIONS
132	Stroke related to cerebral amyloid angiopathy: the significance of systemic vascular disease. Journal of Neurology, 1989, 236, 267-272.	3.6	52
133	Reduced Glucose Transporter at the Bloodâ€Brain Barrier and in Cerebral Cortex in Alzheimer Disease. Journal of Neurochemistry, 1989, 53, 1083-1088.	3.9	315
134	Immunochemical Properties of Ubiquitin Conjugates in the Paired Helical Filaments of Alzheimer Disease. Journal of Neurochemistry, 1989, 52, 1523-1528.	3.9	73
135	Pathological changes in olfactory neurons in patients with Alzheimer's disease. Nature, 1989, 337, 736-739.	27.8	307
136	Prevalence of thyroid abnormalities is not increased in Alzheimer's disease. Neurobiology of Aging, 1989, 10, 247-251.	3.1	20
137	Tau-reactive neurofibrillary tangles in cerebellar cortex from patients with Alzheimer's disease. Neuroscience Letters, 1989, 103, 259-262.	2.1	9
138	Psychiatrists and Alzheimer's disease. Biomedicine and Pharmacotherapy, 1989, 43, 501-504.	5.6	0
139	Cortical cholinergic fibers in aging and Alzheimer's disease: A morphometric study. Neuroscience, 1989, 33, 469-481.	2.3	192
140	Choline acetyltransferase-like immunoreactivity in the hippocampal formation of control subjects and patients with Alzheimer's disease. Neuroscience, 1989, 32, 701-714.	2.3	71
141	Alzheimer's disease: amyloid plaques in the cerebellum. Journal of the Neurological Sciences, 1989, 93, 277-287.	0.6	148
142	Tissue banking and EURAGE. Journal of the Neurological Sciences, 1989, 93, 341-343.	0.6	9
143	The neurobiology of Alzheimer's disease. Journal of Neurosurgery, 1989, 70, 335-353.	1.6	53
144	The presubicular region in Alzheimer's disease: topography of amyloid deposits and neurofibrillary changes. Brain Research, 1989, 494, 198-203.	2.2	63
145	Immunoaffinity demonstration that paired helical filaments of Alzheimer disease share epitopes with neurofilaments, MAP2 and tau. Brain Research, 1989, 484, 150-156.	2.2	30
146	Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Research, 1989, 498, 185-189.	2.2	132
147	Corticotropin-releasing factor immunoreactive neurons persist throughout the brain in Alzheimer's disease. Brain Research, 1989, 501, 392-396.	2.2	25
148	Cholinergic and noradrenergic toxicity of intraventricular aluminum chloride in the rat hippocampus. Brain Research, 1989, 498, 381-384.	2.2	20
149	NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer's disease. Experimental Neurology, 1989, 106, 222-236.	4.1	151

ARTICLE IF CITATIONS The amyloid precursor protein is concentrated in neuronal lysosomes in normal and Alzheimer 150 4.1 140 disease subjects. Experimental Neurology, 1989, 106, 237-250. Excitatory amino acids and Alzheimer's disease. Neurobiology of Aging, 1989, 10, 593-602. 3.1 489 152 Microscopic image analysis in a diagnostic system for Alzheimer's disease., 0, , . 3 Distinguishing Alzheimer's Disease from Other Dementias. Journal of the American Geriatrics Society, 1989, 37, 521-527. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.. 154 7.1 1,695 Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 7611-7615. Elevated levels of an exocrine pancreatic secretory protein in Alzheimer disease brain.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 419-423. 7.1 NONVERBAL RECOGNITION AND RECENCY DISCRIMINATION DEFICITS IN PARKINSON'S DISEASE AND 156 7.6 71 ALZHEIMER'S DISEASE. Brain, 1989, 112, 1503-1517. Lipocortin-1 Immunoreactivity in the Normal Human Central Nervous System and Lesions with 63 Astrocytosis. American Journal of Clinical Pathology, 1989, 92, 424-429. Modification of Brain Processing Techniques: Tissue Embedding in Glycol Methacrylate and Stain 158 0.5 2 Modifications. Journal of Histotechnology, 1989, 12, 201-207. 159 Surgical experience with cerebral amyloid angiopathy.. Stroke, 1990, 21, 1545-1549. Polyadenylated Messenger RNA in Paired Helical Filament-Immunoreactive Neurons in Alzheimer 160 4 1.3 Disease. Alzheimer Disease and Associated Disorders, 1990, 4, 69-78. Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2452-2455. Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from 162 non-Alzheimer senile plaques.. Proceedings of the National Academy of Sciences of the United States 7.1 153 of America, 1990, 87, 2249-2253. Brief Screening Tests versus Clinical Staging in Senile Dementia of the Alzheimer Type. Journal of the American Geriatrics Society, 1990, 38, 129-135. 2.6 Neural Transplantation in Animal Models of Dementia. European Journal of Neuroscience, 1990, 2, 164 120 2.6 567-587. Autopsy Samples of Alzheimer's Cortex Show Increased Peroxidation In Vitro. Journal of 3.9 431 Neurochemistry, 1990, 55, 342-345. Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. 166 27.8 407 Nature, 1990, 347, 194-197. Cognitive screening tests. Journal of General Internal Medicine, 1990, 5, 438-445. 24

#	Article	IF	CITATIONS
168	Cognitive impairment in Parkinson's disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1990, 2, 45-57.	1.2	97
169	Brain iron and ferritin in Parkinson's and Alzheimer's diseases. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1990, 2, 327-340.	1.2	392
170	5HT2 receptors in dementia of the Alzheimer type: A quantitative autoradiographic study of frontal cortex and hippocampus. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1990, 2, 129-137.	1.2	24
171	Ultrastructural evidence that insoluble microtubules are components of the neurofibrillary tangle. European Archives of Psychiatry and Neurological Sciences, 1990, 239, 314-319.	0.9	12
172	The cytoarchitectonic distribution of senile plaques in three aged monkeys. Acta Neuropathologica, 1990, 81, 60-65.	7.7	50
173	Altered angioarchitecture in selected areas of brains with Alzheimer's disease. Acta Neuropathologica, 1990, 79, 672-679.	7.7	166
174	Neurofibrillary changes confined to the entorhinal region and an abundance of cortical amyloid in cases of presenile and senile dementia. Acta Neuropathologica, 1990, 80, 479-486.	7.7	118
175	The human pineal gland in aging and Alzheimer's disease: patterns of cytoskeletal antigen immunoreactivity. Acta Neuropathologica, 1990, 80, 535-540.	7.7	19
176	Distinctive, rapid, and easy labeling of diffuse plaques in the Alzheimer brains by a new methenamine silver stain. Acta Neuropathologica, 1990, 79, 569-572.	7.7	93
177	Senile dementia of Alzheimer type characterized by laminar neuronal loss exclusively in the hippocampus, parahippocampus and medial occipitotemporal cortex. Acta Neuropathologica, 1990, 80, 575-580.	7.7	34
178	Alzheimer neuropathology in non-Down's syndrome mentally retarded adults. Acta Neuropathologica, 1990, 80, 362-367.	7.7	49
179	Ultrastructure of the neuropil threads in the Alzheimer brain: their dendritic origin and accumulation in the senile plaques. Acta Neuropathologica, 1990, 80, 368-374.	7.7	72
180	Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Annals of Neurology, 1990, 27, 457-464.	5.3	2,048
181	?1-Antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Annals of Neurology, 1990, 28, 561-567.	5.3	149
182	Mild senile dementia of the Alzheimer type: 3. Longitudinal and crossâ€sectional assessment. Annals of Neurology, 1990, 28, 648-652.	5.3	49
183	Neuropathological substrate of dementia in Parkinson's disease. Annals of Neurology, 1990, 28, 723-724.	5.3	4
184	Selective reduction of quisqualate (AMPA) receptors in Alzheimer cerebellum. Annals of Neurology, 1990, 28, 805-810.	5.3	33
185	Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal cortex. Journal of Comparative Neurology, 1990, 301, 44-54.	1.6	357

#	Article	IF	CITATIONS
186	Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: II. Primary and secondary visual cortex. Journal of Comparative Neurology, 1990, 301, 55-64.	1.6	293
187	A sandwich enzyme immunoassay for detecting and measuring alzheimer's disease-associated proteins in human brain tissue. Journal of Clinical Laboratory Analysis, 1990, 4, 189-192.	2.1	18
188	Neurotransmitter changes in alzheimer's disease: Implications to diagnostics and therapy. Journal of Neuroscience Research, 1990, 27, 576-586.	2.9	217
189	Production and characterization of a monospecific antiserum (A128) to disaggregated Alzheimer paired helical filaments Journal of Histochemistry and Cytochemistry, 1990, 38, 703-715.	2.5	7
190	Excitatory amino acid binding sites in the hippocampal region of Alzheimer's disease and other dementias Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 314-320.	1.9	92
191	Neurochemical Correlates of Major Depression in Primary Dementia. Archives of Neurology, 1990, 47, 209-214.	4.5	221
192	Advanced Alzheimer's Disease Is a Risk Factor for Late-Onset Seizures. Archives of Neurology, 1990, 47, 847-850.	4.5	219
193	Aged dogs: an animal model to study beta-protein amyloidogenesis. Key Topics in Brain Research, 1990, , 151-168.	0.2	32
194	Biochemical Assay of Alzheimer's Disease—Associated Protein(s) in Human Brain Tissue. JAMA - Journal of the American Medical Association, 1990, 263, 2907.	7.4	34
195	Stroop Color-Word Test performance in patients with Alzheimer's disease. Neuropsychology, Development and Cognition Section A: Journal of Clinical and Experimental Neuropsychology, 1990, 12, 745-758.	1.1	90
196	lofetamine I 123 Single Photon Emission Computed Tomography Is Accurate in the Diagnosis of Alzheimer's Disease. Archives of Internal Medicine, 1990, 150, 752.	3.8	51
197	Intracerebroventricular Bethanechol for Alzheimer's Disease. Archives of Neurology, 1990, 47, 1025.	4.5	23
198	The Diagnosis of Dementia: Demographic Characteristics. Gerontologist, The, 1990, 30, 339-344.	3.9	9
199	Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 1352-1356.	7.1	71
201	Establishing diagnostic criteria for a registry for dementing diseases. Aging Clinical and Experimental Research, 1990, 2, 207-215.	2.9	0
202	New data gathering, instrument selection, and evaluation of existing information for determining entry. Aging Clinical and Experimental Research, 1990, 2, 215-222.	2.9	0
203	Clinical diagnosis of Binswanger's disease Journal of Neurology, Neurosurgery and Psychiatry, 1990, 53, 961-965.	1.9	189
204	"Age-associated memory impairment†A critique. European Journal of Cognitive Psychology, 1990, 2, 275-287.	1.3	7

#	Article	IF	CITATIONS
205	Computer analysis of EEG activity in dementia of the Alzheimer's type and Huntington's disease. Neurobiology of Aging, 1990, 11, 15-20.	3.1	55
206	Early public use of aspirin in the face of probable ischaemic chest pain. Lancet, The, 1990, 335, 163-163.	13.7	1
207	Expression of Î <sup>2</sup> amyloid protein precursor mRNAs: Recognition of a novel alternatively spliced form and quantitation in alzheimer's disease using PCR. Neuron, 1990, 4, 253-267.	8.1	441
208	Differential expression of amyloid precursor protein mRNAs in cases of Alzheimer's disease and in aged nonhuman primates. Neuron, 1990, 4, 97-104.	8.1	118
209	Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging. Neuroscience Letters, 1990, 119, 182-186.	2.1	225
210	Neurofibrillary tangles, Alzheimer's disease, and Lewy bodies. Lancet, The, 1990, 335, 163-163.	13.7	11
211	Brain membrane fluidity and lipid peroxidation in Alzheimer's disease. Neuroscience Letters, 1990, 112, 333-337.	2.1	94
212	A quantitative analysis of CT and cognitive measures in normal aging and Alzheimer's disease. Psychiatry Research - Neuroimaging, 1990, 35, 115-136.	1.8	43
213	Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease. Neurobiology of Aging, 1990, 11, 3-13.	3.1	276
214	Early senile plaques in Alzheimer's disease demonstrated by histochemistry, immunocytochemistry, and electron microscopy. Human Pathology, 1990, 21, 1221-1226.	2.0	46
215	Cerebral amyloid angiopathy and granulomatous angiitis: Immunohistochemical study using antibodies to the Alzheimer A4 peptide. Human Pathology, 1990, 21, 1290-1293.	2.0	39
216	Neuropathological study of the amygdala in presenile Alzheimer's disease. Journal of the Neurological Sciences, 1990, 100, 165-173.	0.6	54
217	Vascular dementia. Journal of the Neurological Sciences, 1990, 96, 1-17.	0.6	135
218	Clinicopathological analysis of dementia disorders in the elderly. Journal of the Neurological Sciences, 1990, 95, 239-258.	0.6	222
219	Rating of the lesions in senile dementia of the Alzheimer type: concordance between laboratories A European multicenter study under the auspices of EURAGE. Journal of the Neurological Sciences, 1990, 97, 295-323.	0.6	98
220	Vasopressin, prolactin and growth hormone in Alzheimer's disease: their evaluation after metoclopramide stimulation. Archives of Gerontology and Geriatrics, 1990, 10, 269-278.	3.0	6
221	Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiology of Aging, 1990, 11, 601-607.	3.1	281
222	Neuritic plaques and vessels of visual cortex in aging and Alzheimer's dementia. Neurobiology of Aging, 1990, 11, 359-370.	3.1	80

#	Article	IF	CITATIONS
223	Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiology of Aging, 1990, 11, 29-37.	3.1	406
224	Neuronal hypertrophy in the human supraoptic and paraventricular nucleus in aging and Alzheimer's disease. Neuroscience Letters, 1990, 109, 62-67.	2.1	40
225	The Alzheimer amyloid precursor-related transcript lacking the β/A4 sequence is specifically increased in Alzheimer's disease brain. Neuron, 1990, 5, 329-338.	8.1	80
226	Astrocytosis in the molecular layer of the dentate gyrus: A study in Alzheimer's disease and schizophrenia. Psychiatry Research - Neuroimaging, 1990, 35, 149-166.	1.8	40
227	Clinical utility of long latency â€~cognitive' event-related potentials (P3): the cons. Electroencephalography and Clinical Neurophysiology, 1990, 76, 6-12.	0.3	121
228	Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients. Brain Research, 1990, 536, 240-244.	2.2	90
229	Selective alterations of high affinity [3H]forskolin binding sites in Alzheimer's disease: a quantitative autoradiographic study. Brain Research, 1990, 511, 241-248.	2.2	39
230	Human striatal cholinergic neurons in development, aging and Alzheimer's disease. Brain Research, 1990, 508, 310-312.	2.2	15
231	Immunoelectron microscopic localization of amyloid β protein in the diffuse plaques of Alzheimer-type dementia. Brain Research, 1990, 508, 320-324.	2.2	68
232	Epidermal growth factor receptor expression in demented and aged human brain. Brain Research, 1990, 512, 347-352.	2.2	36
233	Microangiopathy and the colocalization of heparan sulfate proteoglycan with amyloid in senile plaques of Alzheimer's disease. Brain Research, 1990, 508, 13-19.	2.2	127
234	Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains. Brain Research, 1990, 533, 125-131.	2.2	169
235	Basic fibroblast growth factor in Alzheimer's disease. Biochemical and Biophysical Research Communications, 1990, 171, 690-696.	2.1	173
236	Relative Frequencies of Dementia of the Alzheimer Type and Vascular Dementia in Japanese Nursing Homes. Psychiatry and Clinical Neurosciences, 1990, 44, 551-556.	1.8	4
237	Detection of amyloid beta protein precursor immunoreactivity in normal and Alzheimer's disease cerebrospinal fluid. Life Sciences, 1990, 47, 1163-1171.	4.3	12
238	Demonstration of a novel neurofilament associated antigen with the neurofibrillary pathology of Alzheimer and related diseases. Brain Research, 1991, 558, 43-52.	2.2	15
239	Cell loss and nuclear hypertrophy in topographical subdivisions of the nucleus basalis of Meynert in Alzheimer's disease. Neuroscience, 1991, 41, 33-40.	2.3	53
240	Development of an "early―detection battery for dementia of the Alzheimer type. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1991, 15, 433-479.	4.8	11

#	Article	IF	CITATIONS
241	Alzheimer's disease: specific increases in a G protein subunit (GSα) mRNA in hippocampal and cortical neurons. Molecular Brain Research, 1991, 10, 71-81.	2.3	57
242	Muscarinic cholinoceptive neurons in the frontal cortex in Alzheimer's disease. Brain Research Bulletin, 1991, 27, 631-636.	3.0	38
243	Substance P-like immunoreactive neurons are depleted in Alzheimer's disease cerebral cortex. Neuroscience, 1991, 41, 41-60.	2.3	64
244	Cerebral amyloid angiopathy in Chinese: Incidence and significance. Clinical Neurology and Neurosurgery, 1991, 93, 19-23.	1.4	10
245	Anomalous molecular form of acetylcholinesterase in cerebrospinal fluid in histologically diagnosed Alzheimer's disease. Lancet, The, 1991, 337, 447-450.	13.7	66
246	Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet, The, 1991, 337, 450-452.	13.7	226
247	Entorhinal neurofibrillary tangles in Alzheimer disease with Lewy bodies. Neuroscience Letters, 1991, 129, 269-272.	2.1	47
248	Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiology of Aging, 1991, 12, 259-262.	3.1	153
249	Object recognition deficit in Alzheimer's disease: Possible disconnection of the occipito-temporal component of the visual system. Neuroscience Letters, 1991, 122, 53-56.	2.1	95
250	Adrenergic receptors in aging and Alzheimer's disease: Decreased α2-receptors demonstrated by [3H]p-aminoclonidine binding in prefrontal cortex. Neurobiology of Aging, 1991, 12, 131-136.	3.1	56
251	Absence of aluminium in Alzheimer's disease brain tissue: Electron microprobe and ion microprobe studie. Neuroscience Letters, 1991, 123, 61-64.	2.1	76
252	Differential changes in cell size and number in topographic subdivisions of human basal nucleus in normal aging. Neuroscience, 1991, 43, 445-456.	2.3	95
253	Anomalous acetylcholinesterase in lumbar CSF in Alzheimer's disease. Lancet, The, 1991, 338, 1538.	13.7	9
254	Preservation of 5-hydroxytryptamine1A receptor-G protein interactions in the cerebral cortex of patients with Alzheimer's disease. Neuroscience Letters, 1991, 133, 15-19.	2.1	39
255	Predictors of Decline in Alzheimer's Disease. Cortex, 1991, 27, 9-17.	2.4	74
256	The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's Disease. Cerebral Cortex, 1991, 1, 103-116.	2.9	1,293
257	β-Amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochemical and Biophysical Research Communications, 1991, 174, 572-579.	2.1	114
258	Neocortical neuronal subpopulations labeled by a monoclonal antibody to calbindin exhibit differential vulnerability in Alzheimer's disease. Experimental Neurology, 1991, 111, 293-301.	4.1	184

#	Article	IF	CITATIONS
259	Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: an autoradiographic study of the hippocampus. Brain Research, 1991, 553, 58-64.	2.2	114
260	High-affinity choline uptake carrier in Alzheimer's disease: implications for the cholinergic hypothesis of dementia. Brain Research, 1991, 552, 170-174.	2.2	54
261	Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: reduced cell numbers and co-localization with cholinergic neurons. Brain Research, 1991, 539, 19-30.	2.2	49
262	Microglia are associated with the extracellular neurofibrillary tangles of alzheimer disease. Brain Research, 1991, 558, 312-314.	2.2	80
263	Tropomyosin distinguishes Lewy bodies of Parkinson disease from other neurofibrillary pathology. Brain Research, 1991, 541, 347-349.	2.2	24
264	Tangle-bearing neurons show more extensive dendritic trees than tangle-free neurons in area CA1 of the hippocampus in Alzheimer's disease. Brain Research, 1991, 548, 260-266.	2.2	26
265	Dystrophic neurites infiltrate extracellular neurofibrillary tangles in Alzheimer disease. Brain Research, 1991, 560, 303-305.	2.2	13
266	Preservation of [1251]galanin binding sites despite loss of cholinergic neurons to the hippocampus in Alzheimer's disease. Brain Research, 1991, 568, 303-306.	2.2	20
267	Selective reduction of [125I]apamin binding sites in Alzheimer hippocampus: a quantitative autoradiographic study. Brain Research, 1991, 567, 51-56.	2.2	29
268	Neurofibrillary tangle distribution in the cerebral cortex of parkinsonism-dementia cases from Guam: differences with Alzheimer's disease. Brain Research, 1991, 564, 306-313.	2.2	83
269	Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: Comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson's disease and non-demented elderly control patients. Journal of the Neurological Sciences, 1991, 106, 142-152.	0.6	95
270	Cortex, white matter, and basal ganglia in schizophrenia: A volumetric postmortem study. Biological Psychiatry, 1991, 29, 556-566.	1.3	147
271	Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biological Psychiatry, 1991, 29, 224-232.	1.3	164
272	Retrospective Postmortem Dementia Assessment. Archives of Neurology, 1991, 48, 613.	4.5	69
273	Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer's disease. Journal of Neuroscience, 1991, 11, 3679-3683.	3.6	170
274	Autobiographical Memory in Normal Ageing and Dementia. Behavioural Neurology, 1991, 4, 235-248.	2.1	8
275	Cerebral Amyloid Angiopathy in Alzheimer's Disease: Clinicopathological Correlations. Dementia and Geriatric Cognitive Disorders, 1991, 2, 285-290.	1.5	1
277	Effects of piracetam on the dexamethasone suppression test in Alzheimer's and multi-infarct dementias. European Psychiatry, 1991, 6, 195-200.	0.2	0

#	Article	IF	Citations
278	Alterations in Alzheimer's Disease—Associated Protein in Alzheimer's Disease Frontal and Temporal Cortex. Archives of General Psychiatry, 1991, 48, 1009.	12.3	8
279	The Clinical Differential Diagnosis of Dementia: Concept and Methodology. Psychiatric Clinics of North America, 1991, 14, 237-249.	1.3	10
280	Pathology of Alzheimer's Disease. Psychiatric Clinics of North America, 1991, 14, 397-420.	1.3	46
281	Neuroimaging in Alzheimer's Disease. Psychiatric Clinics of North America, 1991, 14, 443-459.	1.3	7
282	A Family with Multiple Instances of Definite, Probable and Possible Early-Onset Alzheimer's Disease. British Journal of Psychiatry, 1991, 159, 524-530.	2.8	11
283	Neuropil threads of Alzheimer's disease show a marked alteration of the normal cytoskeleton. Journal of Neuroscience, 1991, 11, 1748-1755.	3.6	147
284	Clinical Diagnosis of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1991, 2, 186-194.	1.5	0
285	Case 27-1991. New England Journal of Medicine, 1991, 325, 42-54.	27.0	21
286	Biologic Effects of Nerve Growth Factor on Lesioned Basal Forebrain Neuronsa. Annals of the New York Academy of Sciences, 1991, 640, 102-109.	3.8	15
287	Alzheimer Lesions in the Entorhinal Region and Isocortex in Parkinson's and Alzheimer's Diseasesa. Annals of the New York Academy of Sciences, 1991, 640, 203-209.	3.8	73
288	Diagnosis of Alzheimer's disease. BMJ: British Medical Journal, 1991, 302, 47-48.	2.3	2
289	Diagnosis of Alzheimer's disease. BMJ: British Medical Journal, 1991, 302, 48-48.	2.3	1
290	Diagnosis of Alzheimer's disease: Authors' reply. BMJ: British Medical Journal, 1991, 302, 48-48.	2.3	7
291	Comparison of Postmortem Magnetic Resonance Imaging and Neuropathologic Findings in the Cerebral White Matter. Archives of Neurology, 1991, 48, 293-298.	4.5	156
292	Temporal and Hippocampal Metabolic Rate During an Olfactory Memory Task Assessed by Positron Emission Tomography in Patients With Dementia of the Alzheimer Type and Controls. Archives of General Psychiatry, 1991, 48, 840.	12.3	70
293	Diagnosis of Alzheimer's disease. BMJ: British Medical Journal, 1991, 302, 48-48.	2.3	2
294	Alterations of Phospholipid Metabolites in Postmortem Brain from Patients with Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1991, 640, 110-113.	3.8	43
295	Cellular Distribution and Expression of Cortical Acetylcholine Receptors in Aging and Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1991, 640, 189-192.	3.8	20

#	Article	IF	CITATIONS
296	Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 10540-10543.	7.1	1,212
297	Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7552-7556.	7.1	244
298	The predominant form of the amyloid beta-protein precursor in human brain is protease nexin 2 Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 10302-10306.	7.1	49
299	The Relationship between Cancer and Alzheimer's Disease. Journal of the American Geriatrics Society, 1991, 39, 840-840.	2.6	29
300	Rapid, Reliable and Economical Silver Stain for Neurofibrillary Tangles and Senile Plaques. Journal of Histotechnology, 1991, 14, 39-42.	0.5	33
301	Methyl Methacrylate Embedding of Large Nervous Tissue Blocks for Neurohistologic, Immunocytochemical, and Ultrastructural Studies. Journal of Histotechnology, 1991, 14, 89-95.	0.5	1
302	DOUBLE DISSOCIATION OF SHORT-TERM AND LONG-TERM MEMORY FOR NONVERBAL MATERIAL IN PARKINSON'S DISEASE AND GLOBAL AMNESIA. Brain, 1991, 114, 893-906.	7.6	50
303	Regional and neuronal reductions of polyadenylated messenger RNA in Alzheimer's disease. Psychological Medicine, 1991, 21, 855-866.	4.5	40
304	Are There Clinical and Epidemiological Differences between Familial and Nonâ€familial Alzheimer's Disease?. Journal of the American Geriatrics Society, 1991, 39, 477-483.	2.6	20
305	Structural plasticity of synapses in Alzheimer's disease. Molecular Neurobiology, 1991, 5, 411-419.	4.0	23
306	Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids, 1991, 26, 421-5.	1.7	604
307	Autoradiographic Imaging of [3H]Phorbol 12,13-Dibutyrate Binding to Protein Kinase C in Alzheimer's Disease. Journal of Neurochemistry, 1991, 56, 1121-1129.	3.9	32
308	Normal McCollough effect in Alzheimer's disease and global amnesia. Perception & Psychophysics, 1991, 49, 448-455.	2.3	15
309	Alz-50 immunoreactive neuropil differentiates hippocampal complex subfields in Alzheimer's disease. Journal of Comparative Neurology, 1991, 305, 489-507.	1.6	39
310	Epitopes located in spatially separate domains of each neurofilament subunit are present in parkinson's disease lewy bodies. Journal of Comparative Neurology, 1991, 309, 150-160.	1.6	105
311	The diagnosis of dementia?I clinical and pathological criteria: A review of the literature. International Journal of Geriatric Psychiatry, 1991, 6, 199-208.	2.7	22
312	Relationship between alcohol intake, age of onset and duration of Alzheimer's disease: A pilot survey of 84 autopsy-confirmed cases. International Journal of Geriatric Psychiatry, 1991, 6, 797-800.	2.7	1
313	Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease. Annals of Neurology, 1991, 29, 162-167.	5.3	78

#	Article	IF	CITATIONS
314	Intracerebral hemorrhage related to cerebral amyloid angiopathy and T-PA treatment. Annals of Neurology, 1991, 29, 210-213.	5.3	59
315	Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies. Annals of Neurology, 1991, 29, 256-262.	5.3	142
316	The hypothalamic lateral tuberal nucleus in Alzheimer's disease. Annals of Neurology, 1991, 29, 279-284.	5.3	32
317	Neuritic pathology and dementia in alzheimer's disease. Annals of Neurology, 1991, 30, 156-165.	5.3	368
318	Expression patterns of ?-amyloid precursor protein (?-APP) in neural and nonneural human tissues from alzheimer's disease and control subjects. Annals of Neurology, 1991, 30, 686-693.	5.3	152
319	Association between vascular basement membrane components and the lesions of Alzheimer's disease. Journal of Neuroscience Research, 1991, 30, 673-681.	2.9	98
320	Age-related accumulation of congophilic fibrillar inclusions in endocrine cells. Virchows Archiv A, Pathological Anatomy and Histopathology, 1991, 419, 51-58.	1.4	19
321	Alzheimer's and Parkinson's disease. Molecular and Chemical Neuropathology, 1991, 14, 213-226.	1.0	161
322	Immunoelectron microscopic study of synaptic pathology in Alzheimer's disease. Acta Neuropathologica, 1991, 81, 428-433.	7.7	162
323	Extracellular neurofibrillary tangles associated with degenerating neurites and neuropil threads in Alzheimer-type dementia. Acta Neuropathologica, 1991, 81, 603-609.	7.7	50
324	Increased senile plaques without microglia in Alzheimer's disease. Acta Neuropathologica, 1991, 81, 242-247.	7.7	72
325	Alzheimer's disease affects limbic nuclei of the thalamus. Acta Neuropathologica, 1991, 81, 261-268.	7.7	287
326	Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica, 1991, 82, 239-259.	7.7	13,376
327	Modified tau is present in younger nondemented persons: a study of subcortical nuclei in Alzheimer's disease and progressive supranuclear palsy. Acta Neuropathologica, 1991, 81, 517-523.	7.7	26
328	Ultrastructural localization of argyrophilic substances in diffuse plaques of Alzheimer-type dementia demonstrated by methenamine silver staining. Acta Neuropathologica, 1991, 81, 540-545.	7.7	16
329	Alzheimer's disease: paired helical filament immunoreactivity in cerebrospinal fluid. Acta Neuropathologica, 1991, 82, 6-12.	7.7	48
330	Ultrastructure of diffuse plaques in senile dementia of the Alzheimer type: comparison with primitive plaques. Acta Neuropathologica, 1991, 82, 13-20.	7.7	74
331	A case of progressive supranuclear palsy with widespread senile plaques. Journal of Neurology, 1991, 238, 345-348.	3.6	16

#	ARTICLE Anatomic, Metabolic, Neuropsychological, and Molecular Genetic Studies of Three Pairs of Identical	IF	CITATIONS
332 333	Twins Discordant for Dementia of the Alzheimer's Type. Archives of Neurology, 1991, 48, 160-168. Immunohistochemical Study of the Hippocampus in Parkinsonism-Dementia Complex on Guam. Topics in	4.5 0.8	38
334	Geriatrics, 1991, 4, 134-142. Diffuse Lewy body disease presenting with a supranuclear gaze palsy Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 159-161.	1.9	71
335	Tardive Dyskinesia in Alzheimer's Disease: Clinical Features and Neuropathologic Correlates. Topics in Geriatrics, 1991, 4, 79-85.	0.8	1
336	Aging changes in the central nervous system. Reviews in Clinical Gerontology, 1991, 1, 113-118.	0.5	0
337	Neuropathologically Confirmed Alzheimer's Disease: Clinical Diagnoses in 394 Cases. Topics in Geriatrics, 1991, 4, 26-29.	0.8	9
338	β-Amyloid and the Pathogenesis of Alzheimer's Disease. New England Journal of Medicine, 1991, 325, 1849-1857.	27.0	203
339	Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 8910-8914.	7.1	99
340	Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 972-975.	1.9	19
341	Basic fibroblast growth factor binding is a marker for extracellular neurofibrillary tangles in Alzheimer disease Journal of Histochemistry and Cytochemistry, 1991, 39, 899-904.	2.5	60
342	Neuropathologic and Neurochemical Correlates of Psychosis in Primary Dementia. Archives of Neurology, 1991, 48, 619-624.	4.5	343
343	Registration of Alzheimer patients in an autopsy program: Who does it and why?. American Journal of Alzheimer S Care and Related Disorders & Research, 1991, 6, 33-38.	0.1	0
344	Association of Decreased Paternal Age and Late-Onset Alzheimer's Disease. Archives of Neurology, 1991, 48, 599.	4.5	37
345	Optic Nerve Head and Nerve Fiber Layer in Alzheimer's Disease. JAMA Ophthalmology, 1991, 109, 199.	2.4	143
346	Remote Memory for Visuospatial Information in Patients with Alzheimer's Disease. Topics in Geriatrics, 1991, 4, 14-17.	0.8	22
347	Adult Dementia Due to Intraneuronal Accumulation of Ceroidlipofuscinosis (Kufs' Disease): Ultrastructural Study of Two Cases. Topics in Geriatrics, 1991, 4, 110-115.	0.8	8
348	Alterations in Brain Monoamine Oxidase Activity in Aging, Alzheimer's Disease, and Pick's Disease. Archives of Neurology, 1991, 48, 718-721.	4.5	84
349	Brain Imaging in Dementia of the Alzheimer Type. International Journal of Neuroscience, 1991, 57, 39-49.	1.6	28

#	Article	IF	CITATIONS
350	Should Patients with Alzheimer's Disease Be Told Their Diagnosis?. New England Journal of Medicine, 1992, 326, 947-951.	27.0	126
351	Alzheimer's Disease or Plaque Disease? Two Cases at the Frontier of a Definition. Topics in Geriatrics, 1992, 5, 200-209.	0.8	5
352	Evidence for Early Vulnerability of the Medial and Inferior Aspects of the Temporal Lobe in an 82-Year-Old Patient With Preclinical Signs of Dementia. Archives of Neurology, 1992, 49, 946.	4.5	121
353	New Patterns of Intraneuronal Accumulation of the Microtubular Binding Domain of tau in Granulovacuolar Degeneration. Topics in Geriatrics, 1992, 5, 132-141.	0.8	19
354	Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 190-194.	1.9	136
355	Motor Cortex Involvement in Presenile Dementia: Report of a Case. Topics in Geriatrics, 1992, 5, 85-92.	0.8	29
356	Alzheimer's disease. Postgraduate Medical Journal, 1992, 68, 528-532.	1.8	3
357	Comparative Analysis of Computed Tomographic and Magnetic Resonance Imaging Scans in Alzheimer Patients and Controls. Archives of Neurology, 1992, 49, 381-384.	4.5	40
358	Clinical Diagnosis of Alzheimer's Disease and Other Dementias in a Population Survey. Archives of Neurology, 1992, 49, 927.	4.5	155
359	Retinocalcarine Function in Alzheimer's Disease. Archives of Neurology, 1992, 49, 93.	4.5	91
360	Protein Kinases and Growth Associated Proteins in Plaque Formation in Alzheimer's Disease. Reviews in the Neurosciences, 1992, 3, 99-108.	2.9	15
361	Does Computed Tomographic Brain Imaging Have a Place in the Diagnosis of Dementia?. Archives of Internal Medicine, 1992, 152, 1437.	3.8	14
362	Evaluation of Cerebral Biopsies for the Diagnosis of Dementia. Archives of Neurology, 1992, 49, 28-31.	4.5	27
363	Evidence for a membrane defect in Alzheimer disease brain Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 1671-1675.	7.1	512
364	A Clinicopathological Study of CT Scans in Alzheimer's Disease. Journal of the American Geriatrics Society, 1992, 40, 476-478.	2.6	4
365	Positron Emission Tomography and Familial Alzheimer's Disease: A Pilot Study. Journal of the American Geriatrics Society, 1992, 40, 120-123.	2.6	10
366	Evaluation of the Hachinski Ischemic Scale in a Prospective Study. Dementia and Geriatric Cognitive Disorders, 1992, 3, 10-14.	1.5	1
367	Regional Distribution of Paired Helical Filaments and Normal Tau Proteins in Aging and in Alzheimer's Disease with and without Occipital Lobe Involvement. Dementia and Geriatric Cognitive Disorders, 1992, 3, 61-69.	1.5	5

#	Article	IF	CITATIONS
368	Full Complement Activation Fails in Diffuse Plaques of the Alzheimer's Disease Cerebellum. Dementia and Geriatric Cognitive Disorders, 1992, 3, 308-313.	1.5	6
369	Susceptibility of Brains from Patients with Alzheimer's Disease to Oxygen-Stimulated Lipid Peroxidation and Differential Scanning Calorimetry. Dementia and Geriatric Cognitive Disorders, 1992, 3, 213-222.	1.5	7
370	Morbid Risk to First Degree Relatives of Neuropathologically Confirmed Cases of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1992, 3, 134-139.	1.5	2
371	On the Question of the Mental State of Centenarians. Dementia and Geriatric Cognitive Disorders, 1992, 3, 150-156.	1.5	3
372	Some Immunohistochemical Features of Argyrophilic Grain Dementia With Normal Cortical Choline Acetyltransferase Levels but Extensive Subcortical Pathology and Markedly Reduced Dopamine. Topics in Geriatrics, 1992, 5, 3-13.	0.8	26
373	Cortical neurons express nerve growth factor receptors in advanced age and Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 569-573.	7.1	182
374	Functional Assessment Staging (FAST) in Alzheimer's Disease: Reliability, Validity, and Ordinality. International Psychogeriatrics, 1992, 4, 55-69.	1.0	447
375	Microwave Modification of Bielschowsky Silver Impregnation Method for Diagnosis of Alzheimer's Disease. Journal of Histotechnology, 1992, 15, 299-302.	0.5	17
376	Longitudinal analysis of a two-component model of the memory deficit in Alzheimer's disease. Psychological Medicine, 1992, 22, 437-445.	4.5	34
377	Epidemiology of Alzheimer's Disease. Epidemiologic Reviews, 1992, 14, 59-82.	3.5	261
377 378	Epidemiology of Alzheimer's Disease. Epidemiologic Reviews, 1992, 14, 59-82. Distribution of Alzheimerâ€ŧype pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology, 1992, 42, 1681-1681.	3.5 1.1	261 590
	Distribution of Alzheimerâ€ŧype pathologic changes in nondemented elderly individuals matches the		
378	Distribution of Alzheimerâ€type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology, 1992, 42, 1681-1681. What features improve the accuracy of clinical diagnosis in Parkinson's disease. Neurology, 1992, 42,	1.1	590
378 379	<ul> <li>Distribution of Alzheimerâ€type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology, 1992, 42, 1681-1681.</li> <li>What features improve the accuracy of clinical diagnosis in Parkinson's disease. Neurology, 1992, 42, 1142-1142.</li> <li>The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases.</li> </ul>	1.1	590 1,139
378 379 380	<ul> <li>Distribution of Alzheimerâ€type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology, 1992, 42, 1681-1681.</li> <li>What features improve the accuracy of clinical diagnosis in Parkinson's disease. Neurology, 1992, 42, 1142-1142.</li> <li>The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neuroscience Research, 1992, 15, 6-31.</li> </ul>	1.1 1.1 1.9	590 1,139 303
378 379 380 381	Distribution of Alzheimerâ€type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology, 1992, 42, 1681-1681. What features improve the accuracy of clinical diagnosis in Parkinson's disease. Neurology, 1992, 42, 1142-1142. The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neuroscience Research, 1992, 15, 6-31. Changes in intraneuronal lipopigment in alzheimer's disease. Neurobiology of Aging, 1992, 13, 493-500. Distribution of amyloid in the brainstem of patients with Alzheimer disease. Neuroscience Letters,	1.1 1.1 1.9 3.1	590 1,139 303 22
378 379 380 381 382	<ul> <li>Distribution of Alzheimerâ€type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology, 1992, 42, 1681-1681.</li> <li>What features improve the accuracy of clinical diagnosis in Parkinson's disease. Neurology, 1992, 42, 1142-1142.</li> <li>The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neuroscience Research, 1992, 15, 6-31.</li> <li>Changes in intraneuronal lipopigment in alzheimer's disease. Neurobiology of Aging, 1992, 13, 493-500.</li> <li>Distribution of amyloid in the brainstem of patients with Alzheimer disease. Neuroscience Letters, 1992, 148, 23-26.</li> <li>Soluble and membrane-bound forms of brain acetylcholinesterase in Alzheimer's disease.</li> </ul>	1.1 1.1 1.9 3.1 2.1	<ul> <li>590</li> <li>1,139</li> <li>303</li> <li>22</li> <li>18</li> </ul>

#	Article	IF	CITATIONS
386	Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development—A study of molecular forms. Neurochemistry International, 1992, 21, 381-396.	3.8	298
387	Quantification of plaque types in sulci and gyri of the medial frontal lobe in patients with Alzheimer's disease. Neuroscience Letters, 1992, 143, 23-26.	2.1	19
388	Regional synaptic pathology in Alzheimer's disease. Neurobiology of Aging, 1992, 13, 375-382.	3.1	175
389	Slowing of the dominant occipital rhythm in electroencephalogram is associated with low concentration of noradrenaline in the thalamus in patients with Alzheimer's disease. Neuroscience Letters, 1992, 137, 5-8.	2.1	26
390	Presence of abnormally phosphorylated Tau proteins in the entorhinal cortex of aged non-demented subjects. Neuroscience Letters, 1992, 144, 143-146.	2.1	43
391	Isolation of a cytochrome oxidase gene overexpressed in Alzheimer's disease brain. Molecular and Cellular Neurosciences, 1992, 3, 461-470.	2.2	11
392	Reduced GAP-43 message levels are associated with increased neurofibrillary tangle density in the frontal association cortex (area 9) in Alzheimer's disease. Neurobiology of Aging, 1992, 13, 631-639.	3.1	38
393	Alzheimer's disease and alcoholism: Possible interactions. Alcohol, 1992, 9, 233-240.	1.7	25
394	Slowing of electroencephalogram and choline acetyltransferase activity in post mortem frontal cortex in definite Alzheimer's disease. Neuroscience, 1992, 49, 529-535.	2.3	67
395	Perisomatic sprouts immunoreactive for nerve growth factor receptor and neurofibrillary degeneration affect different neuronal populations in the basal nucleus in patients with Alzheimer's disease. Neuroscience Letters, 1992, 148, 63-66.	2.1	32
396	Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiology of Aging, 1992, 13, 179-189.	3.1	580
397	Increased S100β neurotrophic activity in Alzheimer's disease temporal lobe. Neurobiology of Aging, 1992, 13, 1-7.	3.1	228
398	Clinical and pathological study of two patients with progressive supranuclear palsy and Alzheimer's changes. Antigenic determinants that distinguish cortical and subcortical neurofibrillary tangles. Neuroscience Letters, 1992, 136, 43-46.	2.1	24
399	Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet, The, 1992, 340, 1179-1183.	13.7	260
400	Acetylcholinesterase-rich pyramidal neurons in alzheimer's disease. Neurobiology of Aging, 1992, 13, 455-460.	3.1	31
401	Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiology of Aging, 1992, 13, 413-419.	3.1	175
402	Olfactory bulb lesions in alzheimer's disease. Neurobiology of Aging, 1992, 13, 469-473.	3.1	70
403	In situ hybridization of calcium/calmodulin dependent protein kinase II and tau mRNAs: species differences and relative preservation in Alzheimer's disease. Molecular Brain Research, 1992, 12, 85-94.	2.3	38

#	Article	IF	CITATIONS
404	Decreased prostaglandin synthesis in postmortem cerebral cortex from patients with Alzheimer's disease. Neurochemistry International, 1992, 21, 197-202.	3.8	29
405	Alzheimer's disease and aging: Effects on perforant pathway perikarya and synapses. Neurobiology of Aging, 1992, 13, 405-411.	3.1	115
406	Loss of high-affinity α2-adrenoceptors in Alzheimer's disease: An autoradiographic study in frontal cortex and hippocampus. Neuroscience Letters, 1992, 142, 36-40.	2.1	29
407	Cerebral amyloid angiopathy and alzheimer's disease: two entities or one?. Journal of the Neurological Sciences, 1992, 112, 1-3.	0.6	54
408	Ubiquitin in cerebral amyloid angiopathy. Journal of the Neurological Sciences, 1992, 112, 46-50.	0.6	13
409	Vascular dementia: neuropathologic alterations and metabolic brain changes. Journal of the Neurological Sciences, 1992, 109, 121-131.	0.6	47
410	Neuronal thread protein over-expression in brains with Alzheimer's disease lesions. Journal of the Neurological Sciences, 1992, 113, 152-164.	0.6	33
411	Cerebellar atrophy as a CT marker for mixed dementia. Biological Psychiatry, 1992, 31, 520-524.	1.3	11
412	Alzheimer's Disease Neuropathology: Current Status of Interpretation of Lesion Development. Annals of the New York Academy of Sciences, 1992, 673, 270-284.	3.8	17
413	The Lysosomal System in Neurons Annals of the New York Academy of Sciences, 1992, 674, 65-88.	3.8	98
414	Humoral and Cellular Immunologic Repertoire in Alzheimer's Disease. Annals of the New York Academy of Sciences, 1992, 663, 349-356.	3.8	6
415	Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 1074-1078.	1.9	18
416	Immunochemical characterization of a monoclonal antibody specific for Alzheimer's disease associated protein. Journal of Neuroimmunology, 1992, 41, 111-115.	2.3	0
417	Synaptic pathology in alzheimer's disease: Immunological data for markers of synaptic and large dense-core vesicles. Neuroscience, 1992, 46, 1-8.	2.3	168
418	Cell loss in the nucleus raphes dorsalis in alzheimer's disease. Neurobiology of Aging, 1992, 13, 461-468.	3.1	103
419	Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases Journal of Neurology, Neurosurgery and Psychiatry, 1992, 55, 181-184.	1.9	9,027
420	Phosphatidylinositol-specific phospholipase C activity in the postmortem human brain: no alteration in Alzheimer's disease. Brain Research, 1992, 579, 347-349.	2.2	29
421	Regional localization of the regulatory subunit (RIIβ) of the type II cAMP-dependent protein kinase in human brain. Brain Research, 1992, 578, 61-68.	2.2	9

#	Article	IF	CITATIONS
422	Ultrastructural localization of acetylcholinesterase in neurofibrillary tangles, neuropil threads and senile plaques in aged and Alzheimer's brain. Brain Research, 1992, 569, 229-237.	2.2	43
423	Transferrin receptors of rat and human brain and cerebral microvessels and their status in Alzheimer's disease. Brain Research, 1992, 585, 87-93.	2.2	85
424	Lewy bodies contain beta-amyloid precursor proteins of Alzheimer's disease. Brain Research, 1992, 585, 386-390.	2.2	49
425	Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain. Brain Research, 1992, 589, 307-312.	2.2	40
426	A correlative study of calcium channel antagonist binding and local neuropathological features in the hippocampus in Alzheimer's disease. Brain Research, 1992, 589, 313-319.	2.2	8
427	Senile plaques in cerebral amyloid angiopathy show accumulation of amyloid precursor protein without cytoskeletal abnormalities. Brain Research, 1992, 593, 299-303.	2.2	13
428	Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Research, 1992, 597, 209-219.	2.2	215
429	Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Research, 1992, 596, 142-148.	2.2	73
430	Differential laminar distribution of acetylcholinesterase and butyrylcholinesterase containing tangles in the cerebral cortex of Alzheimer's disease. Brain Research, 1992, 596, 340-344.	2.2	16
431	Serial reconstruction of $\hat{l}^2$ -protein amyloid plaques: relationship to microvessels and size distribution. Brain Research, 1992, 592, 278-282.	2.2	31
432	Alzheimer's disease. Disease-a-Month, 1992, 38, 7-64.	1.1	18
433	Toward a definite diagnosis of Alzheimer's disease. Comprehensive Psychiatry, 1992, 33, 282-290.	3.1	28
434	Quantitative Computer Tomography in Alzheimer's Disease: A Re-Evaluation. Gerontology, 1992, 38, 174-184.	2.8	4
435	Neuropathological Diagnoses in Epidemiologic Studies. Neuroepidemiology, 1992, 11, 100-105.	2.3	4
436	Immunocytochemistry of neurofibrillary tangles with antibodies to subregions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site. Acta Neuropathologica, 1992, 84, 596-605.	7.7	76
437	Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. Acta Neuropathologica, 1992, 84, 638-50.	7.7	95
438	Allocortical neurofibrillary changes in progressive supranuclear palsy. Acta Neuropathologica, 1992, 84, 478-483.	7.7	69
439	Mapping of neurofibrillary degeneration in Alzheimer's disease: evaluation of heterogeneity using the quantification of abnormal tau proteins. Acta Neuropathologica, 1992, 85, 48-54.	7.7	51

#	Article	IF	CITATIONS
440	A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease. Acta Neuropathologica, 1992, 83, 170-178.	7.7	162
441	Clinical correlates of high signal lesions on magnetic resonance imaging in Alzheimer's disease. Journal of Neurology, 1992, 239, 186-190.	3.6	53
442	Absence of aluminium in neuritic plaque cores in Alzheimer's disease. Nature, 1992, 360, 65-68.	27.8	285
443	Characterization of Neutral Proteinases from Alzheimer-Affected and Control Brain Specimens: Identification of Calcium-Dependent Metalloproteinases from the Hippocampus. Journal of Neurochemistry, 1992, 58, 983-992.	3.9	119
444	Comparative Alterations of Nicotinic and Muscarinic Binding Sites in Alzheimer's and Parkinson's Diseases. Journal of Neurochemistry, 1992, 58, 529-541.	3.9	316
445	On the Stability of Messenger RNA and Ribosomal RNA in the Brains of Control Human Subjects and Patients with Alzheimer's Disease. Journal of Neurochemistry, 1992, 58, 1810-1819.	3.9	59
446	Decreased Density of Presynaptic ?2-Adrenoceptors in Postmortem Brains of Patients with Alzheimer's Disease. Journal of Neurochemistry, 1992, 58, 1896-1904.	3.9	44
447	Lipid Composition in Different Regions of the Brain in Alzheimer's Disease/Senile Dementia of Alzheimer's Type. Journal of Neurochemistry, 1992, 59, 1646-1653.	3.9	190
448	Insulin-Like Growth Factor I Receptor Binding in Brains of Alzheimer's and Alcoholic Patients. Journal of Neurochemistry, 1992, 58, 1205-1210.	3.9	40
449	Heterogeneity of NMDA receptors labelled with acid ([3H]CPP): receptor status in Alzheimer's disease brains. European Journal of Pharmacology, 1992, 225, 195-197.	2.6	17
450	Spatial recognition and spatial order memory in patients with dementia of the Alzheimer's type. Neuropsychologia, 1992, 30, 59-67.	1.6	38
451	Ion beam analysis of the bone tissue of Alzheimer's disease patients. Nuclear Instruments & Methods in Physics Research B, 1992, 64, 553-557.	1.4	8
452	Human brain phenolsulfotransferase. Regional distribution in Parkinson's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1992, 4, 267-276.	1.2	3
453	An improved thioflavine S method for staining neurofibrillary tangles and senile plaques in Alzheimer's disease. Experientia, 1992, 48, 8-10.	1.2	124
454	The pathology of dementias: an overview. Acta Neurologica Scandinavica, 1992, 85, 8-15.	2.1	10
455	Primary sequence confirmation of the β-amyloid peptide from hereditary cerebral haemorrhage with amyloidosis (Dutch type) by collisional activation of the doubly charged ion. Biological Mass Spectrometry, 1992, 21, 385-390.	0.5	1
456	Neuronal degeneration in human diseases and animal models. Journal of Neurobiology, 1992, 23, 1277-1294.	3.6	34
457	Diffuse Lewy body disease: Disease, spectrum disorder or variety of Alzheimer disease. International Journal of Geriatric Psychiatry, 1992, 7, 229-234.	2.7	20

		CITATION R	EPORT	
#	Article		IF	CITATIONS
458	Lewy bodies in psychiatric patients. International Journal of Geriatric Psychiatry, 1992,	7, 235-240.	2.7	27
459	Psychotic symptoms in Alzheimer's disease. International Journal of Geriatric Psychiatry 341-345.	y, 1992, 7,	2.7	10
460	Oxiracetam in the treatment of primary dementia of the Alzheimer's type: A small case International Journal of Geriatric Psychiatry, 1992, 7, 905-912.	series.	2.7	6
461	Automated microparticle enzyme immunoassay for neural thread protein in cerebrospi alzheimer's disease patients. Journal of Clinical Laboratory Analysis, 1992, 6, 379-383.	nal fluid from	2.1	6
462	Distribution of neurotensin immunoreactivity within the human amygdaloid complex: with acetylcholinesterase- and Nissl-stained tissue sections. Journal of Comparative Ne 317, 283-297.	A comparison urology, 1992,	1.6	27
463	A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. Jo Neuroscience Research, 1992, 31, 75-83.	urnal of	2.9	450
464	Regional distribution of iron and ironâ€regulatory proteins in the brain in aging and Alz disease. Journal of Neuroscience Research, 1992, 31, 327-335.	heimer's	2.9	363
465	Human serum stimulates alzheimer markers in cultured hippocampal neurons. Journal Neuroscience Research, 1992, 33, 355-369.	of	2.9	13
466	Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Annals of Net 31, 242-249.	urology, 1992,	5.3	115
467	Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheime laser microprobe (LAMMA) study. Annals of Neurology, 1992, 31, 286-292.	r's disease: A	5.3	486
468	Cholinesterases in the amyloid angiopathy of Alzheimer's disease. Annals of Neurology 565-569.	, 1992, 31,	5.3	32
469	Monoaminergic and cholinergic synaptic markers in the nucleus basalis of meynert (nb age-related changes and the effect of heart disease and Alzheimer's disease. Annals of 31, 611-620.		5.3	31
470	Amygdala cell loss and atrophy in Alzheimer's disease. Annals of Neurology, 1992, 32,	555-563.	5.3	95
471	Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neurop and cognitive correlations. Annals of Neurology, 1992, 32, 625-632.	athological,	5.3	219
472	NMR spectroscopy of human post mortem cerebrospinal fluid: Distinction of Alzheime control using pattern recognition and statistics. NMR in Biomedicine, 1993, 6, 163-163		2.8	52
473	Lack of variation in the nucleotide sequence corresponding to the transmembrane dor $\hat{l}^2$ -amyloid precursor protein in Alzheimer's disease. American Journal of Medical Genet 48, 131-136.		2.4	9
474	Laser microprobe analysis of brain aluminum in Alzheimer' disease. Annals of Neurolog	y, 1993, 33, 36-42.	5.3	122
475	Synapse loss in the temporal lobe in Alzheimer's disease. Annals of Neurology, 1993, 3	3, 190-199.	5.3	227

		CITATION REPORT		
#	Article		IF	CITATIONS
476	Rapidly progressive aphasic dementia and motor neuron disease. Annals of Neurology,	1993, 33, 200-207.	5.3	211
477	Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: Relationship tangles, and patterns of selective vulnerability. Annals of Neurology, 1993, 34, 373-38		5.3	209
478	Epidemiology of alzheimer's disease: Research trends in the united states. Internationa Geriatric Psychiatry, 1993, 8, 59-65.	al Journal of	2.7	1
479	Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta Journal of Comparative Neurology, 1993, 329, 328-336.	neurons.	1.6	67
480	Evidence that transmitter-containing dystrophic neurites precede paired helical filamer formation within senile plaques in the amygdala of nondemented elderly and patients Alzheimer's disease. Journal of Comparative Neurology, 1993, 334, 176-191.	וt and Alz-50 with	1.6	52
481	Cholinergic innervation of the amygdaloid complex in the human brain and its alteratic and Alzheimer's disease. Journal of Comparative Neurology, 1993, 336, 117-134.	ons in old age	1.6	63
483	Alzheimer neuropathology in mentally retarded adults: statistical independence of regi plaque and neurofibrillary tangle densities. Acta Neuropathologica, 1993, 85, 260-6.	ional amyloid	7.7	13
484	The distribution of amyloid plaques in the cerebellum and brain stem in Down's syndro Alzheimer's disease: a light microscopical analysis. Acta Neuropathologica, 1993, 85, 5		7.7	56
485	Posterior cortical atrophy in Alzheimer's disease: analysis of a new case and re-evaluati historical report. Acta Neuropathologica, 1993, 86, 215-223.	on of a	7.7	105
486	Colocalization of cholinesterases with ? amyloid protein in aged and Alzheimer's brains Neuropathologica, 1993, 85, 362-369.	s. Acta	7.7	168
487	Quantitative immunohistochemical analysis of the distribution of neurofibrillary tangle plaques in the cerebral cortex of nonagenarians and centenarians. Acta Neuropatholog 602-610.	s and senile gica, 1993, 85,	7.7	61
488	Proteins immunologically related to erythrocyte anion transporter band 3 are altered ir affected by Alzheimer's disease. Acta Neuropathologica, 1993, 86, 353-359.	n brain areas	7.7	14
489	Early Detection of Alzheimer's Disease: A Statistical Approach Using Positron Emission Data. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 438-447.	Tomographic	4.3	101
490	Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Ser Sandwich Enzymeâ€Linked Immunosorbent Assay. Journal of Neurochemistry, 1993, 6		3.9	474
491	?-Amyloid Protein Precursor and ? mRNA Levels Versus ?-Amyloid Plaque and Neurofibri the Aged Human Brain. Journal of Neurochemistry, 1993, 60, 1658-1664.	llary Tangles in	3.9	28
492	Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus fr Alzheimer's disease. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 347, 21	om patients with 4-9.	3.0	16
493	High affinity hippocampal [3H]-glibenclamide binding sites are preserved in Alzheimer' of Neural Transmission Parkinson's Disease and Dementia Section, 1993, 5, 177-184.	s disease. Journal	1.2	5
494	Substance P receptors are differentially affected in Parkinson's and Alzheimer's disease Neural Transmission Parkinson's Disease and Dementia Section, 1993, 6, 199-210.	e. Journal of	1.2	19

#	Article	IF	CITATIONS
495	Differential expression of α 1-antichymotrypsin in the aged human brain. Vigiliae Christianae, 1993, 64, 221-227.	0.1	9
496	Epidermal growth factor receptor expression in demented elderly: localization to vascular endothelial cells of brain, pituitary and skin. Brain Research, 1993, 615, 181-190.	2.2	18
497	Immunocytochemical distribution of peptidergic and cholinergic fibers in the human amygdala: their depletion in Alzheimer's disease and morphologic alteration in non-demented elderly with numerous senile plaques. Brain Research, 1993, 625, 125-138.	2.2	43
498	Differential alterations in adenosine A1 and κ1 opioid receptors in the striatum in Alzheimer's disease. Brain Research, 1993, 616, 211-217.	2.2	33
499	Differential alterations of ion channel binding sites in temporal and occipital regions of the cerebral cortex in Alzheimer's disease. Brain Research, 1993, 630, 50-56.	2.2	5
500	Alterations in the activity of adenylate cyclase and high affinity GTPase in Alzheimer's disease. Brain Research, 1993, 622, 35-42.	2.2	35
501	Cell loss in supraoptic and paraventricular nucleus in Alzheimer's disease. Brain Research, 1993, 609, 154-158.	2.2	17
502	Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease. Brain Research, 1993, 631, 147-150.	2.2	66
503	Localization of the mitogen activated protein kinase ERK2 in Alzheimer's disease neurofibrillary tangles and senile plaque neurites. Brain Research, 1993, 618, 333-337.	2.2	88
504	Alzheimer's disease-like dystrophic neurites characteristically associated with senile plaques are not found within other neurodegenerative disease unless amyloid β-protein deposition is present. Brain Research, 1993, 606, 10-18.	2.2	57
505	Evidence that transmitter-containing dystrophic neurites precede those containing paired helical filaments within senile plaques in the entorhinal cortex of nondemented elderly and Alzheimer's disease patients. Brain Research, 1993, 619, 55-68.	2.2	32
506	Major unipolar depression and mild Alzheimer's disease: differentiation by quantitative tonic REM EEG. Electroencephalography and Clinical Neurophysiology, 1993, 86, 238-246.	0.3	21
507	Evaluation of Neuropathological Stages Based on Quantification of Senile Changes in Non-Demented Elderly Individuals and Alzheimer-Type Dementia. Neuropathology, 1993, 13, 147-152.	1.2	5
508	NMDA, AMPA, and benzodiazepine binding site changes in Alzheimer's disease visual cortex. Neurobiology of Aging, 1993, 14, 343-352.	3.1	52
509	Dopamine D2 receptors in the hippocampus and amygdala in Alzheimer's disease. Neuroscience Letters, 1993, 154, 171-174.	2.1	54
510	Regionally specific loss of neurons in the aging human hippocampus. Neurobiology of Aging, 1993, 14, 287-293.	3.1	572
511	31P magnetic resonance spectroscopy in alzheimer's and pick's disease. Neurobiology of Aging, 1993, 14, 85-92.	3.1	38
512	Platelet of Alzheimer patients: Increased counts and subnormal uptake and accumulation of [14C]5-hydroxytryptamine. Neuroscience Letters, 1993, 163, 8-10.	2.1	25

#	Article	IF	CITATIONS
513	Subpial peptide deposits are closely associated with amyloid angiopathy in the elderly. Neuroscience Letters, 1993, 155, 144-147.	2.1	9
514	Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neuroscience Letters, 1993, 162, 179-182.	2.1	297
515	Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease. Neurobiology of Aging, 1993, 14, 589-596.	3.1	65
516	Non-adrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease. Neuroscience Letters, 1993, 160, 109-112.	2.1	72
517	βA4 deposits are constant in the brain of the oldest old: An immunocytochemical study of 20 french centenarians. Neurobiology of Aging, 1993, 14, 191-194.	3.1	156
518	Cellular specificity and regional distribution of amyloid $\hat{I}^2$ protein precursor alternative transcripts are unaltered in Alzheimer hippocampal formation. Molecular Brain Research, 1993, 18, 246-252.	2.3	38
519	Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer's type. Neurobiology of Aging, 1993, 14, 523-528.	3.1	203
520	The synaptic organization of the neocortex in Alzheimer's disease. Medical Hypotheses, 1993, 41, 334-340.	1.5	79
521	Morphometric image analysis of neuropil threads in alzheimer's disease. Neurobiology of Aging, 1993, 14, 303-307.	3.1	14
522	Coupling of muscarinic receptors to GTP proteins in postmortem human brain — alterations in Alzheimer's disease. Neuroscience Letters, 1993, 150, 39-43.	2.1	65
523	Axonal loss from the olfactory tracts in alzheimer's disease. Neurobiology of Aging, 1993, 14, 353-357.	3.1	62
524	Characterization of brain samples in studies of aging, Alzheimer's, and other neurodegenerative diseases. Neurobiology of Aging, 1993, 14, 539-545.	3.1	7
525	Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex. Neuroscience Letters, 1993, 155, 116-120.	2.1	41
526	Cerebral soluble ubiquitin is increased in patients with Alzheimer's disease. Neuroscience Letters, 1993, 151, 158-161.	2.1	12
527	Microglial reaction in Pick's disease. Neuroscience Letters, 1993, 161, 89-92.	2.1	41
528	The role of cortical connectivity in Alzheimer's disease pathogenesis: A review and model system. Neurobiology of Aging, 1993, 14, 1-16.	3.1	244
529	Alzheimer plaque density and duration of dementia. Archives of Gerontology and Geriatrics, 1993, 16, 1-7.	3.0	6
530	A topographical study of senile plaques and neurofibrillary tangles in the hippocampi of patients with Alzheimer's disease and cognitively impaired patients with schizophrenia. Psychiatry Research, 1993, 49, 41-62.	3.3	48

#	Article	IF	CITATIONS
531	Post-mortem examination of dopaminergic parameters in Alzheimer's disease: Relationship to noncognitive symptoms. Psychiatry Research, 1993, 49, 211-217.	3.3	8
532	Pre- and post-mortem MR imaging of unsuspected multiple sclerosis in a patient with Alzheimer's disease. Journal of the Neurological Sciences, 1993, 117, 175-178.	0.6	15
533	Frequency analysis of catecholamine axonal morphology in human brain. Journal of the Neurological Sciences, 1993, 119, 110-118.	0.6	23
534	Cerebral amyloid angiopathy: A significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. Journal of the Neurological Sciences, 1993, 116, 135-141.	0.6	266
535	Volumetric magnetic resonance imaging in men with dementia of the Alzheimer type: Correlations with disease severity. Biological Psychiatry, 1993, 34, 612-621.	1.3	111
536	Severe cognitive impairment in elderly schizophrenic patients: A clinicopathological study. Biological Psychiatry, 1993, 33, 255-260.	1.3	101
537	Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in alzheimer hippocampus: A quantitative autoradiographic study. Neuroscience, 1993, 52, 843-854.	2.3	81
538	Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain, 1993, 116, 717-725.	7.6	130
539	A Population-Based Study of Dementia in 85-Year-Olds. New England Journal of Medicine, 1993, 328, 153-158.	27.0	697
540	Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology, 1993, 43, 1927-1927.	1.1	161
541	Some Modular Features of Temporal Cortex in Humans as Revealed by Pathological Changes in Alzheimer's Disease. Cerebral Cortex, 1993, 3, 465-475.	2.9	70
542	A Clinicopathologic Study of 100 Cases of Parkinson's Disease. Archives of Neurology, 1993, 50, 140-148.	4.5	881
543	Alzheimer's Disease: The Problem of Incorrect Clinical Diagnosis. Journal of Geriatric Psychiatry and Neurology, 1993, 6, 230-234.	2.3	17
544	Failure of CT Scan to Detect Ischemic Lesions in Patients With Dementia. Journal of Geriatric Psychiatry and Neurology, 1993, 6, 245-250.	2.3	4
545	Reliability and Usefulness of a New Immunochemical Assay for Alzheimer's Disease. Archives of Neurology, 1993, 50, 57-63.	4.5	1
546	Greater Abnormalities of Brain Cerebrospinal Fluid Volumes in Younger Than in Older Patients With Alzheimer's Disease. Archives of Neurology, 1993, 50, 359-373.	4.5	55
547	The Neuropsychology of Attention. Critical Issues in Neuropsychology, 1993, , .	0.4	156
548	Neuropathological Indexes of Alzheimer's Disease in Demented and Nondemented Persons Aged 80 Years and Older. Archives of Neurology, 1993, 50, 349-358.	4.5	247

#	Article	IF	CITATIONS
549	Profiles of Language Impairment in Primary Progressive Aphasia. Archives of Neurology, 1993, 50, 193-201.	4.5	100
550	Pathologists' Participation in Postmortem Examinations for Patients with Dementia. Gerontologist, The, 1993, 33, 461-467.	3.9	4
551	Limbic encephalitis occurring in association with Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 808-811.	1.9	13
552	Vascular Amyloid Deposition in Alzheimer's Disease. Archives of Neurology, 1993, 50, 1088.	4.5	18
553	Alzheimer's Disease and Idiopathic Parkinson's Disease Coexistence. Journal of Geriatric Psychiatry and Neurology, 1993, 6, 170-176.	2.3	19
554	Alzheimer-type Neuropathology in Elderly Schizophrenia Patients. Schizophrenia Bulletin, 1993, 19, 805-816.	4.3	70
555	Abnormalities in rCBF and computed tomography in patients with Alzheimer's disease and in controls. British Journal of Radiology, 1993, 66, 23-27.	2.2	21
556	Structural correlates and cellular mechanisms in entorhinal—hippocampal dysfunction. Hippocampus, 1993, 3, 293-301.	1.9	10
557	Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9649-9653.	7.1	1,421
558	Education and the prevalence of dementia and Alzheimer's disease. Neurology, 1993, 43, 13-13.	1.1	1,019
560	Chapter 6. Perspectives on Amyloid and Alzheimer's Disease: A Critical Review. Annual Reports in Medicinal Chemistry, 1993, 28, 49-58.	0.9	7
561	Aging and Alzheimer Disease in People with Mental Retardation. International Review of Research in Mental Retardation, 1993, , 41-70.	0.7	40
562	Intact acquisition and long-term retention of mirror-tracing skill in Alzheimer's disease and in global amnesia Behavioral Neuroscience, 1993, 107, 899-910.	1.2	174
563	Computer-assisted three-dimensional image analysis of cerebral amyloid angiopathy Stroke, 1993, 24, 1857-1864.	2.0	69
564	Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 2628-2632.	7.1	558
565	Altered <i>Tau</i> and Neurofilament Proteins in Neuroâ€Degenerative Diseases: Diagnostic Implications for Alzheimer's Disease and Lewy Body Dementias. Brain Pathology, 1993, 3, 45-54.	4.1	230
566	Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. Brain, 1993, 116, 281-302.	7.6	119
567	beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 10836-10840.	7.1	663

#	Article	IF	CITATIONS
568	Singleâ€Photon Emission Computed Tomographic Perfusion Imaging in Autopsyâ€Diagnosed Dementia. Journal of Neuroimaging, 1993, 3, 93-99.	2.0	9
569	Relationship between Cognitive Status and Behavioral Symptoms in Alzheimer's Disease and Mixed Dementia. Journal of the American Geriatrics Society, 1993, 41, 732-736.	2.6	25
570	Alzheimer's disease: clinical Features. International Review of Psychiatry, 1993, 5, 327-349.	2.8	16
571	Neuropathological basis for drawing disability (constructional apraxia) in Alzheimer's disease. Psychological Medicine, 1993, 23, 623-629.	4.5	42
572	Entorhinal—hippocampal interaction in mnestic disorders. Hippocampus, 1993, 3, 239-246.	1.9	65
573	Clinicopathological Studies of the Dementias from an Epidemiological Viewpoint. British Journal of Psychiatry, 1993, 162, 439-446.	2.8	28
574	Dendritic pathology of granule cells in Alzheimer's disease is unrelated to neuritic plaques. Journal of Neuroscience, 1994, 14, 5077-5088.	3.6	95
575	Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients: an autoradiographic study. Journal of Neuroscience, 1994, 14, 6317-6324.	3.6	106
576	Neuropathological Differences between Areas B17 and B18: Implications for Visual Evoked Responses in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1994, 5, 247-251.	1.5	4
577	Quantitative Analysis of Lipofuscin and Neurofibrillary Tangles in the Hippocampal Neurons of Alzheimer Disease Brains. Dementia and Geriatric Cognitive Disorders, 1994, 5, 229-233.	1.5	11
578	Dementia in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 1994, 5, 12-16.	1.5	11
579	Increased levels of hemoglobin-derived and other peptides in Alzheimer's disease cerebellum. Journal of Neuroscience, 1994, 14, 2225-2235.	3.6	95
580	Neuropathologic Changes of the Temporal Pole in Alzheimer's Disease and Pick's Disease. Archives of Neurology, 1994, 51, 145-150.	4.5	81
581	Estrogen Replacement Therapy in Older Women. Archives of Neurology, 1994, 51, 896.	4.5	601
582	Clinical Correlates of Cortical and Nucleus Basalis Pathology in Alzheimer Dementia. Archives of Neurology, 1994, 51, 772-778.	4.5	141
583	Cytoskeletal Neurofilament Gene Expression in Brain Tissue from Alzheimer's Disease Patients. I. Decrease in NF-L and NF-M Message. Journal of Geriatric Psychiatry and Neurology, 1994, 7, 153-158.	2.3	27
584	Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations. Reviews in the Neurosciences, 1994, 5, 213-25.	2.9	11
585	Reliability and Validity of NINCDS-ADRDA Criteria for Alzheimer's Disease. Archives of Neurology, 1994, 51, 1198.	4.5	263

#	Article	IF	Citations
586	Attitudes About Autopsy: Implications for Educational Interventions. Gerontologist, The, 1994, 34, 665-673.	3.9	24
587	Clinical-Neuropathological Correlations in Alzheimer's Disease and Related Dementias. Archives of Neurology, 1994, 51, 888-895.	4.5	395
588	The Natural History of Alzheimer's Disease. Archives of Neurology, 1994, 51, 585.	4.5	359
589	Measurement of Severity in Advanced Alzheimer's Disease. Journal of Gerontology, 1994, 49, M223-M226.	1.9	165
590	Posterior Cortical Atrophy. Archives of Neurology, 1994, 51, 269.	4.5	188
591	Management of neurological disorders: dementia Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1451-1456.	1.9	14
592	Microvasculature in Brain Biopsy Specimens from Patients with Alzheimer's Disease: An Immunohistochemical and Ultrastructural Study. Ultrastructural Pathology, 1994, 18, 333-348.	0.9	126
593	Seizures in Alzheimer's Disease: Clinicopathologic Study. Journal of Geriatric Psychiatry and Neurology, 1994, 7, 230-233.	2.3	154
594	Computed detection and quantitative morphometry of Alzheimer senile plaques. Journal of Neuroscience Methods, 1994, 52, 175-189.	2.5	11
595	Diagnostic confirmation, severity, and subtypes of Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 1994, 244, 252-260.	3.2	11
596	Genetic factors in the etiology of idiopathic Parkinson's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1994, 8, 1-37.	1.2	36
597	A comparison of multiplex and simplex families with Alzheimer's disease/senile dementia of Alzheimer type within a well defined population. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1994, 7, 61-72.	1.2	3
598	Kappa-1 opioid receptors of the temporal cortex are preserved in Alzheimer's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1994, 7, 73-79.	1.2	9
599	Selective cortical decrease of high-affinity choline uptake carrier in Alzheimer's disease: An autoradiographic study using3H-hemicholinium-3. Journal of Neural Transmission Parkinson's Disease and Dementia Section, 1994, 8, 161-169.	1.2	23
600	Anomalous binding of radiolabeled oligonucleotide probes to plaques and tangles in Alzheimer disease hippocampus. Molecular and Chemical Neuropathology, 1994, 22, 1-24.	1.0	8
601	Freed-amino acids in human cerebrospinal fluid of alzheimer disease, multiple sclerosis, and healthy control subjects. Molecular and Chemical Neuropathology, 1994, 23, 115-124.	1.0	59
602	Cholinesterases colocalize with sites of neurofibrillary degeneration in aged and Alzheimer's brains. Acta Neuropathologica, 1994, 87, 284-292.	7.7	43
603	Alzheimer's disease with asymmetric atrophy of the cerebral hemispheres: morphometric analysis of four cases. Acta Neuropathologica, 1994, 88, 440-447.	7.7	32

#	Article	IF	CITATIONS
604	Hippocampal sclerosis: a common pathological feature of dementia in very old (≥80 years of age) humans. Acta Neuropathologica, 1994, 88, 212-221.	7.7	256
605	Expression of small heat-shock protein hsp 27 in reactive gliosis in Alzheimer disease and other types of dementia. Acta Neuropathologica, 1994, 87, 511-519.	7.7	140
606	The identification of pathological subtypes of Alzheimer's disease using cluster analysis. Acta Neuropathologica, 1994, 88, 60-66.	7.7	23
607	Quantitative neuropathologic analysis of Pick's disease cases: cortical distribution of Pick bodies and coexistence with Alzheimer's disease. Acta Neuropathologica, 1994, 87, 115-124.	7.7	106
608	Expression of αB-crystallin in Alzheimer's disease. Acta Neuropathologica, 1994, 87, 155-160.	7.7	212
609	Analysis of staining methods for different cortical plaques in Alzheimer's disease. Acta Neuropathologica, 1994, 87, 174-186.	7.7	30
610	Quantitative neuropathologic analysis of Pick's disease cases. Acta Neuropathologica, 1994, 87, 223-224.	7.7	18
611	Neurofibrillary tangle predominant form of senile dementia of Alzheimer type: a rare subtype in very old subjects. Acta Neuropathologica, 1994, 88, 565-570.	7.7	97
612	Hippocampal sclerosis: a common pathological feature of dementia in very old humans. Acta Neuropathologica, 1994, 88, 599-599.	7.7	48
613	Re-evaluation of classic senile plaques by three-dimensional analysis. Journal of Neurology, 1994, 241, 624-627.	3.6	4
614	Loss of dopamine D2 receptors varies along the rostrocaudal axis of the hippocampal complex in alzheimer's disease. Journal of Comparative Neurology, 1994, 348, 94-110.	1.6	38
615	Reflections on the NINCDS/ADRDA criteria for the diagnosis of alzheimer's disease. International Journal of Geriatric Psychiatry, 1994, 9, 173-179.	2.7	9
616	Comparison of clinical state, retrospective informant interview and the neuropathologic diagnosis of alzheimer's disease. International Journal of Geriatric Psychiatry, 1994, 9, 233-236.	2.7	33
617	Association of the apolipoprotein E ε4 allele with clinical subtypes of autopsy-confirmed Alzheimer's disease. American Journal of Medical Genetics Part A, 1994, 54, 199-205.	2.4	90
618	Localization of non-N-methyl-D-aspartate glutamate receptors in normal and Alzheimer hippocampal formation. Annals of Neurology, 1994, 35, 31-37.	5.3	32
619	Alzheimer's disease and Lewy body disease: A comparative clinicopathological study. Annals of Neurology, 1994, 35, 81-88.	5.3	162
620	Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Annals of Neurology, 1994, 35, 546-551.	5.3	429
621	Are the associations between Alzheimer's disease and polymorphisms in the apolipoprotein E and the apolipoprotein CII genes due to linkage disequilibrium?. Annals of Neurology, 1994, 36, 97-100.	5.3	87

#	Article	IF	CITATIONS
622	Decreased levels of soluble amyloid ?-protein precursor are associated with Alzheimer's disease in concordant and discordant monozygous twin pairs. Annals of Neurology, 1994, 36, 215-220.	5.3	14
623	Phenotype of chromosome 14-linked familial Alzheimer's disease in a large kindred. Annals of Neurology, 1994, 36, 368-378.	5.3	115
624	Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Annals of Neurology, 1994, 36, 722-727.	5.3	233
625	Predictive value of apolipoprotein E genotyping in Alzheimer's disease: Results of an autopsy series and an analysis of several combined studies. Annals of Neurology, 1994, 36, 889-895.	5.3	134
626	Priming in perceptual identification of pseudowords is normal in Alzheimer's disease. Neuropsychologia, 1994, 32, 343-356.	1.6	79
627	Oxidative stress: Free radical production in neural degeneration. , 1994, 63, 37-122.		454
628	Degenerative changes in epinephrine tonic vasomotor neurons in Alzheimer's disease. Brain Research, 1994, 661, 35-42.	2.2	41
629	BrainN-acetyl-l-aspartic acid in Alzheimer's disease: a proton magnetic resonance spectroscopy study. Brain Research, 1994, 667, 167-174.	2.2	74
630	Synapse alterations in the hippocampal-entorhinal formation in Alzheimer's disease with and without Lewy body disease. Brain Research, 1994, 667, 24-32.	2.2	97
631	Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genetics, 1994, 7, 180-184.	21.4	1,732
632	<i>N</i> -Acetylaspartate as an in vivo Marker of Neuronal Viability in Kainate-Induced Status Epilepticus: 1H Magnetic Resonance Spectroscopic Imaging. Journal of Cerebral Blood Flow and Metabolism, 1994, 14, 373-382.	4.3	120
633	Increased Cortisol Levels in Aging and Alzheimer's Disease in Postmortem Cerebrospinal Fluid. Journal of Neuroendocrinology, 1994, 6, 681-687.	2.6	138
634	Incidence and Distribution of Senile Plaques and Neurofibrillary Tangles in Late-onset Diffuse Lewy Body Disease. Neuropathology, 1994, 14, 7-11.	1.2	11
635	Neuropathological Diagnosis of Senile Dementia of the Alzheimer Type (SDAT): Proposal of Diagnostic Criteria and Report of the Japanese Research Meeting on Neuropathological Diagnosis of SDAT. Neuropathology, 1994, 14, 91-103.	1.2	26
636	Borderline State between Senile Dementia of 'Szheimer Type and Norm's Aging: A Clinico-pathologic's An'sysis. Neuropathology, 1994, 14, 119-125.	1.2	2
637	A modified NOR–silver impregnation technique for amyloid plaques and neurofibrillary tangles: comparative assessment. Neuropathology and Applied Neurobiology, 1994, 20, 478-486.	3.2	12
638	Immunohistochemistry with an antibody to human liver carboxylesterase in human brain tissues. Brain Research, 1994, 658, 163-167.	2.2	39
639	Content and fatty acid composition of cardiolipin in the brain of patients with alzheimer's disease. Neurochemistry International, 1994, 25, 295-300.	3.8	45

#	Article	IF	CITATIONS
640	Excitotoxic mechanisms in the pathogenesis of dementia. Neurochemistry International, 1994, 25, 203-219.	3.8	54
641	Blood markers in Alzheimer disease: Subnormal acetylcholinesterase and butyrylcholinesterase in lymphocytes and erythrocytes. Journal of the Neurological Sciences, 1994, 122, 1-5.	0.6	35
642	Presence of neuronal proteins in serially cultured cells from autopsy human brain. Journal of the Neurological Sciences, 1994, 121, 132-138.	0.6	13
643	Blood pressure regulation in alzheimer's disease. Journal of the Autonomic Nervous System, 1994, 48, 65-71.	1.9	86
644	Microtubule-associated protein MAP1B showing a fetal phosphorylation pattern is present in sites of neurofibrillary degeneration in brains of Alzheimer's disease patients. Molecular Brain Research, 1994, 26, 113-122.	2.3	86
645	Neurofibrillary tangles have no obligatory predilection for acetylcholinesterase-rich neurons. Neurobiology of Aging, 1994, 15, 615-619.	3.1	6
646	Apolipoprotein E-immunoreactivity in aged rhesus monkey cortex: Colocalization with amyloid plaques. Neurobiology of Aging, 1994, 15, 621-627.	3.1	56
647	Attenuated protein kinase C activity and translocation in Alzheimer's Disease brain. Neurobiology of Aging, 1994, 15, 293-298.	3.1	117
648	Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions. Neurobiology of Aging, 1994, 15, 299-303.	3.1	56
649	Broad-band visual capacities are not selectively impaired in Alzheimer's disease. Neurobiology of Aging, 1994, 15, 305-311.	3.1	63
650	No global neocortical nerve cell loss in brains from patients with senile dementia of Alzheimer's type. Neurobiology of Aging, 1994, 15, 347-352.	3.1	158
651	Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiology of Aging, 1994, 15, 355-356.	3.1	157
652	Development of small molecule probes for the Beta-amyloid protein of Alzheimer's Disease. Neurobiology of Aging, 1994, 15, 691-698.	3.1	171
653	Cortical and subcortical neuropeptides in Alzheimer's disease. Neurobiology of Aging, 1994, 15, 589-595.	3.1	21
654	Amyloid plaques in cerebellar cortex and the integrity of Purkinje cell dendrites. Neurobiology of Aging, 1994, 15, 1-9.	3.1	70
655	Mass and physical dimensions of two distinct populations of paired helical filaments. Neurobiology of Aging, 1994, 15, 11-19.	3.1	54
656	Neuron loss and shrinkage in the amygdala in Alzheimer's disease. Neurobiology of Aging, 1994, 15, 45-54.	3.1	70
657	Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43). Neuron, 1994, 13, 45-53.	8.1	1,673

#	Article	IF	CITATIONS
658	Human striatum: Chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer's disease. Neuroscience, 1994, 60, 621-636.	2.3	97
659	Ampa/kainate receptor gene expression in normal and alzheimer's disease hippocampus. Neuroscience, 1994, 61, 41-49.	2.3	45
660	Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience, 1994, 63, 637-652.	2.3	251
661	Tau immunoreactivity and SDS solubility of two populations of paired helical filaments that differ in morphology. Brain Research, 1994, 649, 185-196.	2.2	30
662	Human striatum: the distribution of neurofibrillary tangles in Alzheimer's disease. Brain Research, 1994, 648, 327-331.	2.2	49
663	Immunohistochemistry with antibodies to hepatocyte growth factor and its receptor protein (c-MET) in human brain tissues. Brain Research, 1994, 637, 308-312.	2.2	74
664	Expression of protein phosphatases (PP-1, PP-2A, PP-2B and PTP-1B) and protein kinases (MAP kinase and) Tj ETG Research, 1994, 655, 70-76.	Qq0 0 0 rg 2.2	BT /Overlock 81
665	Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain. Brain Research, 1994, 655, 153-160.	2.2	13
666	AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of non-demented elderly and patients with Alzheimer's disease. Brain Research, 1994, 639, 207-216.	2.2	86
667	Ultrastructural localization of butyrylcholinesterase on neurofibrillary degeneration sites in the brains of aged and Alzheimer's disease patients. Brain Research, 1994, 640, 17-24.	2.2	42
668	An extensive network of PHFÏ,,-rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease. FEBS Letters, 1994, 344, 69-73.	2.8	50
669	Cytoplasmic inclusions in neocortical astrocytes associated with arteriopathic encephalopathy and dementia. Human Pathology, 1994, 25, 1366-1370.	2.0	4
670	Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet, The, 1994, 343, 993-997.	13.7	131
671	Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease. Lancet, The, 1994, 344, 1307.	13.7	43
672	Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet, The, 1994, 344, 769-772.	13.7	1,142
673	Cholinergic and serotonergic stimulation of phosphoinositide hydrolysis is decreased in Alzheimer's disease. Life Sciences, 1994, 55, 1993-2002.	4.3	39
674	Taxol protects against calcium-mediated death of differentiated rat pheochromocytoma cells. Life Sciences, 1994, 55, PL313-PL319.	4.3	23
675	Mitochondria from Alzheimer's fibroblasts show decreased uptake of calcium and increased sensitivity to free radicals. Life Sciences, 1994, 54, 1855-1860.	4.3	64

#	Article	IF	CITATIONS
676	Alzheimer brain proteins investigated by two-dimensional gel electrophoresis with immobilized pH gradients in the first dimension. Electrophoresis, 1994, 15, 721-725.	2.4	9
677	A quick silver method for senile plaques and neurofibrillary tangles in paraffin sections. Brain Research Bulletin, 1994, 35, 279-284.	3.0	5
678	Receptor-mediated activation of G proteins is reduced in postmortem brains from Alzheimer's disease patients. Neuroscience Letters, 1994, 173, 37-39.	2.1	52
679	Dissociations Among Structural-Perceptual, Lexical-Semantic, and Event-Fact Memory Systems in Alzheimer, Amnesic, and Normal Subjects. Cortex, 1994, 30, 75-103.	2.4	176
680	Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. Molecular Brain Research, 1994, 24, 336-340.	2.3	195
681	Increased accumulation of cAMP in cerebral microvessels in Alzheimer's disease. Neurobiology of Aging, 1994, 15, 113-116.	3.1	38
682	Cortical cholinergic markers in schizophrenia. Schizophrenia Research, 1994, 12, 137-144.	2.0	69
683	Neurofibrillary tangles without cell loss in the lateral vestibular nucleus of patients with Alzheimer's disease. Neuroscience Letters, 1994, 177, 11-14.	2.1	6
684	Lewy bodies in the brain of two members of a family with the 717 (Val to Ile) mutation of the amyloid precursor protein gene. Neuroscience Letters, 1994, 172, 77-79.	2.1	58
685	Abnormally phosphorylated tau protein in Alzheimer's disease: Heterogeneity of individual regional distribution and relationship to clinical severity. Neuroscience, 1994, 63, 499-516.	2.3	86
686	Analysis of magnetic resonance spectra by mole percent: Comparison to absolute units. Neurobiology of Aging, 1994, 15, 133-140.	3.1	76
687	Association of education with incidence of cognitive impairment in three established populations for epidemiologic studies of the elderly. Journal of Clinical Epidemiology, 1994, 47, 363-374.	5.0	137
688	Apolipoprotein-E Îμ-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease. Neuroscience Letters, 1994, 182, 63-65.	2.1	45
689	Regional Brain Activity of Free Radical Defense Enzymes in Autopsy Samples from Patients with Alzheimer's Disease and from Nondemented Controls. International Journal of Neuroscience, 1994, 75, 83-90.	1.6	58
690	Levels of explanation – symptoms, neuropsychological deficit and morphological abnormalities in schizophrenia. Psychological Medicine, 1994, 24, 541-545.	4.5	39
691	Demonstration of Senile Plaques and Neurofibrillary Tangles in Alzheimer's Disease with Uranyl and Silver Nitrates. Journal of Histotechnology, 1994, 17, 353-356.	0.5	1
692	Perceptual organization in Alzheimer's disease Psychology and Aging, 1994, 9, 562-567.	1.6	25
693	Agreement in the Clinical Diagnosis of Dementia: Evaluation of a Case Series with Mild Cognitive Impairment. Neuroepidemiology, 1994, 13, 89-96.	2.3	10

	CITATION R	EPORT	
# 694	ARTICLE Electron transport chain defects in Alzheimer's disease brain. Neurology, 1994, 44, 1090-1090.	IF 1.1	CITATIONS
094	Lieuton transport chain delects in Alzheimer's disease brain. Neurology, 1994, 44, 1090 1090.	1.1	773
695	Emerging drugs for alzheimer's disease: Mechanisms of Action and Prospects for Cognitive Enhancing Medications. Medical Clinics of North America, 1994, 78, 911-934.	2.5	28
696	Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 9382-9386.	7.1	165
697	Aluminum modifies the properties of Alzheimer's disease PHF tau proteins in vivo and in vitro. Journal of Neuroscience, 1994, 14, 7221-7233.	3.6	124
698	Magnetic Resonance Imaging of Neurodegenerative Diseases. Journal of Neuroimaging, 1994, 4, 146-158.	2.0	16
699	Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 8378-8382.	7.1	421
700	Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. NeuroReport, 1995, 6, 1063-1066.	1.2	206
701	Apolipoprotein E and Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 4725-4727.	7.1	498
702	The Natural History of Alzheimer's Disease: A Brain Bank Study. Journal of the American Geriatrics Society, 1995, 43, 1248-1255.	2.6	100
703	Altered serotonin transporter sites in Alzheimer's disease raphe and hippocampus. NeuroReport, 1995, 6, 1207-1210.	1.2	71
704	SPECT in Dementia: Clinical and Pathological Correlation. Journal of the American Geriatrics Society, 1995, 43, 1243-1247.	2.6	100
705	Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction. Neurology, 1995, 45, 649-658.	1.1	150
706	The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive) Tj ETQq0 0 0 rgB	T /Qverloc 7.6	k 10 Tf 50 26 298
707	Alzheimer's disease in the NAS–NRC Registry of ageing twin veterans, IV. Performance characteristics of a two-stage telephone screening procedure for Alzheimer's dementia. Psychological Medicine, 1995, 25, 1211-1219.	4.5	152
708	Death Certificate Reporting of Dementia and Mortality in an Alzheimer's Disease Research Center Cohort. Journal of the American Geriatrics Society, 1995, 43, 890-893.	2.6	48
709	Impact of Alzheimer's-type dementia and information source on the assessment of depression Psychological Assessment, 1995, 7, 42-48.	1.5	27
710	Relative Roles of Plaques and Tangles in the Dementia of Alzheimer's Disease: Correlations Using Three Sets of Neuropathological Criteria. Dementia and Geriatric Cognitive Disorders, 1995, 6, 21-31.	1.5	156
711	Neuropathological Diagnoses in Elderly Patients in Oslo: Alzheimers Disease, Lewy Body Disease, Vascular Lesions. Dementia and Geriatric Cognitive Disorders, 1995, 6, 162-168.	1.5	42

#	Article	IF	CITATIONS
712	Neuropathological Analysis of Dementia in a Japanese Leprosarium. Dementia and Geriatric Cognitive Disorders, 1995, 6, 157-161.	1.5	10
713	La diagnostica neuroradiologica TC nelle demenze. The Neuroradiology Journal, 1995, 8, 535-556.	0.1	0
714	Multiscale detection and analysis of the senile plaques of Alzheimer's disease. IEEE Transactions on Biomedical Engineering, 1995, 42, 1218-1224.	4.2	9
715	Morphometrical comparison of neurofibrillary tangles and senile plaques in Alzheimer's disease and the senile dementia of Alzheimer type. Neuropathology, 1995, 15, 21-26.	1.2	6
716	Simple cerebral atrophy of non-Alzheimer type: A comprehensive category for non-specific cortical degeneration. Neuropathology, 1995, 15, 27-42.	1.2	2
717	SSCP analysis and sequencing of the human prion protein gene (PRNP) detects two different 24 bp deletions in an atypical Alzheimer's disease family. American Journal of Medical Genetics Part A, 1995, 60, 12-18.	2.4	19
718	Damage to dopamine systems differs between parkinson's disease and alzheimer's disease with parkinsonism. Annals of Neurology, 1995, 37, 300-312.	5.3	126
719	Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Annals of Neurology, 1995, 38, 6-14.	5.3	254
720	Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy. Annals of Neurology, 1995, 38, 254-259.	5.3	488
721	Amyloid ?-proteins 1?40 and 1?42(43) in the soluble fraction of extra- and intracranial blood vessels. Annals of Neurology, 1995, 38, 421-428.	5.3	119
722	Reduction of βâ€∎myloid peptide <sub>42</sub> in the cerebrospinal fluid of patients with Alzheimer's disease. Annals of Neurology, 1995, 38, 643-648.	5.3	673
723	Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease. Annals of Neurology, 1995, 38, 649-652.	5.3	293
724	The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. Annals of Neurology, 1995, 38, 653-658.	5.3	40
725	Differential expression of exons 10 and 11 in normal tau and tau associated with paired helical filaments. Journal of Neuroscience Research, 1995, 41, 583-593.	2.9	24
726	Infrared spectra of human central nervous system tissue: Diagnosis of alzheimer's disease by multivariate analyses. Biospectroscopy, 1995, 1, 141-148.	0.6	67
727	An english translation of alzheimer's 1907 paper, "über eine eigenartige erkankung der hirnrinde― Clinical Anatomy, 1995, 8, 429-431.	2.7	973
728	Autopsy services for old age psychiatrists in england and wales: Can neuropathologists help?. International Journal of Geriatric Psychiatry, 1995, 10, 179-183.	2.7	1
729	Autopsy diagnoses of Alzheimer disease: Independent reviews and clinical implications. International Journal of Geriatric Psychiatry, 1995, 10, 505-510.	2.7	4

#	Article	IF	CITATIONS
730	Non-cognitive psychiatric symptoms in vascular and Alzheimer brain disease. International Journal of Geriatric Psychiatry, 1995, 10, 695-701.	2.7	0
731	AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal formation of patients with Alzheimer's disease. Hippocampus, 1995, 5, 469-486.	1.9	44
732	Dendritic reorganisation in the basal forebrain under degenerative conditions and its defects in Alzheimer's disease. II. Ageing, Korsakoff's disease, Parkinson's disease, and Alzheimer's disease. Journal of Comparative Neurology, 1995, 351, 189-222.	1.6	92
733	Dendritic reorganisation in the basal forebrain under degenerative conditions and its defects in Alzheimer's disease. III. The basal forebrain compared with other subcortical areas. Journal of Comparative Neurology, 1995, 351, 223-246.	1.6	66
734	cAMP-dependent protein kinase in cerebral microvessels in aging and Alzheimer disease. Molecular and Chemical Neuropathology, 1995, 26, 247-258.	1.0	23
735	Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease. Molecular and Chemical Neuropathology, 1995, 24, 69-91.	1.0	56
736	Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathologica, 1995, 91, 6-14.	7.7	175
737	Neural membrane phospholipids in alzheimer disease. Neurochemical Research, 1995, 20, 1329-1333.	3.3	155
738	Alzheimer-type pathology in melanin-bleached sections of substantia nigra. Journal of Neurology, 1995, 242, 485-489.	3.6	22
739	Selective localization of gelatinase A, an enzyme degrading ?-amyloid protein, in white matter microglia and in Schwann cells. Acta Neuropathologica, 1995, 89, 199-203.	7.7	44
740	Alzheimer's disease-type neurofibrillary degeneration in verrucose dysplasias of the cerebral cortex. Acta Neuropathologica, 1995, 90, 356-365.	7.7	8
741	Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathologica, 1995, 89, 35-41.	7.7	424
742	Alzheimer's changes in non-demented and demented patients: a statistical approach to their relationships. Acta Neuropathologica, 1995, 89, 57-62.	7.7	29
743	Alzheimer's changes in non-demented and demented patients. Acta Neuropathologica, 1995, 89, 112-113.	7.7	14
744	Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: differentiation from progressive supranuclear palsy. Acta Neuropathologica, 1995, 90, 37-43.	7.7	96
745	White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues. Acta Neuropathologica, 1995, 90, 421-424.	7.7	78
746	A lysosomal marker for activated microglial cells involved in Alzheimer classic senile plaques. Acta Neuropathologica, 1995, 90, 493-503.	7.7	30
747	Lack of topographical relationship between sites of aluminum deposition and senile plaques in the Alzheimer's disease brain. Acta Neuropathologica, 1995, 90, 526-531.	7.7	16

#	Article	IF	CITATIONS
748	The topographic distribution of brain atrophy in cortical Lewy body disease: comparison with Alzheimer's disease. Acta Neuropathologica, 1995, 89, 178-183.	7.7	24
749	Apolipoprotein E genotype and neuropathological phenotype in two members of a German family with chromosome 14-linked early onset Alzheimer's disease. Acta Neuropathologica, 1995, 90, 257-265.	7.7	22
750	Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients. Acta Neuropathologica, 1995, 89, 544-551.	7.7	204
751	A4POE*4-associated Alzheimer's disease risk is modified by α1–antichymotrypsin polymorphism. Nature Genetics, 1995, 10, 486-488.	21.4	347
752	Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nature Genetics, 1995, 11, 207-209.	21.4	169
753	Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature, 1995, 378, 284-287.	27.8	222
754	Hypomethylation of the amyloid precursor protein gene in the brain of an alzheimer's disease patient. Journal of Molecular Neuroscience, 1995, 6, 141-146.	2.3	186
755	Characterization of the association of phospholipase C-δ with Alzheimer neurofibrillary tangles. Brain Research, 1995, 669, 217-224.	2.2	20
756	Increased number of NADPH-d-positive neurons within the substantia innominata in Alzheimer's disease. Brain Research, 1995, 670, 351-355.	2.2	45
757	Human neurons that constitutively secrete Al² do not induce Alzheimer's disease pathology following transplantation and long-term survival in the rodent brain. Brain Research, 1995, 671, 333-337.	2.2	22
758	Peptidergic neurons of subcortical white matter in aging and Alzheimer's brain. Brain Research, 1995, 674, 329-335.	2.2	27
759	Glucocorticoid receptor mRNA in Alzheimer's diseased hippocampus. Brain Research, 1995, 679, 72-81.	2.2	32
760	Quantitation of Alzheimer's amyloid peptide and identification of related amyloid proteins by dot-blot immunoassay. Brain Research, 1995, 685, 154-162.	2.2	22
761	Binding of Alz 50 depends on Phe8 in tau synthetic peptides and varies between native and denatured tau proteins. Brain Research, 1995, 697, 63-75.	2.2	19
762	Amyloid β-protein ending at Thr43 is a minor component of some diffuse plaques in the Alzheimer's disease brain, but is not found in cerebrovascular amyloid. Brain Research, 1995, 702, 275-278.	2.2	29
763	Episodic memory function in advanced aging and early Alzheimer's disease. Journal of the International Neuropsychological Society, 1995, 1, 100-103.	1.8	21
764	Apolipoprotein E genotype in diverse neurodegenerative disorders. Annals of Neurology, 1995, 38, 131-135.	5.3	79
765	Amyloid, aluminium and the aetiology of Alzheimer's disease. Medical Journal of Australia, 1995, 163, 256-259.	1.7	29

#	Article	IF	CITATIONS
766	Molecular Genetic Advances in Neurodegenerative Disorders. Clinics in Laboratory Medicine, 1995, 15, 915-926.	1.4	2
767	Cumulative Risk of Alzheimer-Like Dementia in Relatives of Autopsy-Confirmed Cases of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1995, 6, 355-356.	1.5	1
768	Vigabatrin edema. Neurology, 1995, 45, 2115-2116.	1.1	1
769	Genes and Recent Developments in the Epidemiology of Alzheimer's Disease and Related Dementia. Epidemiologic Reviews, 1995, 17, 39-47.	3.5	19
770	Alzheimers Disease: Distribution of Changes in Intraneuronal Lipopigment in the Frontal Cortex. Dementia and Geriatric Cognitive Disorders, 1995, 6, 334-342.	1.5	3
771	Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. Journal of Neuroscience, 1995, 15, 6213-6221.	3.6	270
772	Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 280-283.	1.9	81
773	Comparison of New and Traditional Methods for Detection of Senile Plaques in Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 1995, 8, 125-131.	2.3	4
774	Vision in Alzheimer's Disease. Gerontologist, The, 1995, 35, 370-376.	3.9	92
775	Immunohistochemical analysis of COOH-termini of amyloid beta protein (AÎ <sup>2</sup> ) using end-specific antisera for AÎ <sup>2</sup> 40 and AÎ <sup>2</sup> 42 in Alzheimer's disease and normal aging. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1995, 2, 7-16.	3.0	24
776	Rate of Progression of Alzheimer's Disease Is Associated With Genetic Risk. Archives of Neurology, 1995, 52, 918-923.	4.5	26
777	Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology, 1995, 45, 1323-1328.	1.1	165
778	Age-Related Distribution of Neuropathologic Changes in the Cerebral Cortex of Patients With Down's Syndrome. Archives of Neurology, 1995, 52, 379.	4.5	226
779	Cerebral Infarction in Alzheimer's Disease Is Associated With Severe Amyloid Angiopathy and Hypertension. Archives of Neurology, 1995, 52, 702-708.	4.5	222
780	Study of Alzheimer's Dementia Patients with Parkinsonian Features. Journal of Geriatric Psychiatry and Neurology, 1995, 8, 154-158.	2.3	23
781	Slowly progressive apraxia in Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 312-315.	1.9	43
782	Head injury as a risk factor in Alzheimer's disease. Brain Injury, 1995, 9, 213-219.	1.2	138
783	Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. American Journal of Psychiatry, 1995, 152, 738-748.	7.2	296

#	Article	IF	CITATIONS
784	Chronic whiplash syndrome. Neurology, 1995, 45, 2116-2117.	1.1	0
785	Regional Distribution of Neurofibrillary Tangles and Senile Plaques in the Cerebral Cortex of Very Old Patients. Archives of Neurology, 1995, 52, 1150-1159.	4.5	67
786	Ubiquitin-positive CA2/3 neurites in hippocampus coexist with cortical Lewy bodies. Neurology, 1995, 45, 1768-1770.	1.1	46
787	Longitudinal Volumetric Computed Tomographic Analysis of Regional Brain Changes in Normal Aging and Alzheimer's Disease. Archives of Neurology, 1995, 52, 392-402.	4.5	73
788	Alzheimer's Disease in the National Academy of Sciences—National Research Council Registry of Aging Twin Veterans. Archives of Neurology, 1995, 52, 763.	4.5	171
789	Nonsteroidal antiâ€inflammatory drugs in Alzheimer's disease. Neurology, 1995, 45, 2116-2116.	1.1	4
790	Alzheimer's disease with and without coexisting Parkinson's disease changes. Neurology, 1995, 45, 1985-1990.	1.1	65
791	Spastic tetraplegia as an initial manifestation of familial Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry, 1995, 59, 395-399.	1.9	6
792	The noncognitive features of dementia. Reviews in Clinical Gerontology, 1995, 5, 57-75.	0.5	39
793	Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron, 1995, 14, 457-466.	8.1	554
794	Altered G-protein coupling of a frontal cortical low affinity [3H]8-hydroxy-N,N-dipropyl-2-aminotetralin serotonergic binding site in Alzheimer's disease. Behavioural Brain Research, 1995, 73, 325-329.	2.2	10
795	Calbindin D28k mRNA in hippocampus, superior temporal gyrus and cerebellum: comparison between control and Alzheimer disease subjects. Molecular Brain Research, 1995, 30, 362-366.	2.3	25
796	Increased levels of statin, a marker of cell cycle arrest, in response to hippocampal neuronal injury. Molecular Brain Research, 1995, 34, 57-64.	2.3	2
797	Cortical mapping of Alzheimer pathology in brains of aged non-demented subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1995, 19, 1035-1047.	4.8	23
798	Galanin receptor binding sites in the temporal and occipital cortex are minimally affected in Alzheimer's disease. Neuroscience Letters, 1995, 192, 37-40.	2.1	17
799	Decreased protein synthetic activity of the hypothalamic tuberomamillary nucleus in Alzheimer's disease as suggested by smaller Golgi apparatus. Neuroscience Letters, 1995, 193, 29-32.	2.1	32
800	Dementia: Diagnosis and emergency behavioral complications. Journal of Emergency Medicine, 1995, 13, 519-525.	0.7	22
801	Autoimmune alterations in choroid plexus basement membrane of some patients with Alzheimer's disease. Human Pathology, 1995, 26, 1168-1169.	2.0	О

#	Article	IF	CITATIONS
802	Localisation and association of pathomorphological changes at the brainstem in Alzheimer's disease. Mechanisms of Ageing and Development, 1995, 84, 209-226.	4.6	10
803	The Pharmacotherapy of Alzheimer's Disease Based on the Cholinergic Hypothesis: an Update. Experimental Neurology, 1995, 4, 349-356.	1.7	96
804	On the metabolism of apolipoprotein E and the Alzheimer diseases. Experimental Neurology, 1995, 132, 149-156.	4.1	53
805	Apolipoprotein E immunoreactivity within neurofibrillary tangles: relationship to tau and PHF in Alzheimer's disease. Experimental Neurology, 1995, 132, 162-171.	4.1	48
806	Amyloid beta protein (25-35) stimulation of phospholipases A, C and D activities of LA-N-2 cells. FEBS Letters, 1995, 365, 125-128.	2.8	35
807	Analysis of the core components of Alzheimer paired helical filaments A gas chromatography/mass spectrometry characterization of fatty acids, carbohydrates and long-chain bases. FEBS Letters, 1995, 366, 81-85.	2.8	23
808	Alterations in hippocampal mossy fiber pathway in Schizophrenia and Alzheimer' s disease. Biological Psychiatry, 1995, 37, 122-126.	1.3	43
809	Lack of association between clinical symptoms and postmortem indices of brain serotonin function in Alzheimer's disease. Biological Psychiatry, 1995, 37, 895-896.	1.3	8
810	Does vitamin E prevent tardive dyskinesia?. Biological Psychiatry, 1995, 37, 896-897.	1.3	2
811	Concurrence of Alzheimer's disease, Parkinson's disease, diffuse Lewy body disease, and amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 1995, 128, 219-224.	0.6	31
812	Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. Journal of the Neurological Sciences, 1995, 131, 162-169.	0.6	205
813	The role of transition metals in the pathogenesis of Parkinson's disease. Journal of the Neurological Sciences, 1995, 134, 69-78.	0.6	134
814	Dualâ€Task Paradigm: A Means To Examine the Central Executive. Annals of the New York Academy of Sciences, 1995, 769, 161-172.	3.8	136
815	Apolipoprotein E genotype, Alzheimer's pathologies and related gene expression in the aged population. Molecular Brain Research, 1995, 29, 92-98.	2.3	47
816	Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiology of Aging, 1995, 16, 285-298.	3.1	391
817	Staging of alzheimer's disease-related neurofibrillary changes. Neurobiology of Aging, 1995, 16, 271-278.	3.1	1,943
818	Cerebral microvessels in Alzheimer's have reduced protein kinase C activity. Neurobiology of Aging, 1995, 16, 563-569.	3.1	26
819	Chrysamine-G binding to Alzheimer and control brain: Autopsy study of a new amyloid probe. Neurobiology of Aging, 1995, 16, 541-548.	3.1	127

#	Article	IF	CITATIONS
820	†Lewy body disease': clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. Clinical Neurology and Neurosurgery, 1995, 97, 13-22.	1.4	75
821	Neocortical Neurofibrillary Tangles Correlate With Dementia Severity in Alzheimer's Disease. Archives of Neurology, 1995, 52, 81-88.	4.5	456
822	Clinical Validity of the Mattis Dementia Rating Scale in Detecting Dementia of the Alzheimer Type. Archives of Neurology, 1995, 52, 899.	4.5	168
823	Carnitine and Acetyl-L-Carnitine Content of Human Hippocampus and Erythrocytes in Alzheimer's Disease. Journal of Nutritional and Environmental Medicine, 1995, 5, 35-39.	0.1	1
824	Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology, 1995, 45, 1594-1601.	1.1	597
825	Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience, 1995, 64, 209-217.	2.3	213
826	Struggling over Subjectivity: Debates about the "Self" and Alzheimer's Disease. Medical Anthropology Quarterly, 1995, 9, 146-164.	1.4	157
827	Increased immunostaining for l-ornithine decarboxylase occurs in neocortical neurons of Alzheimer's disease patients. Neuroscience Letters, 1995, 186, 123-126.	2.1	40
828	Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience, 1995, 66, 583-587.	2.3	163
829	Increased expression and subcellular translocation of the mitogen activated protein kinase kinase and mitogen-activated protein kinase in Alzheimer's disease. Neuroscience, 1995, 68, 5-18.	2.3	118
830	Functional Connectivity in Auditory–Verbal Short-Term Memory in Alzheimer's Disease. NeuroImage, 1996, 4, 67-77.	4.2	42
831	THE CLINICAL EPIDEMIOLOGY OF ALZHEIMER'S DISEASE. Neurologic Clinics, 1996, 14, 337-351.	1.8	38
832	APOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASE. Annual Review of Medicine, 1996, 47, 387-400.	12.2	604
833	Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. Journal of the Neurological Sciences, 1996, 143, 137-142.	0.6	500
834	In situ characterization of beta-amyloid in Alzheimer's diseased tissue by synchrotron Fourier transform infrared microspectroscopy. Biophysical Journal, 1996, 71, 1672-1679.	0.5	222
835	Carboxy terminal of β-amyloid deposits in aged human, canine, and polar bear brains. Neurobiology of Aging, 1996, 17, 249-257.	3.1	64
836	Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiology of Aging, 1996, 17, 377-384.	3.1	301
837	Neurofibrillary tangle-associated alteration of stathmin in Alzheimer's disease. Neurobiology of Aging, 1996, 17, 331-341.	3.1	33

#	Article	IF	CITATIONS
838	Neuropathology in controls and demented subjects from the Baltimore longitudinal study of aging. Neurobiology of Aging, 1996, 17, 365-371.	3.1	136
839	Quantitative 1H and 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiology of Aging, 1996, 17, 349-357.	3.1	81
840	Eyeblink classical conditioning in Alzheimer's disease and cerebrovascular dementia. Neurobiology of Aging, 1996, 17, 505-512.	3.1	61
841	Interleukin-6-associated inflammatory processes in Alzheimer's disease: New therapeutic options. Neurobiology of Aging, 1996, 17, 795-800.	3.1	87
842	Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients. Journal of the Neurological Sciences, 1996, 138, 97-104.	0.6	45
843	Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biological Psychiatry, 1996, 39, 82-91.	1.3	89
844	A case of REM sleep behavior disorder with autopsy-confirmed alzheimer's disease: postmortem brain stem histochemical analyses. Biological Psychiatry, 1996, 40, 422-425.	1.3	71
845	Apolipoprotein E, Plaques, Tangles and Cholinergic Dysfunction in Alzheimer's Diseasea. Annals of the New York Academy of Sciences, 1996, 777, 166-174.	3.8	82
846	High Affinity Choline Transporter Status in Alzheimer's Disease Tissue from Rapid Autopsya. Annals of the New York Academy of Sciences, 1996, 777, 197-204.	3.8	36
847	Point Substitution in the Central Hydrophobic Cluster of a Human β-Amyloid Congener Disrupts Peptide Folding and Abolishes Plaque Competenceâ€. Biochemistry, 1996, 35, 13914-13921.	2.5	188
849	The participation of interleukin-6, a stress-inducible cytokine, in the pathogenesis of Alzheimer's disease. Behavioural Brain Research, 1996, 78, 37-41.	2.2	111
850	The primate temporal pole: its putative role in object recognition and memory. Behavioural Brain Research, 1996, 77, 53-77.	2.2	105
851	Gap-43 message levels in anterior cerebellum in Alzheimer's disease. Molecular Brain Research, 1996, 36, 145-151.	2.3	8
852	Alzheimer's disease and the eye. Ophthalmic and Physiological Optics, 1996, 16, S2-S8.	2.0	23
853	Magnetic resonance imaging of Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1996, 20, 597-626.	4.8	20
854	Distribution of isoforms of the microtubule-associated protein tau in grey and white matter areas of human brain: A two-dimensional gelelectrophoretic analysis. FEBS Letters, 1996, 379, 222-226.	2.8	39
855	Manganese and Copper-Zinc Superoxide Dismutases in the Human Olfactory Mucosa: Increased Immunoreactivity in Alzheimer's Disease. Experimental Neurology, 1996, 140, 115-125.	4.1	22
856	Amyloid Load and Neural Elements in Alzheimer's Disease and Nondemented Individuals with High Amyloid Plaque Density. Experimental Neurology, 1996, 142, 89-102.	4.1	37

#	Article	IF	CITATIONS
857	Cytosolic Phospholipase A2(cPLA2) Immunoreactivity Is Elevated in Alzheimer's Disease Brain. Neurobiology of Disease, 1996, 3, 51-63.	4.4	206
858	Association of Aβ40-positive Senile Plaques with Microglial Cells in the Brains of Patients with Alzheimer's Disease and in Non-demented Aged Individuals. Experimental Neurology, 1996, 5, 13-17.	1.7	59
859	Improved Selectivity and Sensitivity in the Visualization of Neurofibrillary Tangles, Plaques and Neuropil Threads. Experimental Neurology, 1996, 5, 177-187.	1.7	19
860	Neuropsychological Deficits Associated with Diffuse Lewy Body Disease. Brain and Cognition, 1996, 31, 148-165.	1.8	169
861	Clinical and Neuropathological Findings in Lewy Body Dementias. Brain and Cognition, 1996, 31, 166-175.	1.8	157
862	Alteration in Brain Presenilin 1 mRNA Expression in Early Onset Familial Alzheimer's Disease. Experimental Neurology, 1996, 5, 213-218.	1.7	12
863	Quantification of Alzheimer-Type Neurofibrillary Lesions by Automated Image Analysis. Experimental Neurology, 1996, 5, 251-258.	1.7	5
864	Comparative Investigation of Neurofibrillary Damage in the Temporal Lobe in Alzheimer's Disease, Down's Syndrome and Dementia Pugilistica. Experimental Neurology, 1996, 5, 259-264.	1.7	22
865	Structural Correlates of Cognition in Dementia: Quantification and Assessment of Synapse Change. Experimental Neurology, 1996, 5, 417-421.	1.7	345
866	APOE Îμ4 allele in Alzheimer's and non-Alzheimer's dementias. Lancet, The, 1996, 348, 960-961.	13.7	10
867	Neurofibrillary pathology — correlation with hippocampal formation atrophy in Alzheimer disease. Neurobiology of Aging, 1996, 17, 909-919.	3.1	116
868	Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex. Molecular Brain Research, 1996, 42, 175-178.	2.3	95
869	The significance of the activity of CSF cholinesterases in dementias. Medical Hypotheses, 1996, 47, 363-376.	1.5	15
870	Evolution of the neuropathology of Alzheimer's disease. Acta Neurologica Scandinavica, 1996, 94, 3-12.	2.1	573
871	Diagnosis of Alzheimer's disease: defining genetic profiles (genotype vs phenotype). Acta Neurologica Scandinavica, 1996, 94, 72-84.	2.1	18
872	Correlative Memory Deficits, Al² Elevation, and Amyloid Plaques in Transgenic Mice. Science, 1996, 274, 99-103.	12.6	4,040
873	Posterior cortical atrophy: Unusual feature of alzheimer's disease. Neurocase, 1996, 2, 495-501.	0.6	24
874	Platelets from patients with Alzheimer's disease or other dementias exhibit disease-specific and apolipoprotein E correlatable defects. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1996, 3, 13-19	3.0	7

#	Article	IF	CITATIONS
875	The clinical diagnosis and misdiagnosis of Lewy body dementia. , 1996, , 9-20.		2
876	Clinical features of patients with Alzheimer's disease and Lewy bodies. , 1996, , 46-56.		3
877	Dementia with Lewy bodies: relationships to Parkinson's and Alzheimer's diseases. , 1996, , 268-286.		13
878	Tautological tangles in neuropathologic criteria for dementias associated with Lewy bodies. , 1996, , 204-211.		9
879	Cytoskeletal and Alzheimer-type pathology in Lewy body disease. , 1996, , 224-237.		8
880	Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease. Clinical Chemistry, 1996, 42, 298-302.	3.2	34
882	The Use of Multivariate Methods in the Identification of Subtypes of Alzheimer's Disease: A Comparison of Principal Components and Cluster Analysis. Dementia and Geriatric Cognitive Disorders, 1996, 7, 215-220.	1.5	4
883	Hippocampal Pathology Reflects Memory Deficit and Brain Imaging Measurements in Alzheimers Disease: Clinicopathologic Correlations Using Three Sets of Pathologic Diagnostic Criteria. Dementia and Geriatric Cognitive Disorders, 1996, 7, 76-81.	1.5	53
884	Contingent Vulnerability of Entorhinal Parvalbumin-Containing Neurons in Alzheimer's Disease. Journal of Neuroscience, 1996, 16, 3311-3321.	3.6	79
885	Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-l² Peptide (1–40). Journal of Neuroscience, 1996, 16, 7910-7919.	3.6	345
886	Depletion of Choline Acetyltransferase Activity but Preservation of Ml and M2 Muscarinic Receptor Binding Sites in Temporal Cortex following Head Injury: A Preliminary Human Postmortem Study. Journal of Neurotrauma, 1996, 13, 181-187.	3.4	67
887	Correlation of Astrocytic S100β Expression with Dystrophic Neurites in Amyloid Plaques of Alzheimer's Disease. Journal of Neuropathology and Experimental Neurology, 1996, 55, 273-279.	1.7	202
888	Normal ageing, impaired cognitive functioning and senile dementia – a mixture distribution analysis. Psychological Medicine, 1996, 26, 785-790.	4.5	17
889	What can artificial neural networks teach us about neurodegenerative disorders with extrapyramidal features?. Brain, 1996, 119, 831-839.	7.6	11
890	The significance of cortical pathology in progressive supranuclear palsy: Clinico-pathological data in 10 cases. Brain, 1996, 119, 1123-1136.	7.6	116
891	Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease. NeuroReport, 1996, 8, 25-29.	1.2	101
893	Microwave Modification of the Methenamine Silver Technique for the Demonstration of Alzheimer-Type Pathology. Journal of Histotechnology, 1996, 19, 33-38.	0.5	6
894	Neuropathological Diagnosis of Dementia Using Silver Stains and Immunohistochemical Techniques. Journal of Histotechnology, 1996, 19, 235-240.	0.5	2

#	Article	IF	CITATIONS
895	Water-soluble Aβ(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains. Journal of Biological Chemistry, 1996, 271, 4077-4081.	3.4	547
896	Biological Markers for the Clinical Diagnosis of Alzheimer's Disease Tohoku Journal of Experimental Medicine, 1996, 179, 65-79.	1.2	22
897	The Neurobiology Of Alzheimer'S Disease. Acta Clinica Belgica, 1996, 51, 80-90.	1.2	7
898	Greater relative impairment of object recognition than of visuospatial abilities in Alzheimer's disease Neuropsychology, 1996, 10, 74-81.	1.3	65
899	Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer's Disease. Journal of Neuroscience, 1996, 16, 4491-4500.	3.6	1,570
900	Frequency of neuropathology in a brain bank from a long-term, domiciliary population. Journal of Psychiatric Research, 1996, 30, 45-49.	3.1	6
901	Endogenous Alzheimer's brain factor and oxidized glutathione inhibit antagonist binding to the muscarinic receptor. Brain Research, 1996, 714, 87-94.	2.2	21
902	Effects of freezing storage time on the density of muscarinic receptors in the human postmortem brain: an autoradiographic study in control and Alzheimer's disease brain tissues. Brain Research, 1996, 728, 65-71.	2.2	26
903	Immunocytochemistry of tau phosphoserine 413 and tau protein kinase I in Alzheimer pathology. Brain Research, 1996, 737, 119-132.	2.2	71
904	Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathologica, 1996, 91, 174-179.	7.7	98
905	Diagnostic accuracy of alzheimer's disease: A neuropathological study. Acta Neuropathologica, 1996, 91, 185-193.	7.7	105
906	Diagnostic accuracy of Alzheimer's disease: A clinicopathological study. Acta Neuropathologica, 1996, 91, 219-220.	7.7	63
907	Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer's disease. Acta Neuropathologica, 1996, 91, 226-235.	7.7	90
908	Clial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia. Acta Neuropathologica, 1996, 91, 269-277.	7.7	106
909	Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathologica, 1996, 91, 475-481.	7.7	116
910	Differential expression of intercellular adhesion molecule-1 (ICAM-1) in the A'-containing lesions in brains of patients with dementia of the Alzheimer type. Acta Neuropathologica, 1996, 91, 608-615.	7.7	36
911	Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathologica, 1996, 91, 633-641.	7.7	121
912	Inconstant apolipoprotein E (ApoE)-like immunoreactivity in amyloid β protein deposits: relationship with APOE genotype in aging brain and Alzheimer's disease. Acta Neuropathologica, 1996, 92, 180-185.	7.7	24

#	Article	IF	CITATIONS
913	Alzheimer-type pathology in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neuropathologica, 1996, 92, 312-318.	7.7	31
914	A novel mutation of presenilin 1 in familial Alzheimer's disease in Israel detected by denaturing gradient gel electrophoresis. Human Genetics, 1996, 98, 700-702.	3.8	23
915	Cholecystokinin peptides and receptor binding in Alzheimer's disease. Journal of Neural Transmission, 1996, 103, 851-860.	2.8	22
916	Cortical cathepsin D activity and immunolocalization in Alzheimer disease, critical coronary artery disease, and aging. Molecular and Chemical Neuropathology, 1996, 29, 1-14.	1.0	25
917	Oxidative posttranslational modifications in Alzheimer disease. Molecular and Chemical Neuropathology, 1996, 28, 41-48.	1.0	62
918	Inflammatory mechanisms in Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 1996, 246, 124-128.	3.2	48
919	Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia. European Archives of Psychiatry and Clinical Neuroscience, 1996, 246, 137-146.	3.2	120
920	Argyrophilic meshwork structures in the cerebral cortex of patients with progressive supranuclear palsy. Neuropathology, 1996, 16, 1-5.	1.2	7
921	Dementia of the Alzheimer type and related dementias in the aged: DAT subgroups and senile dementia of the neurofibrillary tangle type. Neuropathology, 1996, 16, 89-98.	1.2	46
922	Pathologic processes leading to cerebral hemorrhage in amyloid angiopathy. Neuropathology, 1996, 16, 99-105.	1.2	8
923	A Morphometric study of subcortical neurofibrillary tangles in Alzheimer's disease. Neuropathology, 1996, 16, 231-238.	1.2	3
924	Immunohistochemical examination of phosphorylated tau in granulovacuolar degeneration granules. Psychiatry and Clinical Neurosciences, 1996, 50, 137-140.	1.8	27
925	Pathological diagnosis of Alzheimerâ€ŧype dementia for oldâ€old and oldestâ€old patients. Pathology International, 1996, 46, 842-854.	1.3	22
926	Temporal Bone Findings in Alzheimer's Disease. Laryngoscope, 1996, 106, 1-5.	2.0	210
927	Brain Parenchymal and Microvascular Amyloid in Alzheimer's Disease. Brain Pathology, 1996, 6, 179-195.	4.1	166
928	Pupil response to tropicamide in Alzheimer's disease and other neurodegenerative disorders. Acta Neurologica Scandinavica, 1996, 94, 104-109.	2.1	37
929	Disappearance of actinâ€binding protein, drebrin, from hippocampal synapses in alzheimer's disease. Journal of Neuroscience Research, 1996, 43, 87-92.	2.9	188
930	Amyloid ?-peptide and the dementia of Parkinson's diease. Movement Disorders, 1996, 11, 647-653.	3.9	45

#	Article	IF	CITATIONS
931	Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease. Annals of Neurology, 1996, 39, 62-70.	5.3	380
932	Genetic studies in Alzheimer's disease with an NACP/?-synuclein polymorphism. Annals of Neurology, 1996, 40, 207-215.	5.3	117
933	LATE ONSET HUNTINGTON'S DISEASE AS A CAUSE OF DEMENTIA: WHERE SHOULD THE CLINICIAN'S INDEX OF SUSPICION LIE?. International Journal of Geriatric Psychiatry, 1996, 11, 729-733.	2.7	1
934	KEY PAPERS IN GERIATRIC PSYCHIATRY. SERIES EDITOR: ALISTAIR BURNS The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects. G. Blessed, B. Tomlinson and M. Roth,British Journal of Psychiatry (1968)114, 797-811 International Journal of Geriatric Psychiatry. 1996. 11, 1035-1040.	2.7	3
935	Severe cardiovascular disease and Alzheimer's disease: Senile plaque formation in cortical areas. Clinical Anatomy, 1996, 9, 118-127.	2.7	47
936	Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides. Chemistry and Biology, 1996, 3, 351-358.	6.0	75
937	Comparison of positron emission tomography, cognition, and brain volume in Alzheimer's disease with and without severe abnormalities of white matter Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 158-167.	1.9	68
938	Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 531-538.	1.9	52
939	Selective Loss of Cerebral Keratan Sulfate in Alzheimer's Disease. Journal of Biological Chemistry, 1996, 271, 16991-16994.	3.4	59
940	Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease Journal of Histochemistry and Cytochemistry, 1996, 44, 1421-1427.	2.5	72
941	Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Human Molecular Genetics, 1996, 5, 985-988.	2.9	259
943	Diffuse Vacuolization (Spongiosis) and Arteriolosclerosis in the Frontal White Matter Occurs in Vascular Dementia. Archives of Neurology, 1996, 53, 325-332.	4.5	100
944	Sex Differences in Human Brain Morphometry and Metabolism: An In Vivo Quantitative Magnetic Resonance Imaging and Positron Emission Tomography Study on the Effect of Aging. Archives of General Psychiatry, 1996, 53, 585.	12.3	477
945	Associations of Status and Change Measures of Neuropsychological Function With Pathologic Changes in Elderly, Originally Nondemented Subjects. Archives of Neurology, 1996, 53, 82-87.	4.5	25
946	Psychiatric Illnesses in the Elderly: A Review. Journal of Geriatric Psychiatry and Neurology, 1996, 9, 57-82.	2.3	21
947	Linguistic Ability in Early Life and Cognitive Function and Alzheimer's Disease in Late Life. JAMA - Journal of the American Medical Association, 1996, 275, 528.	7.4	596
948	Neuropathologic Diagnostic Outcomes From a Cohort of Outpatients With Suspected Dementia. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 1996, 51A, M313-M318.	3.6	25
949	Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry, 1996, 60, 452-454.	1.9	21

#	Article	IF	CITATIONS
950	Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1996, 3, 130-133.	3.0	7
951	The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry, 1996, 61, 352-356.	1.9	47
952	Stroke recovery. Neurology, 1996, 46, 1187-1187.	1.1	3
953	Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology, 1996, 47, 462-466.	1.1	236
954	Incorrect Diagnosis of Alzheimer's Disease. Archives of Neurology, 1996, 53, 35.	4.5	124
955	Intact implicit memory for novel patterns in Alzheimer's disease Learning and Memory, 1996, 3, 305-312.	1.3	24
956	Blood Glucose Monitoring in Gestational Diabetes Mellitus. New England Journal of Medicine, 1996, 334, 598-599.	27.0	4
957	Apolipoprotein E and the Neuropathology of Dementia. New England Journal of Medicine, 1996, 334, 599-600.	27.0	22
958	Maintenance Therapies for Reflux Esophagitis. New England Journal of Medicine, 1996, 334, 600-601.	27.0	4
959	Anticytomegalovirus T-Cell Clones. New England Journal of Medicine, 1996, 334, 601-601.	27.0	5
960	Chromosomal Translocations in Secondary Acute Myeloid Leukemia. New England Journal of Medicine, 1996, 334, 601-603.	27.0	15
961	Lichen Planus after Consumption of a Gold-Containing Liquor. New England Journal of Medicine, 1996, 334, 603-603.	27.0	23
962	Our Ailing Public Hospitals. New England Journal of Medicine, 1996, 334, 597-597.	27.0	2
963	Cerebral amyloid deposition and diffuse plaques in ``normal'' aging. Neurology, 1996, 46, 707-719.	1.1	595
964	Increased Concentrations of Presynaptic Proteins in the Cingulate Cortex of Subjects With Schizophrenia. Archives of General Psychiatry, 1997, 54, 559.	12.3	126
965	Molecular Neurobiology of Alzheimer's Disease (Syndrome?). Harvard Review of Psychiatry, 1997, 5, 177-213.	2.1	33
966	Criteria for Alzheimer's Disease and the Nosology of Dementia with Lewy Bodies. Neurology, 1997, 48, 126-132.	1.1	153
967	Brain Mercury in Neurodegenerative Disorders. Journal of Toxicology: Clinical Toxicology, 1997, 35, 49-54.	1.5	26

#	Article	IF	CITATIONS
968	Organotin compounds in trimethyltin-treated rats and in human brain in Alzheimer's Disease. Human and Experimental Toxicology, 1997, 16, 512-515.	2.2	7
969	Selective Cortical and Hippocampal Volume Correlates of Mattis Dementia Rating Scale in Alzheimer Disease. Archives of Neurology, 1997, 54, 719-728.	4.5	88
970	Autopsy-Proven Alzheimer Disease in a Patient With Dementia Who Retained Musical Skill in Life. Archives of Neurology, 1997, 54, 1448-1448.	4.5	15
971	Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. American Journal of Psychiatry, 1997, 154, 165-172.	7.2	310
972	Altered pupillary size and darkness and light reflexes in Alzheimer's disease Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 665-668.	1.9	88
973	The autonomic-related cortex: pathology in Alzheimer's disease. Cerebral Cortex, 1997, 7, 86-95.	2.9	79
974	Brain Infarction and the Clinical Expression of Alzheimer Disease <subtitle>The Nun Study</subtitle> . JAMA - Journal of the American Medical Association, 1997, 277, 813.	7.4	1,473
975	Complete Genomic Screen in Late-Onset Familial Alzheimer Disease. JAMA - Journal of the American Medical Association, 1997, 278, 1237.	7.4	200
976	Criterion-related validity of the geriatric depression scale in alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 489-499.	1.3	38
977	Dementia with Lewy bodies. Reviews in Clinical Gerontology, 1997, 7, 163-170.	0.5	5
978	A Neural Dissociation within Language: Evidence that the Mental Dictionary Is Part of Declarative Memory, and that Grammatical Rules Are Processed by the Procedural System. Journal of Cognitive Neuroscience, 1997, 9, 266-276.	2.3	830
979	Microscope field size and the neuropathologic criteria for Alzheimer's disease. Neurology, 1997, 49, 1175-1176.	1.1	15
980	Brachial plexus neuropathy after botulinum toxin injection. Neurology, 1997, 49, 1176-1177.	1.1	20
981	The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology, 1997, 49, 1570-1576.	1.1	183
982	Neuropathologic assessment of Alzheimer's disease. Neurology, 1997, 49, S14-6.	1.1	30
983	The impact of apolipoprotein E4 on cause of death in Alzheimer's disease. Neurology, 1997, 49, 76-81.	1.1	23
984	Midline cerebral morphometry distinguishes frontotemporal dementia and Alzheimer's disease. Neurology, 1997, 48, 978-984.	1.1	48
985	Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease. JAMA - Journal of the American Medical Association, 1997, 278, 1349.	7.4	3,321

#	Article	IF	CITATIONS
986	Postmortem Studies of the Hippocampal Formation in Schizophrenia. Schizophrenia Bulletin, 1997, 23, 385-402.	4.3	95
987	Neuropathology of Schizophrenia: Cortex, Thalamus, Basal Ganglia, and Neurotransmitter-specific Projection Systems. Schizophrenia Bulletin, 1997, 23, 403-421.	4.3	163
988	Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1997, 56, 1095-1097.	1.7	872
989	Age-related loss of calbindin from human basal forebrain cholinergic neurons. NeuroReport, 1997, 8, 2209-2213.	1.2	37
990	An CSF anomalous molecular form of acetylcholinesterase in demented and non-demented subjects. NeuroReport, 1997, 8, 3229-3232.	1.2	8
991	Reduction of Synaptophysin Immunoreactivity in the Prefrontal Cortex of Subjects With Schizophrenia. Archives of General Psychiatry, 1997, 54, 943.	12.3	268
992	The Etiologic Heterogeneity of Schizophrenia. Harvard Review of Psychiatry, 1997, 4, 317-327.	2.1	29
993	Familial nature and continuing morbidity of the amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam. Neurology, 1997, 49, 400-409.	1.1	70
994	Amyloid precursor protein processing and Aβ <sub>42</sub> deposition in a transgenic mouse model of Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 1550-1555.	7.1	616
995	Periventricular heterotopias display cortical degenerative neuropathology. Neurology, 1997, 49, 884-887.	1.1	8
996	Chapter VII Chemical neuroanatomy of the primate insula cortex: Relationship to cytoarchitectonics, connectivity, function and neurodegeneration. Handbook of Chemical Neuroanatomy, 1997, , 377-454.	0.3	8
997	Chapter VIII Primate cingulate cortex chemoarchitecture and its disruption in Alzheimer's disease. Handbook of Chemical Neuroanatomy, 1997, 13, 455-528.	0.3	20
998	Synthesis of alkylene linked bis-THA and alkylene linked benzyl-THA as highly potent and selective inhibitors and molecular probes of acetylcholinesterase. Journal of the Chemical Society Perkin Transactions 1, 1997, , 171-176.	0.9	24
999	Mapping Histology to Metabolism: Coregistration of Stained Whole-Brain Sections to Premortem PET in Alzheimer's Disease. NeuroImage, 1997, 5, 147-153.	4.2	137
1000	HORMONE REPLACEMENT THERAPY AND OTHER POTENTIAL TREATMENTS FOR DEMENTIAS. Endocrinology and Metabolism Clinics of North America, 1997, 26, 329-345.	3.2	23
1001	Herpes simplex virus and risk of Alzheimer's disease. Lancet, The, 1997, 349, 1101.	13.7	2
1002	Herpes simplex virus and risk of Alzheimer's disease. Lancet, The, 1997, 349, 1102.	13.7	58
1003	Counting plaques and tangles in Alzheimer's disease: Concordance of technicians and pathologists. Journal of the Neurological Sciences, 1997, 145, 141-146.	0.6	4

#	Article	IF	CITATIONS
1004	Alzheimer-type of pathological changes in Chinese. Journal of the Neurological Sciences, 1997, 145, 97-103.	0.6	7
1005	Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. Journal of the Neurological Sciences, 1997, 152, 73-83.	0.6	292
1006	Clinical Features of Early-Onset Alzheimer Disease in a Large Kindred With an E280A Presenilin-1 Mutation. JAMA - Journal of the American Medical Association, 1997, 277, 793.	7.4	209
1007	"Mixed Dementiaâ€: Adequate or Antiquated?: A Critical Review. American Journal of Geriatric Psychiatry, 1997, 5, 279-283.	1.2	18
1008	Isolation, Chemical Characterization, and Quantitation of Aβ 3-Pyroglutamyl Peptide from Neuritic Plaques and Vascular Amyloid Deposits. Biochemical and Biophysical Research Communications, 1997, 237, 188-191.	2.1	170
1009	Reduction in p140-TrkA Receptor Protein within the Nucleus Basalis and Cortex in Alzheimer's Disease. Experimental Neurology, 1997, 146, 91-103.	4.1	175
1010	The Expression of Creatine Kinase Isoenzymes in Neocortex of Patients with Neurodegenerative Disorders: Alzheimer's and Pick's Disease. Experimental Neurology, 1997, 146, 458-465.	4.1	71
1011	Apolipoprotein E, a Gene with Complex Biological Interactions in the Aging Brain. Neurobiology of Disease, 1997, 4, 170-185.	4.4	91
1012	Current Concepts in the Pathogenesis of Alzheimer's Disease. American Journal of Medicine, 1997, 103, 3S-10S.	1.5	199
1013	Discontinuous distribution of senile plaques within striate cortex hypercolumns in Alzheimer's disease. Vision Research, 1997, 37, 3573-3591.	1.4	14
1014	Cytochrome oxidase in Alzheimer's disease: Biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. Vision Research, 1997, 37, 3593-3608.	1.4	121
1015	Apolipoprotein E4 in schizophrenia: A study of one hundred sixteen cases with concomitant neuropathological examination. Biological Psychiatry, 1997, 42, 296-298.	1.3	16
1016	Cerebral cortex pathology in aging and Alzheimer's disease: a quantitative survey of large hospital-based geriatric and psychiatric cohorts. Brain Research Reviews, 1997, 25, 217-245.	9.0	163
1017	Decreased expression of nuclear and mitochondrial DNA-encoded genes of oxidative phosphorylation in association neocortex in Alzheimer disease. Molecular Brain Research, 1997, 44, 99-104.	2.3	84
1019	Neuropathological Staging of Alzheimer-Related Lesions: The Challenge of Establishing Relations to Age. Neurobiology of Aging, 1997, 18, 369-375.	3.1	12
1020	The Challenge of Characterizing Normal Brain Aging in Relation to Alzheimer's Disease. Neurobiology of Aging, 1997, 18, 388-389.	3.1	12
1021	Consensus Recommendations for the Postmortem Diagnosis of Alzheimer's Disease. Neurobiology of Aging, 1997, 18, S1-S2.	3.1	865
1022	The CERAD Neuropathology Protocol and Consensus Recommendations for the Postmortem Diagnosis of Alzheimer's Disease: A Commentary. Neurobiology of Aging, 1997, 18, S91-S94.	3.1	210

#	Article	IF	CITATIONS
1023	Research Uses of Neuropathological Data. Neurobiology of Aging, 1997, 18, S97-S98.	3.1	4
1024	Current Diagnostic Criteria for Assessment of Neuropathological Alzheimer's Disease. Neurobiology of Aging, 1997, 18, S95-S96.	3.1	1
1025	Comparison of Neuropathologic Criteria for the Diagnosis of Alzheimer's Disease. Neurobiology of Aging, 1997, 18, S99-S105.	3.1	88
1026	Neuropathological Criteria for the Diagnosis of Alzheimer's Disease. Neurobiology of Aging, 1997, 18, S13-S19.	3.1	70
1027	Neuropathological Diagnosis of Alzheimer's Disease: A Perspective from Longitudinal Clinicopathological Studies. Neurobiology of Aging, 1997, 18, S21-S26.	3.1	142
1028	The Neuropathological Diagnosis of Alzheimer's Disease: Clinical-Pathological Studies. Neurobiology of Aging, 1997, 18, S27-S32.	3.1	128
1029	Diagnosis and Staging of Alzheimer Disease. Neurobiology of Aging, 1997, 18, S33-S42.	3.1	54
1030	Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's disease: Current Status and Major Issues. Neurobiology of Aging, 1997, 18, S43-S50.	3.1	22
1031	Diagnostic Criteria for the Neuropathologic Assessment of Alzheimer's Disease. Neurobiology of Aging, 1997, 18, S53-S54.	3.1	11
1032	Proposals for Re-evaluation of Current Autopsy Criteria for the Diagnosis of Alzheimer's Disease. Neurobiology of Aging, 1997, 18, S55-S65.	3.1	21
1033	Diagnostic Criteria for Alzheimer's Disease. Neurobiology of Aging, 1997, 18, S67-S70.	3.1	36
1034	Position Paper on Diagnostic Criteria for Alzheimer Disease. Neurobiology of Aging, 1997, 18, S71-S73.	3.1	18
1035	Neuropathological Criteria for the Diagnosis of Alzheimer's Disease: Are We Really Ready Yet?. Neurobiology of Aging, 1997, 18, S3-S12.	3.1	23
1036	Strategies for Improving the Postmortem Neuropathological Diagnosis of Alzheimer's Disease. Neurobiology of Aging, 1997, 18, S75-S79.	3.1	34
1037	Elevated 4-Hydroxynonenal in Ventricular Fluid in Alzheimer's Disease. Neurobiology of Aging, 1997, 18, 457-461.	3.1	390
1038	GLUT-1 Expression in the Cerebra of Patients with Alzheimer's Disease. Neurobiology of Aging, 1997, 18, 469-474.	3.1	177
1039	Modeling the Relation Between Neurofibrillary Tangles and Intellectual Status. Neurobiology of Aging, 1997, 18, 267-273.	3.1	137
1040	Decrease in Adenylate Cyclase Activity Antecedes Neurofibrillary Tangle Formation. Neurobiology of Aging, 1997, 18, 275-279.	3.1	16

#	Article	IF	CITATIONS
1041	Further evidence for an association between a mutation in the APP gene and Lewy body formation. Neuroscience Letters, 1997, 227, 49-52.	2.1	27
1042	Indomethacin and nordihydroguaiaretic acid inhibition of amyloid β protein (25–35) activation of phospholipases A2 and D of LA-N-2 cells. Neuroscience Letters, 1997, 222, 5-8.	2.1	22
1043	Neuritic plaques in the Lewy body variant of Alzheimer disease lack paired helical filaments. Neuroscience Letters, 1997, 223, 73-76.	2.1	14
1044	Decreased expression of N-methyl-d-aspartate receptor 1 messenger RNA in select regions of Alzheimer brain. Neuroscience, 1997, 79, 973-982.	2.3	52
1045	Parvalbumin-immunoreactive neurons in the hippocampal formation of Alzheimer's diseased brain. Neuroscience, 1997, 80, 1113-1125.	2.3	105
1046	Non-plaque dystrophic dendrites in Alzheimer hippocampus: a new pathological structure revealed by glutamate receptor immunocytochemistry. Neuroscience, 1997, 82, 979-991.	2.3	46
1047	Plastic Neuronal Remodeling Is Impaired in Patients with Alzheimer's Disease Carrying Apolipoprotein ε4 Allele. Journal of Neuroscience, 1997, 17, 516-529.	3.6	314
1048	Apolipoprotein E and Neurofibrillary Tangles in Alzheimer's Disease. , 1997, 167, 119-122.		0
1049	Lewy bodies and progressive dementia: A critical review and meta-analysis. Journal of the International Neuropsychological Society, 1997, 3, 179-194.	1.8	42
1050	Subpial Amyloid Plaques in the Cerebellum in a Case of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1997, 8, 157-162.	1.5	3
1051	Concurrence of amyotrophic lateral sclerosis with limbic degeneration and Alzheimer's disease. Neuropathology, 1997, 17, 334-339.	1.2	6
1052	Identification of monocyte chemoattractant proteinâ€1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry and Clinical Neurosciences, 1997, 51, 135-138.	1.8	226
1053	The distribution of amyloid β protein deposition in the corpus striatum of patients with Alzheimer's disease. Neuropathology and Applied Neurobiology, 1997, 23, 322-325.	3.2	43
1054	Coronary Artery Disease, Hypertension, ApoE, and Cholesterol: A Link to Alzheimer's Disease?. Annals of the New York Academy of Sciences, 1997, 826, 128-146.	3.8	246
1055	Serum Protein Leakage in Alzheimer's Disease Revisited. Annals of the New York Academy of Sciences, 1997, 826, 173-189.	3.8	26
1056	Types of Cerebrovascular Lesions Associated with Severe Cerebral Amyloid Angiopathy in Alzheimer's Disease. Annals of the New York Academy of Sciences, 1997, 826, 493-497.	3.8	55
1057	Neuropathology of Suicide Annals of the New York Academy of Sciences, 1997, 836, 201-219.	3.8	16
1058	Increased Susceptibility of Alzheimer's Disease Temporal Cortex to Oxygen Free Radical-Mediated Processes. Free Radical Biology and Medicine, 1997, 23, 183-190.	2.9	84

#	Article	IF	CITATIONS
1059	Oxidative Stress Hypothesis in Alzheimer's Disease. Free Radical Biology and Medicine, 1997, 23, 134-147.	2.9	2,055
1060	Expression of presenilin-1 and -2 mRNAs in rat and Alzheimer's disease brains. Brain Research, 1997, 748, 122-130.	2.2	57
1061	Expression of activating transcription factor-2 (ATF-2), one of the cyclic AMP response element (CRE) binding proteins, in Alzheimer disease and non-neurological brain tissues. Brain Research, 1997, 749, 329-334.	2.2	40
1062	Heme from Alzheimer's brain inhibits muscarinic receptor binding via thiyl radical generation1An abstract of some of these findings was published in Mol. Biol. Cell, 7:S (1996) #3765.1. Brain Research, 1997, 764, 93-100.	2.2	33
1063	Paired helical filaments in corticobasal degeneration: the fine fibrillary structure with NanoVan. Brain Research, 1997, 773, 33-44.	2.2	23
1064	Association of cholinesterases with amyloid in extracellular neurofibrillary tangles. Brain Research, 1997, 769, 173-177.	2.2	4
1065	Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Research, 1997, 769, 385-390.	2.2	133
1066	Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Research, 1997, 769, 391-395.	2.2	182
1067	Cyclooxygenases and the Central Nervous System. Prostaglandins, 1997, 54, 601-624.	1.2	278
1068	Aging and Alzheimer's Disease: Lessons From the Nun Study. Gerontologist, The, 1997, 37, 150-156.	3.9	284
1069	Reduction of Synaptophysin Immunoreactivity in the Prefrontal Cortex of Subjects With Schizophrenia. Archives of General Psychiatry, 1997, 54, 660.	12.3	139
1070	Ultrastructural localization of butyrylcholinesterase in senile plaques in the brains of aged and Alzheimer disease patients. Molecular and Chemical Neuropathology, 1997, 30, 161-173.	1.0	46
1071	The effects of aging and neurodegeneration on apoptosis-associated DNA fragmentation and the benefits of nicotinamide. Molecular and Chemical Neuropathology, 1997, 32, 59-74.	1.0	25
1072	N-acetylaspartylglutamate,N-acetylaspartate, andN-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer diseases. Molecular and Chemical Neuropathology, 1997, 31, 97-118.	1.0	63
1073	Microglial activation in early stages of amyloid $\hat{l}^2$ protein deposition. Acta Neuropathologica, 1997, 94, 316-322.	7.7	122
1074	Low prevalence of apolipoprotein E ε4 allele in the neurofibrillary tangle predominant form of senile dementia. Acta Neuropathologica, 1997, 94, 403-409.	7.7	67
1075	Association of urodynamic function and brain neuropathology in elderly institutionalized patients. Archives of Gerontology and Geriatrics, 1997, 25, 167-174.	3.0	2
1076	Threeâ€dimensional reconstruction of senile plaques in Alzheimer's disease. Journal of Microscopy, 1997, 186, 263-269.	1.8	3

#	Article	IF	CITATIONS
1077	Tau Released from Paired Helical Filaments with Formic Acid or Guanidine Is Susceptible to Calpain-Mediated Proteolysis. Journal of Neurochemistry, 1997, 69, 1548-1558.	3.9	23
1078	Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Annals of Neurology, 1997, 41, 17-24.	5.3	1,243
1079	A subset of senile dementia with high incidence of the apolipoprotein E ?2 allele. Annals of Neurology, 1997, 41, 693-695.	5.3	51
1080	A novel presenilinâ€1 mutation: Increased βâ€amyloid and neurofibrillary changes. Annals of Neurology, 1997, 41, 809-813.	5.3	71
1081	Amyloid ?-protein deposition in the leptomeninges and cerebral cortex. Annals of Neurology, 1997, 42, 899-908.	5.3	45
1082	Butyrylcholinesterase in the life cycle of amyloid plaques. Annals of Neurology, 1997, 42, 909-918.	5.3	275
1083	Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with parkinson's, alzheimer's with parkinsonism, and alzheimer's disease. Movement Disorders, 1997, 12, 885-897.	3.9	98
1084	Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. Journal of Comparative Neurology, 1997, 379, 482-494.	1.6	436
1085	Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse, 1997, 26, 341-350.	1.2	98
1086	Regional cerebral blood flow during word and nonword reading. Human Brain Mapping, 1997, 5, 84-92.	3.6	251
1087	Amyloid-? proteins activate Ca2+-permeable channels through calcium-sensing receptors. Journal of Neuroscience Research, 1997, 47, 547-554.	2.9	107
1088	Activation of LA-N-2 cell phospholipase D by amyloid beta protein (25-35). Neurochemical Research, 1998, 23, 1225-1232.	3.3	18
1089	Regional membrane phospholipid alterations in Alzheimer's disease. Neurochemical Research, 1998, 23, 81-88.	3.3	402
1090	The Expression of Key Oxidative Stress-Handling Genes in Different Brain Regions in Alzheimer's Disease. Journal of Molecular Neuroscience, 1998, 11, 151-164.	2.3	117
1091	Transgenic Mouse Models of Alzheimer's Disease and Amyotrophic Lateral Sclerosis. Brain Pathology, 1998, 8, 735-757.	4.1	27
1092	Variability of senile dementia of Alzheimer type: A clinicopathological viewpoint. Neuropathology, 1998, 18, 77-79.	1.2	0
1093	A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer's disease, normal controls and nonâ€Alzheimer neuropsychiatric diseases. Psychiatry and Clinical Neurosciences, 1998, 52, 593-599.	1.8	70
1094	Germline mutational analysis of presenilin 1 and APP genes in Jewish-Israeli individuals with familial or early-onset Alzheimer disease using denaturing gradient gel electrophoresis (DGGE). European Journal of Human Genetics, 1998, 6, 176-180.	2.8	10

#	Article	IF	CITATIONS
1095	Alzheimer changes are common in aged drivers killed in single car crashes and at intersections. Forensic Science International, 1998, 96, 115-127.	2.2	22
1096	Dopamine D2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease. Brain Research, 1998, 784, 7-17.	2.2	47
1097	Cerebrovascular muscle atrophy is a feature of Alzheimer's disease. Brain Research, 1998, 791, 63-66.	2.2	70
1098	Cholinergic structures and neuropathologic alterations in the olfactory bulb of Alzheimer's disease brain samples. Brain Research, 1998, 789, 167-170.	2.2	21
1099	Downregulation of oxidative phosphorylation in Alzheimer disease: loss of cytochrome oxidase subunit mRNA in the hippocampus and entorhinal cortex. Brain Research, 1998, 796, 13-19.	2.2	48
1100	Loss of inositol 1,4,5-trisphosphate receptor sites and decreased PKC levels correlate with staging of Alzheimer's disease neurofibrillary pathology. Brain Research, 1998, 796, 209-221.	2.2	57
1101	Immunohistochemical and in situ analysis of amyloid precursor-like protein-1 and amyloid precursor-like protein-2 expression in Alzheimer disease and aged control brains. Brain Research, 1998, 804, 45-51.	2.2	39
1102	Ribosomal RNA in Alzheimer's disease and ageing. Mechanisms of Ageing and Development, 1998, 105, 265-272.	4.6	40
1103	Tau in Alzheimer's disease. Trends in Cell Biology, 1998, 8, 425-427.	7.9	526
1104	Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Annals of Neurology, 1998, 43, 303-310.	5.3	173
1105	Cerebrospinal fluid F <sub>2</sub> â€isoprostane levels are increased in Alzheimer's disease. Annals of Neurology, 1998, 44, 410-413.	5.3	250
1106	Production of paired helical filament, tau-like proteins by PC12 cells: A model of neurofibrillary degeneration. Journal of Neuroscience Research, 1998, 52, 498-504.	2.9	11
1107	A sandwich enzyme immunoassay for measuring AD7C-NTP as an Alzheimer's disease marker: AD7C test. , 1998, 12, 223-226.		30
1108	Biochemical assay for AD7C-NTP in urine as an Alzheimer's disease marker. , 1998, 12, 285-288.		61
1109	Alzheimer diseases: a model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases. American Journal of Medical Genetics Part A, 1998, 81, 49-57.	2.4	74
1110	Multiple threshold model for the onset of alzheimer's disease in the NAS-NRC twin panel. American Journal of Medical Genetics Part A, 1998, 81, 92-97.	2.4	51
1111	Initial results of a genome survey for novel alzheimer's disease risk genes: association with a locus on the X chromosome. , 1998, 81, 98-107.		17
1113	m2 muscarinic acetylcholine receptor-immunoreactive neurons are not reduced within the nucleus basalis in Alzheimer's disease: Relationship with cholinergic and galaninergic perikarya. Journal of Comparative Neurology, 1998, 392, 313-329.	1.6	19

#	Article	IF	CITATIONS
1114	Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. , 1998, 393, 374-390.		127
1115	Ultrastructural aspects of neurofibrillary tangle formation in aging and Alzheimer's disease. , 1998, 43, 49-58.		11
1116	Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathologica, 1998, 96, 116-122.	7.7	136
1117	Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala→Gly mutation. Acta Neuropathologica, 1998, 96, 253-260.	7.7	96
1118	Ubiquitin immunoreactivity of paired helical filaments differs in Alzheimer's disease and corticobasal degeneration. Acta Neuropathologica, 1998, 96, 520-526.	7.7	21
1119	Amyloid angiopathy of the human brain: immunohistochemical studies using markers for components of extracellular matrix, smooth muscle actin and endothelial cells. Acta Neuropathologica, 1998, 96, 558-563.	7.7	24
1120	Subcellular distribution of protein phosphatases and abnormally phosphorylated Ï,, in the temporal cortex from Alzheimer's disease and control brains. Journal of Neural Transmission, 1998, 105, 69-84.	2.8	59
1121	Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. Journal of Neural Transmission, 1998, 105, 423.	2.8	658
1122	Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease. Journal of Neural Transmission, 1998, 105, 709-717.	2.8	36
1123	Neuronal expression of cycline dependent kinase inhibitors of the INK4 family in Alzheimer's disease. Journal of Neural Transmission, 1998, 105, 949-960.	2.8	122
1124	Ascorbate-stimulated lipid peroxidation and non-heme iron concentrations in Alzheimer disease. Molecular and Chemical Neuropathology, 1998, 33, 15-26.	1.0	6
1125	Trace elements in Alzheimer's disease pituitary glands. Biological Trace Element Research, 1998, 62, 107-114.	3.5	44
1126	Using neural networks for differential diagnosis of Alzheimer disease and vascular dementia. Expert Systems With Applications, 1998, 14, 219-225.	7.6	8
1127	Synaptic loss reflected by secretoneurin-like immunoreactivity in the human hippocampus in Alzheimer's disease. European Journal of Neuroscience, 1998, 10, 1084-1094.	2.6	52
1128	Medical costs preceding diagnosis of probable alzheimer disease. Archives of Gerontology and Geriatrics, 1998, 26, 247-254.	3.0	5
1129	HSV-1 in brain and risk of Alzheimer's disease. Lancet, The, 1998, 351, 1330-1331.	13.7	72
1130	Four-Hydroxynonenal, a Product of Lipid Peroxidation, is Increased in the Brain in Alzheimer's Disease. Neurobiology of Aging, 1998, 19, 33-36.	3.1	653
1131	Complete Genomic Screen in Late-Onset Familial Alzheimer's Disease. Neurobiology of Aging, 1998, 19, S39-S42.	3.1	54

#	Article	IF	CITATIONS
1132	Metabolic alterations in postmortem Alzheimer's disease brain are exaggerated by Apo-E4. Neurobiology of Aging, 1998, 19, 511-515.	3.1	49
1133	Absence of aluminium in neurofibrillary tangles in Alzheimer's disease. Neuroscience Letters, 1998, 240, 123-126.	2.1	28
1134	Absence of association between Alzheimer disease and the â~'491 regulatory region polymorphism of APOE. Neuroscience Letters, 1998, 250, 189-192.	2.1	48
1135	Reduced O-glycosylated clathrin assembly protein AP180: implication for synaptic vesicle recycling dysfunction in Alzheimer's disease. Neuroscience Letters, 1998, 252, 33-36.	2.1	60
1136	Clâ^'-ATPase and Na+/K+-ATPase activities in Alzheimer's disease brains. Neuroscience Letters, 1998, 254, 141-144.	2.1	120
1137	Cortical distribution of neurofibrillary tangles in Alzheimer's disease matches the pattern of neurons that retain their capacity of plastic remodelling in the adult brain. Neuroscience, 1998, 83, 991-1002.	2.3	122
1138	Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience, 1998, 87, 319-324.	2.3	432
1139	Alzheimer's disease as a defect of neuronal autotrophism: a hypothetical analogy with amateur radio operation. Medical Hypotheses, 1998, 50, 515-520.	1.5	0
1140	Copper, iron and zinc in Alzheimer's disease senile plaques. Journal of the Neurological Sciences, 1998, 158, 47-52.	0.6	1,943
1141	Abnormal content of nâ~6 and nâ~3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl CoA content. International Journal of Biochemistry and Cell Biology, 1998, 30, 197-207.	2.8	84
1142	Receptor binding of an apolipoprotein E-rich subfraction of high density lipoprotein to rat and human brain membranes. International Journal of Biochemistry and Cell Biology, 1998, 30, 407-415.	2.8	14
1143	Alzheimer's disease: a neuropathologic perspective. Current Diagnostic Pathology, 1998, 5, 109-117.	0.4	3
1144	What are the facts and artifacts of the pathogenensis and etiology of Alzheimer disease?. Journal of Chemical Neuroanatomy, 1998, 16, 35-41.	2.1	36
1145	Metabolic brain mapping in Alzheimer's disease using proton magnetic resonance spectroscopy. Psychiatry Research - Neuroimaging, 1998, 82, 95-106.	1.8	45
1146	No neuropathologic evidence for an increased frequency of Alzheimer's disease among elderly schizophrenics. Biological Psychiatry, 1998, 43, 205-209.	1.3	25
1147	Somatic Mutation Analysis of the <i>APP</i> and <i>Presenilin 1</i> and <i>2</i> Genes in Alzheimer's Disease Brains. Journal of Neurogenetics, 1998, 12, 55-65.	1.4	9
1148	Structure and Functions of Human Cerebrospinal Fluid Lipoproteins from Individuals of Different APOE Genotypes. Experimental Neurology, 1998, 149, 175-182.	4.1	58
1149	Absence of Association of α1-Antichymotrypsin Polymorphisms with Alzheimer's Disease: A Report on Autopsy-Confirmed Cases. Experimental Neurology, 1998, 151, 237-240.	4.1	16

#	Article	IF	CITATIONS
1150	Multivariate Analysis of Laminar Patterns of Neurodegeneration in Posterior Cingulate Cortex in Alzheimer's Disease. Experimental Neurology, 1998, 153, 8-22.	4.1	54
1151	White Matter Astrocytes Produce Hepatocyte Growth Factor Activator Inhibitor in Human Brain Tissues. Experimental Neurology, 1998, 153, 60-64.	4.1	13
1152	A Genome Survey for Novel Alzheimer Disease Risk Loci: Results at 10-cM Resolution. Genomics, 1998, 50, 121-128.	2.9	96
1153	An Overview of Alzheimer's Disease Research. American Journal of Medicine, 1998, 104, 26S-31S.	1.5	15
1154	Immunohistochemical Study of the β-Chemokine Receptors CCR3 and CCR5 and Their Ligands in Normal and Alzheimer's Disease Brains. American Journal of Pathology, 1998, 153, 31-37.	3.8	274
1155	Association of apolipoprotein E genotype and intronic polymorphism of the presenilin-1 gene with Alzheimer's disease in elderly Taiwan Chinese. Journal of the Neurological Sciences, 1998, 157, 158-161.	0.6	22
1156	Lack of specific association of presenilin 1 (PS-1) protein with plaques and tangles in Alzheimer's disease. Journal of the Neurological Sciences, 1998, 158, 15-23.	0.6	6
1157	Alzheimer's disease with asymmetric parietal lobe atrophy: A case report. Journal of the Neurological Sciences, 1998, 160, 96-99.	0.6	46
1158	Autopsy study of Alzheimer's disease brain pathology in schizophrenia. Schizophrenia Research, 1998, 31, 177-184.	2.0	22
1159	Cholinergic Deficiency in Alzheimer's Disease: Pathogenic Model. American Journal of Geriatric Psychiatry, 1998, 6, S49-S55.	1.2	10
1160	Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease. New England Journal of Medicine, 1998, 338, 506-511.	27.0	530
1161	Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease. Human Molecular Genetics, 1998, 7, 933-935.	2.9	42
1162	Increased Total 7Â-Hydroxy-Dehydroepiandrosterone in Serum of Patients With Alzheimer's Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 1998, 53A, B125-B132.	3.6	36
1163	Increased Density of Olfactory Receptor Neurons Immunoreactive for Apolipoprotein E in Patients with Alzheimer's Disease. Annals of Otology, Rhinology and Laryngology, 1998, 107, 421-426.	1.1	16
1164	Formation of Isoprostane-like Compounds (Neuroprostanes) in Vivo from Docosahexaenoic Acid. Journal of Biological Chemistry, 1998, 273, 13605-13612.	3.4	377
1165	Clinicopathologic Studies in Cognitively Healthy Aging and Alzheimer Disease. Archives of Neurology, 1998, 55, 326.	4.5	630
1166	Fallacies in the pathological confirmation of the diagnosis of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 18-24.	1.9	123
1167	Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 15598-15602.	7.1	90

#	Article	IF	CITATIONS
1168	Cortical variability and asymmetry in normal aging and Alzheimer's disease. Cerebral Cortex, 1998, 8, 492-509.	2.9	243
1169	Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease. Neurology, 1998, 50, 1556-1562.	1.1	31
1170	Loss of Dopamine D2 Receptors in Alzheimer's Disease with Parkinsonism But Not Parkinson's or Alzheimer's Disease. Neuropsychopharmacology, 1998, 19, 472-480.	5.4	37
1171	Cognitive Profiles of Autopsy-Confirmed Lewy Body Variant vs Pure Alzheimer Disease. Archives of Neurology, 1998, 55, 994.	4.5	111
1172	Evidence for an Alzheimer Disease Susceptibility Locus on Chromosome 12 and for Further Locus Heterogeneity. JAMA - Journal of the American Medical Association, 1998, 280, 614.	7.4	142
1173	Hereditary dysphasic disinhibition dementia A frontotemporal dementia linked to 17 q21â€â€⊋2. Neurology, 1998, 50, 1546-1555.	1.1	163
1174	Relating anatomy to function in Alzheimer's disease. Neurology, 1998, 50, 979-985.	1.1	126
1175	A Prospective Study of Cognitive Function and Onset of Dementia in Cognitively Healthy Elders. Archives of Neurology, 1998, 55, 395.	4.5	281
1176	Assessment of the Pathological Stages of Alzheimer's Disease in Thin Paraffin Sections: A Comparative Study. Dementia and Geriatric Cognitive Disorders, 1998, 9, 140-144.	1.5	40
1177	Memory Changes during Normal Aging. , 1998, , 247-287.		10
1178	Cortical Cholinergic Dysfunction After Human Head Injury. Journal of Neurotrauma, 1998, 15, 295-305.	3.4	112
1178 1179	Cortical Cholinergic Dysfunction After Human Head Injury. Journal of Neurotrauma, 1998, 15, 295-305. Fluency Performance Patterns in Alzheimer's Disease and Parkinson's Disease. Clinical Neuropsychologist, 1998, 12, 487-499.	3.4 2.3	112 24
	Fluency Performance Patterns in Alzheimer's Disease and Parkinson's Disease. Clinical		
1179	Fluency Performance Patterns in Alzheimer's Disease and Parkinson's Disease. Clinical Neuropsychologist, 1998, 12, 487-499.	2.3	24
1179 1180	Fluency Performance Patterns in Alzheimer's Disease and Parkinson's Disease. Clinical Neuropsychologist, 1998, 12, 487-499. Neurofibrillary Tangles and Alzheimer's Disease. European Neurology, 1998, 40, 130-140. Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia.	2.3 1.4	24 138
1179 1180 1181	Fluency Performance Patterns in Alzheimer's Disease and Parkinson's Disease. Clinical Neuropsychologist, 1998, 12, 487-499. Neurofibrillary Tangles and Alzheimer's Disease. European Neurology, 1998, 40, 130-140. Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 653-656.	2.3 1.4 1.9	24 138 61
1179 1180 1181 1182	Fluency Performance Patterns in Alzheimer's Disease and Parkinson's Disease. Clinical Neuropsychologist, 1998, 12, 487-499. Neurofibrillary Tangles and Alzheimer's Disease. European Neurology, 1998, 40, 130-140. Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 653-656. Alzheimer Disease and Related Neurodegenerative Diseases in Elderly Patients With Schizophrenia. Archives of General Psychiatry, 1998, 55, 205.	2.3 1.4 1.9 12.3	24 138 61 168

ARTICLE IF CITATIONS # Alzheimer's disease and parkinson's disease: Distinct entities or extremes of a spectrum of 1186 5.3 133 neurodegeneration?. Annals of Neurology, 1998, 44, S19-31. Severe pathological changes of parabrachial nucleus in Alzheimer's disease. NeuroReport, 1998, 9, 1187 1.2 4151-4154. Structural MRI correlates of recognition memory in Alzheimer's disease. Journal of the International 1188 1.8 65 Neuropsychological Society, 1998, 4, 106-114. The Overlap between Alzheimer's Disease and Vascular Dementia: The Role of White Matter Changes. Dementia and Geriatric Cognitive Disorders, 1998, 9, 30-35. Accuracy of Clinical Operational Diagnostic Criteria for Alzheimer's Disease in Relation to Different 1190 1.5 82 Pathological Diagnostic Protocols. Dementia and Geriatric Cognitive Disorders, 1998, 9, 219-226. Normal Aging and Alzheimer's Disease., 1998, , 83-92. Neuropathology and memory dysfunction in neurodegenerative disease., 1998,, 36-86. 1192 2 Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer's Disease. Journal of Alzheimer's Disease, 1998, 1, 119-134. Alzheimer's Disease Pathology in Non-Demented Elderly. Journal of Alzheimer's Disease, 1998, 1, 81-89. 2.6 1194 15 Interaction of Presenilins with the Filamin Family of Actin-Binding Proteins. Journal of Neuroscience, 3.6 123 1998, 18, 914-922. The Pathology of Dementia. The Journal of the British Menopause Society, 1998, 4, 66-72. 1196 1.3 0 Expression of Adult T Cell Leukemia-Derived Factor in Human Brain and Peripheral Nerve Tissues. 1.5 Dementia and Geriatric Cognitive Disorders, 1998, 9, 181-185. Lipopigment Changes in Purkinje Cells in Alzheimer's Disease. Journal of Alzheimer's Disease, 1998, 1, 1198 2.6 9 71-79. Differentiating Alzheimer's Disease and Frontotemporal Dementia: Receiver Operator Characteristic 1199 1.5 Curve Analysis of Four Rating Scales. Dementia and Geriatric Cognitive Disorders, 1998, 9, 164-174. Establishing the limits of normal cerebral ageing and senile dementias. British Journal of Psychiatry, 1200 2.8 9 1998, 173, 97-101. Reduction of O-Linked<i>N</i>-Acetylglucosamine-Modified Assembly Protein-3 in Alzheimer's Disease. Journal of Neuroscience, 1998, 18, 2399-2411. Activity of Hippocampal CA1 Neurons in Alzheimer's Disease is not Affected by the Presence of Adjacent 1202 2.6 3 Neuritic Plaques. Journal of Alzheimer's Disease, 1998, 1, 107-118. Doença de Alzheimer. Revista Brasileira De Psiquiatria, 1999, 21, 03-07.

CITATION RE	PORT

#	Article	IF	CITATIONS
1204	Neurochemical Markers Do Not Correlate With Cognitive Decline in the Lewy Body Variant of Alzheimer Disease. Archives of Neurology, 1999, 56, 1458.	4.5	28
1205	Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease. Archives of Neurology, 1999, 56, 713.	4.5	194
1206	A Neuropathological Study of Dementia in Nursing Homes over a 17-Year Period, in Shimane Prefecture, Japan. Gerontology, 1999, 45, 44-48.	2.8	26
1207	Astrogliosis and the ApoE Genotype. Dementia and Geriatric Cognitive Disorders, 1999, 10, 252-257.	1.5	63
1208	RNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimer's Disease. Journal of Neuroscience, 1999, 19, 1959-1964.	3.6	708
1209	Classification learning in Alzheimer's disease. Brain, 1999, 122, 1063-1068.	7.6	28
1210	Marital status and risk of Alzheimer's disease. Neurology, 1999, 53, 1953-1953.	1.1	152
1211	Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease. JAMA - Journal of the American Medical Association, 1999, 281, 1401.	7.4	444
1212	The Neurobiology and Pharmacotherapy of Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 1999, 11, 19-31.	1.8	50
1213	Oxidation of Cytosolic Proteins and Expression of Creatine Kinase BB in Frontal Lobe in Different Neurodegenerative Disorders. Dementia and Geriatric Cognitive Disorders, 1999, 10, 158-165.	1.5	95
1214	Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology, 1999, 53, 1969-1969.	1.1	214
1215	Gender differences in the incidence of AD and vascular dementia. Neurology, 1999, 53, 1992-1992.	1.1	564
1216	In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology, 1999, 52, 691-691.	1.1	337
1217	The occurrence of depressive symptoms in the preclinical phase of AD. Neurology, 1999, 53, 1998-1998.	1.1	214
1218	Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology, 1999, 53, 1974-1974.	1.1	152
1219	Functional anatomy of neuropsychological deficits after severe traumatic brain injury. Neurology, 1999, 53, 1963-1963.	1.1	132
1220	Rate of memory decline in AD is related to education and occupation. Neurology, 1999, 53, 1942-1942.	1.1	479
1221	Cognitive decline in individuals with high blood pressure. Neurology, 1999, 53, 1948-1948.	1.1	337

		CITATION R	EPORT	
#	Article		IF	CITATIONS
1222	Head trauma and risk of dementia and Alzheimer's disease. Neurology, 1999, 53, 1	959-1959.	1.1	243
1223	Challenging the Cholinergic Hypothesis in Alzheimer Disease. JAMA - Journal of the Ame Association, 1999, 281, 1433.	rican Medical	7.4	48
1224	Error behaviors associated with loss of competency in Alzheimer's disease. Neurolo 1983-1983.	gy, 1999, 53,	1.1	33
1225	Does HHV-8 have a protective role on the development of HIV encephalopathy?. Neuro 2032-2032.	logy, 1999, 53,	1.1	15
1226	Agrin in Alzheimer's disease: Altered solubility and abnormal distribution within microva and brain parenchyma. Proceedings of the National Academy of Sciences of the United America, 1999, 96, 6468-6472.	asculature States of	7.1	90
1227	The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, n changes and neuronal loss in the familial Alzheimer's disease brain. Brain, 1999, 122, 1		7.6	116
1228	ALZHEIMER'S DISEASE, DENTAL AMALGAM AND MERCURY. Journal of the American De 1999, 130, 191-199.	ntal Association,	1.5	68
1229	A morphometric study of subcortical changes in Alzheimer's disease. Neuropathology,	1999, 19, 161-171.	1.2	2
1230	Hierarchical Phosphorylation of Recombinant Tau by the Paired-Helical Filament-Associa Kinase Is Dependent on Cyclic AMP-Dependent Protein Kinase. Journal of Neurochemist 214-224.		3.9	64
1231	Inflammatory pathogenesis in Alzheimer's disease: biological mechanisms and cognitive Neuroscience and Biobehavioral Reviews, 1999, 23, 615-633.	e sequeli.	6.1	97
1232	Functional Brain Imaging in the Resting State and during Activation in Alzheimer's Dise Implications for Disease Mechanisms Involving Oxidative Phosphorylation. Annals of th Academy of Sciences, 1999, 893, 138-153.	ase: e New York	3.8	37
1233	The expression of several mitochondrial and nuclear genes encoding the subunits of electransport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, i regions in Alzheimer's disease. Neurochemical Research, 1999, 24, 767-774.	ectron n different brain	3.3	90
1234	N-acetylaspartic acid (NAA) and N-acetylaspartylglutamic acid (NAAG) in human ventric subarachnoid, and lumbar cerebrospinal fluid. Neurochemical Research, 1999, 24, 1249		3.3	21
1235	99m Tc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease. E of Nuclear Medicine and Molecular Imaging, 1999, 26, 1392-1399.	uropean Journal	6.4	82
1236	Prevalence of Alzheimer's Disease in Patients Investigated for Presumed Normal Pressu Hydrocephalus: A Clinical and Neuropathological Study. Acta Neurochirurgica, 1999, 14		1.7	135
1237	Cortical load of PHF-tau in Alzheimer's disease is correlated to cholinergic dysfunction. Neural Transmission, 1999, 106, 513-523.	Journal of	2.8	22
1238	Amyloid precursor proteins in the cerebellar cortex of Alzheimer's disease patients devo cerebellar β-amyloid deposits: immunocytochemical study of five cases. Journal of Neu 1999, 106, 1151-1169.		2.8	12
1239	Entorhinal cortex of aged subjects with Down's syndrome shows severe neuronal loss on neurofibrillary pathology. Acta Neuropathologica, 1999, 97, 156-164.	caused by	7.7	39

#	Article	IF	CITATIONS
1240	No increased incidence of Alzheimer's disease in elderly schizophrenics. Acta Neuropathologica, 1999, 97, 165-169.	7.7	41
1241	Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue. Acta Neuropathologica, 1999, 97, 383-392.	7.7	87
1242	Neuropathological changes in the nucleus basalis correlate with clinical measures of dementia. Acta Neuropathologica, 1999, 98, 186-196.	7.7	61
1243	Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathologica, 1999, 98, 273-280.	7.7	94
1244	Leukoencephalopathy with cerebral amyloid angiopathy: a semiquantitative and morphometric study. Journal of Neurology, 1999, 246, 661-666.	3.6	45
1245	Neuropsychiatric aspects of dementia with lewy bodies. Current Psychiatry Reports, 1999, 1, 85-92.	4.5	22
1246	Lack of association of presenilin-1 intron-8 polymorphism with neuropathological features of Alzheimer's disease. Brain Research, 1999, 816, 295-298.	2.2	10
1247	Signal transduction abnormalities in Alzheimer's disease: evidence of a pathogenic stimuli. Brain Research, 1999, 815, 237-242.	2.2	84
1248	Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Research, 1999, 843, 87-94.	2.2	125
1249	DNA strand breaks in Alzheimer's disease. Brain Research, 1999, 849, 67-77.	2.2	162
1250	Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin?. Free Radical Biology and Medicine, 1999, 26, 1508-1512.	2.9	72
1251	Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radical Biology and Medicine, 1999, 27, 544-553.	2.9	233
1252	Modulation byDLST of the genetic risk of Alzheimer's disease in a very elderly population. Annals of Neurology, 1999, 45, 48-53.	5.3	44
1253	Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Annals of Neurology, 1999, 46, 325-332.	5.3	140
1254	A genealogical study of Alzheimer disease in the Saguenay region of Quebec. Genetic Epidemiology, 1999, 16, 412-425.	1.3	17
1255	Ca2+ and Mg2+ selectively induce aggregates of PHF-tau but not normal human tau. Journal of Neuroscience Research, 1999, 55, 36-43.	2.9	28
1256	Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease. Journal of Neuroscience Research, 1999, 55, 218-229.	2.9	89
1257	Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. Journal of Neuroscience Research, 1999, 55, 713-723.	2.9	110

ARTICLE IF CITATIONS Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. 1258 2.9 219 Journal of Neuroscience Research, 1999, 57, 295-303. Phylogenetic analysis of the mitochondrial genome indicates significant differences between patients 1259 108 with Azheimer disease and controls in a French-Canadian founder population. , 1999, 85, 20-30. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. 1260 1.6 235 Journal of Comparative Neurology, 1999, 411, 693-704. A unifying hypothesis of Alzheimer's disease. II. Pathophysiological processes. Human Psychopharmacology, 1999, 14, 525-581. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an 1262 115 autopsy-verified sample., 1999, 14, 526-533. Diabetes mellitus and the risk of dementia. Neurology, 1999, 53, 1937-1937. 1.1 1,896 Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5598-5603. 1264 7.1 501 Neuropathology of three clinical cases prospectively diagnosed as dementia with Lewy bodies. Journal 1265 1.5 of Clinical Neuroscience, 1999, 6, 149-154. Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease 1266 2.3 142 neurofibrillary and Î<sup>2</sup>-amyloid pathologies. Neuroscience, 1999, 92, 499-513. Cortical areas abundant in extracellular matrix chondroitin sulphate proteoglycans are less affected 2.3 by cytoskeletal changes in Alzheimer's disease. Neuroscience, 1999, 92, 791-805. Changes in synaptic expression of clathrin assembly protein AP180 in Alzheimer's disease analysed by 1268 2.3 48 immunohistochemistry. Neuroscience, 1999, 94, 389-394. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Progress in 5.7 410 Neurobiology, 1999, 57, 301-323. Activity of phosphatidylethanolamine-N-methyltransferase in brain affected by Alzheimers disease. 1270 3.8 24 Neurochemistry International, 1999, 34, 41-47. Memory and mental status correlates of modified Braak staging. Neurobiology of Aging, 1999, 20, 573-579. 1271 3.1 231 l-type calcium channels in the hippocampus and cerebellum of Alzheimer's disease brain tissue. 1272 3.147 Neurobiology of Aging, 1999, 20, 597-603. Phospholipase pathway in Alzheimer's disease brains: decrease in Gαi in dorsolateral prefrontal cortex. Molecular Brain Research, 1999, 66, 188-190. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet, 1274 13.7 457 The, 1999, 354, 919-920. Comparison of A68 levels in Alzheimer Diseased and non-Alzheimer's diseased brain by two ALZ50 based 4.3 methods. Life Sciences, 1999, 65, 2215-2222.

	CHAHON R		
#	Article	IF	CITATIONS
1276	Transgenic animals relevant to Alzheimer's disease. Neuropharmacology, 1999, 38, 1-17.	4.1	59
1277	Reductions in brain phosphatidylinositol kinase activities in alzheimer's disease. Biological Psychiatry, 1999, 45, 731-736.	1.3	32
1278	Clinical and neurobiological correlates of D10S1423 genotype in Alzheimer's disease. Biological Psychiatry, 1999, 46, 740-749.	1.3	18
1279	Clinical and neurobiological correlates of DXS1047 genotype in Alzheimer's disease. Biological Psychiatry, 1999, 46, 173-181.	1.3	14
1280	Cognitive and functional changes with aging in schizophrenia. Biological Psychiatry, 1999, 46, 921-928.	1.3	50
1281	Synthesis of Novel Phenserine-Based-Selective Inhibitors of Butyrylcholinesterase for Alzheimer's Diseaseâ€. Journal of Medicinal Chemistry, 1999, 42, 1855-1861.	6.4	207
1282	Application of cognitive scales to medical records of schizophrenia inpatients. Schizophrenia Research, 1999, 35, 131-140.	2.0	8
1283	Activation of Caspase-3 in Single Neurons and Autophagic Granules of Granulovacuolar Degeneration in Alzheimer's Disease. American Journal of Pathology, 1999, 155, 1459-1466.	3.8	415
1284	Protein Kinase C Anchoring Deficit in Postmortem Brains of Alzheimer's Disease Patients. Experimental Neurology, 1999, 159, 559-564.	4.1	79
1285	Increased Neuronal Glucose-6-phosphate Dehydrogenase and Sulfhydryl Levels Indicate Reductive Compensation to Oxidative Stress in Alzheimer Disease. Archives of Biochemistry and Biophysics, 1999, 370, 236-239.	3.0	116
1286	Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology, 1999, 53, 2003-2003.	1.1	108
1287	Progression of Clinical Deterioration and Pathological Changes in Patients With Alzheimer Disease Evaluated at Biopsy and Autopsy. Archives of Neurology, 1999, 56, 1254.	4.5	40
1288	Neurofibrillary Pathology in Alzheimer Disease With Lewy Bodies. Archives of Neurology, 1999, 56, 203.	4.5	42
1289	A Clinicopathological Comparison of Community-Based and Clinic-Based Cohorts of Patients With Dementia. Archives of Neurology, 1999, 56, 1368.	4.5	87
1290	[23] Deposition of soluble amyloid-Î <sup>2</sup> onto amyloid templates: With application for the identification of amyloid fibril extension inhibitors. Methods in Enzymology, 1999, 309, 350-374.	1.0	18
1291	In Vivo Brain Concentrations of N-Acetyl Compounds, Creatine, and Choline in Alzheimer Disease. Archives of General Psychiatry, 1999, 56, 185.	12.3	127
1292	Clinicoâ€Neuropathological Correlation of Alzheimer's Disease in a Communityâ€Based Case Series. Journal of the American Geriatrics Society, 1999, 47, 564-569.	2.6	354
1293	Rapid and Economical Silver Impregnation Technique to Demonstrate Nerve Fibers, Axons, Neurons, and Senile Plaques and Neurofibrillary Tangles of Alzheimer's Disease. Journal of Histotechnology, 1999, 22, 37-41.	0.5	2

#	Article	IF	Citations
1294	Brain structural and cognitive correlates of clock drawing performance in Alzheimer's disease. Journal of the International Neuropsychological Society, 1999, 5, 502-509.	1.8	81
1295	Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. NeuroReport, 1999, 10, 2411-2415.	1.2	278
1296	Dementia, gliosis and expression of the small heat shock proteins hsp27 and αB-crystallin in Parkinson's disease. NeuroReport, 1999, 10, 2273-2276.	1.2	145
1297	Prospective Study of Risk Factors for Alzheimer's Disease: Results at 7.5 Years. American Journal of Psychiatry, 1999, 156, 50-57.	7.2	27
1298	β-Amyloid Load Is Not Influenced by the Severity of Cardiovascular Disease in Aged and Demented Patients. Stroke, 1999, 30, 613-618.	2.0	53
1299	Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology, 2000, 55, 1068-1069.	1.1	33
1300	Diagnostic Accuracy of Dementia With Lewy Bodies. Archives of Neurology, 2000, 57, 347.	4.5	127
1301	Structural brain correlates of verbal and nonverbal fluency measures in Alzheimer's disease Neuropsychology, 2000, 14, 29-40.	1.3	44
1302	Extent, pattern, and correlates of remote memory impairment in Alzheimer's disease and Parkinson's disease Neuropsychology, 2000, 14, 265-276.	1.3	42
1303	Association Between Severe Cerebral Amyloid Angiopathy and Cerebrovascular Lesions in Alzheimer Disease Is Not a Spurious One Attributable to Apolipoprotein E4. Archives of Neurology, 2000, 57, 869.	4.5	101
1304	The Role of Routine Laboratory Studies and Neuroimaging in the Diagnosis of Dementia: A Clinicopathological Study. Journal of the American Geriatrics Society, 2000, 48, 1204-1210.	2.6	41
1305	Imaging in the dementias. The Journal of the British Menopause Society, 2000, 6, 100-105.	1.3	0
1306	A Unifying Hypothesis of Alzheimer's Disease. IV. Causation and Sequence of Events. Reviews in the Neurosciences, 2000, 11, 213-328.	2.9	78
1307	Activation of p38 Kinase Links Tau Phosphorylation, Oxidative Stress, and Cell Cycle-Related Events in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2000, 59, 880-888.	1.7	328
1308	Phosphorylation of MARCKS in Alzheimer disease brains. NeuroReport, 2000, 11, 869-873.	1.2	27
1309	Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype. Annals of Neurology, 2000, 48, 297-303.	5.3	157
1310	Reduction in TrkAâ€Immunoreactive Neurons Is Not Associated with an Overexpression of Galaninergic Fibers Within the Nucleus Basalis in Down's Syndrome. Journal of Neurochemistry, 2000, 74, 1185-1196.	3.9	63
1311	Distribution of amyloid beta protein precursor in the Alzheimer's disease brain. Psychiatry and Clinical Neurosciences, 2000, 54, 45-54.	1.8	6

#	Article	IF	CITATIONS
1312	Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. Psychiatry and Clinical Neurosciences, 2000, 54, 419-426.	1.8	86
1313	Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. Neuropathology and Applied Neurobiology, 2000, 26, 347-355.	3.2	94
1314	The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment. Neuroscience and Biobehavioral Reviews, 2000, 24, 365-374.	6.1	300
1315	Do susceptibility loci contribute to the expression of more than one mental disorder? A view from the genetics of Alzheimer's disease. Molecular Psychiatry, 2000, 5, 131-136.	7.9	22
1316	Role of Blood Vessels in Producing Pathological Changes in the Brain with Alzheimer's Disease. Annals of the New York Academy of Sciences, 2000, 903, 46-54.	3.8	45
1317	Quantitative evaluation of the rRNA in Alzheimer's disease. Mechanisms of Ageing and Development, 2000, 120, 57-64.	4.6	48
1318	Aberrant expression of nNOS in pyramidal neurons in Alzheimer's disease is highly co-localized with p21ras and p16INK4a. Brain Research, 2000, 852, 45-55.	2.2	102
1319	Distribution of tau protein kinase I/glycogen synthase kinase-3β, phosphatases 2A and 2B, and phosphorylated tau in the developing rat brain. Brain Research, 2000, 857, 193-206.	2.2	49
1320	Functional brain imaging as a looking-glass into the degraded brain: reviewing evidence from Alzheimer disease in relation to normal aging. Acta Psychologica, 2000, 105, 255-277.	1.5	16
1321	Executive control functions in degenerative dementias: a comparative review. Neuropsychology Review, 2000, 10, 75-99.	4.9	117
1322	Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease. European Journal of Clinical Pharmacology, 2000, 55, 815-819.	1.9	25
1323	Distribution of chromogranin B-like immunoreactivity in the human hippocampus and its changes in Alzheimer's disease. Acta Neuropathologica, 2000, 100, 205-212.	7.7	36
1324	Clinical validity of Braak staging in the oldest-old. Acta Neuropathologica, 2000, 99, 583-584.	7.7	24
1325	Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun Study. American Journal of Clinical Nutrition, 2000, 71, 993-998.	4.7	256
1326	E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease. Neurology, 2000, 54, 403-403.	1.1	38
1327	The Relative Frequency of "Dementia of Unknown Etiology" Increases With Age and Is Nearly 50% in Nonagenarians. Archives of Neurology, 2000, 57, 713.	4.5	153
1328	Amyloid-ß and Treatment Opportunities for Alzheimer's Disease. Journal of Alzheimer's Disease, 2000, 2, 231-259.	2.6	7
1329	Revisiting Alzheimer's Disease from a New Perspective: Can "Risk Factors―Play a Key Role?. Journal of Alzheimer's Disease, 2000, 2, 97-108.	2.6	8

#	Article	IF	CITATIONS
1330	Small Concomitant Vascular Lesions Do Not Influence Rates of Cognitive Decline in Patients With Alzheimer Disease. Archives of Neurology, 2000, 57, 1474-9.	4.5	87
1332	Cholinergic dysfunction in diseases with Lewy bodies. Neurology, 2000, 54, 407-407.	1.1	316
1333	Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology, 2000, 54, 1498-1504.	1.1	113
1334	The Expression of Presenilin 1 mRNA in Skin Fibroblasts and Brains from Sporadic Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2000, 11, 245-250.	1.5	14
1335	Protein Disulfide Isomerase in Alzheimer Disease. Antioxidants and Redox Signaling, 2000, 2, 485-489.	5.4	53
1336	Increased Neocortical Neurofibrillary Tangle Density in Subjects With Alzheimer Disease and Psychosis. Archives of General Psychiatry, 2000, 57, 1165.	12.3	147
1337	Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland. Journal of Medical Genetics, 2000, 37, 182-185.	3.2	55
1338	"Preclinical―AD revisited. Neurology, 2000, 55, 370-376.	1.1	347
1339	Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology, 2000, 54, 1916-1921.	1.1	545
1340	α2 Macroglobulin and the risk of Alzheimer's disease. Neurology, 2000, 54, 438-438.	1.1	74
1341	Internal carotid artery dissection. Neurology, 2000, 54, 442-442.	1.1	9
1342	The Frequency of Point Mutations in Mitochondrial DNA Is Elevated in the Alzheimer's Brain. Biochemical and Biophysical Research Communications, 2000, 273, 203-208.	2.1	60
1343	Amyloid Î <sup>2</sup> Protein Starting Pyroglutamate at Position 3 Is a Major Component of the Amyloid Deposits in the Alzheimer's Disease Brain. Biochemical and Biophysical Research Communications, 2000, 276, 422-427.	2.1	183
1344	Activation Barriers to Structural Transition Determine Deposition Rates of Alzheimer's Disease AÎ <sup>2</sup> Amyloid. Journal of Structural Biology, 2000, 130, 174-183.	2.8	60
1345	Oxidative Insults Are Associated with Apolipoprotein E Genotype in Alzheimer's Disease Brain. Neurobiology of Disease, 2000, 7, 23-37.	4.4	173
1346	The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology, 2000, 55, 1278-1283.	1.1	113
1347	Density and pharmacology of α5 subunit-containing GABAA receptors are preserved in hippocampus of Alzheimer's disease patients. Neuroscience, 2000, 98, 669-675.	2.3	65
1348	Up-regulation of the lysosomal system in experimental models of neuronal injury: implications for Alzheimer's disease. Neuroscience, 2000, 100, 663-675.	2.3	106

#	Article	IF	CITATIONS
1349	Regional distribution of cortical microglia parallels that of neurofibrillary tangles in Alzheimer's disease. Neuroscience Letters, 2000, 285, 165-168.	2.1	89
1350	A frontal variant of Alzheimer's disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. Neurochemistry International, 2000, 37, 17-31.	3.8	62
1351	Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patientsâ~†. Neurobiology of Aging, 2000, 21, 11-17.	3.1	99
1352	Agrin and microvascular damage in Alzheimer's disease. Neurobiology of Aging, 2000, 21, 349-355.	3.1	154
1353	Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease. Neurobiology of Aging, 2000, 21, 741-746.	3.1	47
1354	Quantitative neurohistological features of frontotemporal degeneration. Neurobiology of Aging, 2000, 21, 913-919.	3.1	70
1355	Clathrin assembly protein AP-2 is detected in both neurons and glia, and its reduction is prominent in layer II of frontal cortex in Alzheimer's disease. Neurobiology of Aging, 2000, 21, 921-929.	3.1	12
1356	Autopsy in dementing disorders of the elderly. Current Diagnostic Pathology, 2000, 6, 181-191.	0.4	2
1357	Activation of oncogenic pathways in degenerating neurons in Alzheimer disease. International Journal of Developmental Neuroscience, 2000, 18, 433-437.	1.6	90
1358	Part III. Neuropathology of Alzheimer's disease. Disease-a-Month, 2000, 46, 688-706.	1.1	8
1359	Neuronal CDK7 in hippocampus is related to aging and Alzheimer disease. Neurobiology of Aging, 2000, 21, 807-813.	3.1	66
1360	NEUROPATHOLOGY OF ALZHEIMER'S DISEASE AND RELATED DISORDERS. Neurologic Clinics, 2000, 18, 847-864.	1.8	48
1361	Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients. Biological Psychiatry, 2000, 48, 184-196.	1.3	76
1362	The Precursor Pro-Nerve Growth Factor Is the Predominant Form of Nerve Growth Factor in Brain and Is Increased in Alzheimer's Disease. Molecular and Cellular Neurosciences, 2001, 18, 210-220.	2.2	467
1363	Oxidation of Aβ and Plaque Biogenesis in Alzheimer's Disease and Down Syndrome. Neurobiology of Disease, 2001, 8, 792-806.	4.4	71
1364	Apolipoprotein C-I Expression in the Brain in Alzheimer's Disease. Neurobiology of Disease, 2001, 8, 953-963.	4.4	53
1365	Alzheimer's disease: a review concerning immune response and microischemia. Medical Hypotheses, 2001, 56, 124-127.	1.5	23
1366	Neuropathological epidemiology of cerebral aging: a study of two genetic polymorphisms. Neurobiology of Aging, 2001, 22, 227-235.	3.1	19

		CITATION R	EPORT	
# 1367	ARTICLE Author's response to commentaries. Neurobiology of Aging, 2001, 22, 353-354.		IF 3.1	Citations
1368	Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alz disease and to identify high-risk subgroups. Neuroscience, 2001, 108, 541-554.	heimer's	2.3	57
1369	Review of the next generation of Alzheimer's disease therapeutics: challenges for drug d Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2001, 25, 27-57.	evelopment.	4.8	59
1370	Tau protein expression in frontotemporal dementias. Neuroscience Letters, 2001, 315, 2	1-24.	2.1	19
1371	Alzheimer's Disease. Survey of Ophthalmology, 2001, 45, 516-524.		4.0	38
1372	Pathological correlates of late-onset dementia in a multicentre, community-based popula England and Wales. Lancet, The, 2001, 357, 169-175.	ation in	13.7	1,294
1373	Gene identification in Alzheimer's disease. Pharmacogenomics, 2001, 2, 239-249.		1.3	24
1374	Ceruloplasmin immunoreactivity in neurodegenerative disorders. Free Radical Research, 111-118.	2001, 35,	3.3	23
1375	Where do Alzheimer s plaques and tangles come from aging-induced protein degradatio Frontiers in Bioscience - Landmark, 2001, 6, e1-11.	n inefficiency.	3.0	1
1376	Alzheimer movement re-examined 25 years later is it a disease or a senile condition in mo Frontiers in Bioscience - Landmark, 2001, 6, e30-40.	edical nature.	3.0	7
1377	Memory Changes with Aging and Dementia. , 2001, , 53-63.			9
1378	A quantitative assessment of glycolipid and protein associated with paired helical filame preparations from Alzheimer's diseased brain. Journal of Alzheimer's Disease, 2001, 3, 4	nt 55-466.	2.6	9
1379	High Expression of Apolipoprotein E mRNA in the Brains with Sporadic Alzheimer's D and Geriatric Cognitive Disorders, 2001, 12, 57-62.	isease. Dementia	1.5	48
1380	The severity of cortical Alzheimer's type changes is positively correlated with increased a Levels: Resolubilization of amyloid-Î <sup>2</sup> with transition metal ion chelators. Journal of Alzhe Disease, 2001, 3, 209-219.	myloid-β imer's	2.6	44
1381	Clinical and Pathologic Features of Two Groups of Patients With Dementia With Lewy Bo of Coexisting Alzheimer-Type Lesion Load. Alzheimer Disease and Associated Disorders, 2		1.3	101
1382	Expression of the kallikrein gene family in normal and Alzheimer's disease brain. NeuroRe 2747-2751.	port, 2001, 12,	1.2	56
1383	Accuracy of clinical criteria for AD in the Honolulu–Asia Aging Study, a population-bas Neurology, 2001, 57, 226-234.	ed study.	1.1	135
1384	Alzheimer's disease-related synapse loss in the cingulate cortex. Journal of Alzheimer's D 3, 495-505.	isease, 2001,	2.6	62

~		_		
( ПТ	ATIC	NN R	'FPO	DT.
	/ \     \			TO DE

#	Article	IF	CITATIONS
1385	Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies. Journal of Neural Transmission, 2001, 108, 1149-1157.	2.8	24
1386	Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's disease. Journal of Neural Transmission, 2001, 108, 1043-1050.	2.8	15
1387	Toluidine blue-O staining of prion protein deposits. Histochemistry and Cell Biology, 2001, 116, 519-524.	1.7	5
1388	Senile plaques exert no mass lesion effect on surrounding neurons. Journal of Neuroscience Methods, 2001, 110, 125-133.	2.5	4
1389	Activation and redistribution of c-Jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. Journal of Neurochemistry, 2001, 76, 435-441.	3.9	419
1390	GlutamateNMDA receptor NR1 subunit mRNA expression in Alzheimer's disease. Journal of Neurochemistry, 2001, 78, 175-182.	3.9	55
1391	The relationship between αB-crystallin and neurofibrillary tangles in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2001, 27, 180-188.	3.2	30
1392	Down syndrome and Alzheimer's disease: A link between development and aging. Mental Retardation and Developmental Disabilities Research Reviews, 2001, 7, 172-178.	3.6	260
1393	Apolipoprotein E ϵ4 allele is a risk factor for lateâ€onset Alzheimer's disease and vascular dementia in Han Chinese. International Journal of Geriatric Psychiatry, 2001, 16, 438-439.	2.7	17
1394	Long-term memory correlates negatively with plasma transcobalamin in healthy elderly with normal plasma cobalamin levels. International Journal of Geriatric Psychiatry, 2001, 16, 439-441.	2.7	5
1395	Largeâ€scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Annals of Neurology, 2001, 50, 150-156.	5.3	229
1396	Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation. Annals of Neurology, 2001, 50, 358-365.	5.3	498
1397	Brain membrane phospholipid alterations in Alzheimer's disease. Neurochemical Research, 2001, 26, 771-782.	3.3	265
1398	Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease. Journal of Molecular Neuroscience, 2001, 17, 101-118.	2.3	449
1399	Abortive apoptosis in Alzheimer's disease. Acta Neuropathologica, 2001, 101, 305-310.	7.7	146
1400	D10S1423 identifies a susceptibility locus for Alzheimer's disease in a prospective, longitudinal, double-blind study of asymptomatic individuals. Molecular Psychiatry, 2001, 6, 413-419.	7.9	31
1401	Neurons in Alzheimer disease emerge from senescence. Mechanisms of Ageing and Development, 2001, 123, 3-9.	4.6	32
1402	Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Research, 2001, 913, 57-67.	2.2	168

#	Article	IF	CITATIONS
1403	Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Research, 2001, 920, 32-40.	2.2	151
1404	Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype. BMC Neurology, 2001, 1, 3.	1.8	69
1405	Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease. Archives of Neurology, 2001, 58, 1395.	4.5	509
1406	Oxidative Damage Is the Earliest Event in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 759-767.	1.7	1,670
1407	O-Glycosylation in Sprouting Neurons in Alzheimer Disease, Indicating Reactive plasticity. Journal of Neuropathology and Experimental Neurology, 2001, 60, 441-448.	1.7	23
1408	Cotton Wool Plaques in Non-Familial Late-Onset Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 1051-1061.	1.7	57
1409	Is ApoE gene a risk factor for vascular dementia in Han Chinese?. International Journal of Molecular Medicine, 2001, 7, 217-9.	4.0	16
1410	SPECT perfusion imaging in the diagnosis of Alzheimer's disease. Neurology, 2001, 56, 950-956.	1.1	232
1411	Alzheimer's disease: Its diagnosis and pathogenesis. International Review of Neurobiology, 2001, 48, 167-217.	2.0	17
1412	Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease. Archives of Neurology, 2001, 58, 397-405.	4.5	1,532
1413	ls Dementia with Lewy Bodies the Second Most Common Cause of Dementia?. Journal of Geriatric Psychiatry and Neurology, 2002, 15, 182-187.	2.3	60
1414	Cognitive decline in AD and mild cognitive impairment is associated with global brain damage. Neurology, 2002, 59, 874-879.	1.1	62
1415	Parkinson Disease Neuropathology. Archives of Neurology, 2002, 59, 102.	4.5	366
1416	Human Eyeblink Classical Conditoning in Normal Aging and Alzheimer's Disease. , 2002, , 163-189.		1
1417	Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD. Neurology, 2002, 58, 1801-1808.	1.1	176
1418	Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease. Archives of General Psychiatry, 2002, 59, 946.	12.3	155
1419	Hippocampal volume as an index of Alzheimer neuropathology. Neurology, 2002, 58, 1476-1482.	1.1	308
1420	A New Hypothesis (Concept) of Diagnosing Alzheimer's Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2002, 57, M645-M647.	3.6	2

#	Article	IF	Citations
1421	Aging and dementia: principles, evaluation and diagnosis. , 2002, , 237-251.		1
1422	Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease. NeuroReport, 2002, 13, 1825-1828.	1.2	60
1423	The Relationship of Major Depressive Disorder to Alzheimer's Disease. , 2002, , 257-275.		0
1424	Incipient Alzheimer's Disease as the Underlying Cause of a Motor Vehicle Crash. Medicine, Science and the Law, 2002, 42, 233-236.	1.0	13
1425	Cerebral Hypoperfusion Generates Cortical Watershed Microinfarcts in Alzheimer Disease. Stroke, 2002, 33, 1986-1992.	2.0	210
1426	Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and Hippocampal Sclerosis in the State of Florida Brain Bank. Alzheimer Disease and Associated Disorders, 2002, 16, 203-212.	1.3	568
1427	Progressive Reduction of Synaptophysin Message in Single Neurons in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2002, 61, 384-395.	1.7	52
1428	Dense-Core Senile Plaques in the Flemish Variant of Alzheimer's Disease Are Vasocentric. American Journal of Pathology, 2002, 161, 507-520.	3.8	108
1429	Increased p75NTR Expression in Hippocampal Neurons Containing Hyperphosphorylated Ï,, in Alzheimer Patients. Experimental Neurology, 2002, 178, 104-111.	4.1	76
1430	Insights into AÎ <sup>2</sup> and Presenilin from a Canine Model of Human Brain Aging. Neurobiology of Disease, 2002, 9, 1-10.	4.4	33
1431	Oxidative Damage to Nucleic Acids in Human Prion Disease. Neurobiology of Disease, 2002, 9, 275-281.	4.4	68
1432	Hippocampal, but not parahippocampal, damage in a case of dense retrograde amnesia: a pathological study. Neuroscience Letters, 2002, 329, 61-64.	2.1	16
1433	Neuropsychological functioning in elderly patients with schizophrenia and Alzheimer's disease. Schizophrenia Research, 2002, 55, 217-227.	2.0	26
1434	Inherited dementias. Neurologic Clinics, 2002, 20, 779-808.	1.8	12
1435	Aβ as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiology of Aging, 2002, 23, 1051-1072.	3.1	140
1436	The challenges of developing and validating molecular and biochemical markers of Alzheimer's disease. Neurobiology of Aging, 2002, 23, 509-511.	3.1	15
1437	Early chronic aluminium exposure impairs long-term potentiation and depression to the rat dentate gyrus in vivo. Neuroscience, 2002, 112, 879-887.	2.3	28
1438	Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with β-amyloid 1–42 in vitro. Neuroscience Letters, 2002, 322, 121-125.	2.1	97

#	Article	IF	CITATIONS
1439	FisiopatologÃa de la enfermedad de Alzheimer. EMC - Tratado De Medicina, 2002, 6, 1-11.	0.0	0
1440	Dementia and Parkinson's Disease. , 0, , 265-267.		0
1441	Neuroinflammation in Neurodegeneration: Lessons from Alzheimer's Disease. , 0, , 283-294.		0
1442	CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer's disease. Journal of Neuroimmunology, 2002, 132, 164-172.	2.3	52
1443	Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer's brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants. Brain Research, 2002, 950, 10-20.	2.2	56
1444	Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Research, 2002, 953, 135-143.	2.2	215
1445	Interactions of oxidative stress with cellular calcium dynamics and glucose metabolism in Alzheimer's disease 1,2 1Guest Editors: Mark A. Smith and George Perry 2This article is a part of a series of reviews on "Causes and Consequences of Oxidative Stress in Alzheimer's Disease.―The full list of papers may be found on the homepage of the journal Free Radical Biology and Medicine, 2002, 32, 1061-1070.	2.9	60
1446	Amyloid-Î <sup>2</sup> and Ï,, serve antioxidant functions in the aging and Alzheimer brain. Free Radical Biology and Medicine, 2002, 33, 1194-1199.	2.9	194
1447	Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Annals of Neurology, 2002, 51, 145-155.	5.3	639
1448	Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease. Annals of Neurology, 2002, 52, 62-67.	5.3	127
1449	Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: The emerging role of oligomeric assemblies. Journal of Neuroscience Research, 2002, 69, 567-577.	2.9	540
1450	Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. Journal of Neuroscience Research, 2002, 70, 514-518.	2.9	122
1451	Progressive supranuclear palsy diagnosis and confounding features: Report on 16 autopsied cases. Movement Disorders, 2002, 17, 1255-1264.	3.9	123
1452	High-resolution localization of clathrin assembly protein AP180 in the presynaptic terminals of mammalian neurons. Journal of Comparative Neurology, 2002, 447, 152-162.	1.6	31
1453	Oxidative imbalance and lipid peroxidation in Alzheimer's disease. Drug Development Research, 2002, 56, 446-451.	2.9	9
1454	Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. Acta Neuropathologica, 2002, 104, 92-104.	7.7	93
1455	Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathologica, 2002, 103, 26-35.	7.7	849
1456	Spermine modulation of the glutamatenmda receptor is differentially responsive to conantokins in normal and Alzheimer's disease human cerebral cortex. Journal of Neurochemistry, 2002, 81, 765-779.	3.9	26

#	Article	IF	CITATIONS
1457	Heat-Shock 70 Messenger RNA Levels in Human Brain: Correlation with Agonal Fever. Journal of Neurochemistry, 2002, 64, 235-246.	3.9	42
1458	Decreased Catalase Activity but Unchanged Superoxide Dismutase Activity in Brains of Patients with Dementia of Alzheimer Type. Journal of Neurochemistry, 1995, 64, 1216-1223.	3.9	149
1459	Variant Forms of Neuronal Glutamate Transporter Sites in Alzheimer's Disease Cerebral Cortex. Journal of Neurochemistry, 1995, 64, 2193-2202.	3.9	63
1460	Monoclonal Antibodies Against the Human Metalloprotease EC 3.4.24.15 Label Neurofibrillary Tangles in Alzheimer's Disease Brain. Journal of Neurochemistry, 1996, 66, 2011-2018.	3.9	14
1461	Characterization of the Clycolipid Associated with Alzheimer Paired Helical Filaments. Journal of Neurochemistry, 2002, 67, 723-733.	3.9	19
1462	Changes of Activity and Isozyme Pattern of Phosphofructokinase in the Brains of Patients with Alzheimer's Disease. Journal of Neurochemistry, 2002, 67, 1164-1171.	3.9	33
1463	Rapid Degeneration of Cultured Human Brain Pericytes by Amyloid β Protein. Journal of Neurochemistry, 1997, 68, 1135-1141.	3.9	144
1464	Corticotropin-Releasing Factor (CRF), CRF-Binding Protein (CRF-BP), and CRF/CRF-BP Complex in Alzheimer's Disease and Control Postmortem Human Brain. Journal of Neurochemistry, 2002, 68, 2053-2060.	3.9	49
1465	4â€Hydroxynonenalâ€Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease. Journal of Neurochemistry, 1997, 68, 2092-2097.	3.9	892
1466	Amyloid $\hat{I}^2$ Protein (25-35) Stimulation of Phospholipase C in LA-N-2 Cells. Journal of Neurochemistry, 2002, 69, 252-258.	3.9	20
1467	Twoâ€Dimensional Characterization of Paired Helical Filamentâ€Tau from Alzheimer's Disease: Demonstration of an Additional 74â€kDa Component and Ageâ€Related Biochemical Modifications. Journal of Neurochemistry, 1997, 69, 834-844.	3.9	69
1468	Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2002, 28, 238-251.	3.2	92
1469	Neuropathological diagnosis of Alzheimer's disease in forensic autopsy of elderly persons with fatal accident. Legal Medicine, 2002, 4, 223-231.	1.3	7
1470	Atherosclerotic Lesions and Mitochondria DNA Deletions in Brain Microvessels as a Central Target for the Development of Human AD and ADâ€Like Pathology in Aged Transgenic Mice. Annals of the New York Academy of Sciences, 2002, 977, 45-64.	3.8	88
1471	Pathological Lesions in Vascular Dementia. Annals of the New York Academy of Sciences, 2002, 977, 279-291.	3.8	16
1472	Brain SPET perfusion in early Alzheimer's disease: where to look?. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 975-978.	6.4	17
1473	Excited to death: different ways to lose your neurones. Biogerontology, 2002, 3, 51-56.	3.9	47
1474	Usefulness of behavioral and electrophysiological studies in transgenic models of Alzheimer's disease. Neurochemical Research, 2003, 28, 1009-1015.	3.3	16

#	Article	IF	CITATIONS
1475	Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Lewy bodies. Neurochemical Research, 2003, 28, 1743-1756.	3.3	73
1476	The Induction of the TNFÂ Death Domain Signaling Pathway in Alzheimer's Disease Brain. Neurochemical Research, 2003, 28, 307-318.	3.3	117
1477	Head Circumference, Education and Risk of Dementia: Findings from the Nun Study. Journal of Clinical and Experimental Neuropsychology, 2003, 25, 671-679.	1.3	226
1478	Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study. Acta Neuropathologica, 2003, 105, 14-17.	7.7	110
1479	Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study. Acta Neuropathologica, 2003, 105, 415-419.	7.7	124
1480	Decreased estrogen receptor-? expression in hippocampal neurons in relation to hyperphosphorylated tau in Alzheimer patients. Acta Neuropathologica, 2003, 106, 213-220.	7.7	54
1481	Heat-induced immunoreactivity of tau protein in neocortical neurons of fire fatalities. International Journal of Legal Medicine, 2003, 117, 282-286.	2.2	11
1482	The impact of cerebrovascular lesions in Alzheimer disease. Journal of Neurology, 2003, 250, 1050-1055.	3.6	86
1483	Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer disease. Journal of Neural Transmission, 2003, 110, 1013-1027.	2.8	45
1484	Prevalence of vascular lesions in Dementia with Lewy Bodies. A postmortem study. Journal of Neural Transmission, 2003, 110, 771-778.	2.8	32
1485	Loss of calbindinâ€Ð <sub>28k</sub> from aging human cholinergic basal forebrain: Relation to neuronal loss. Journal of Comparative Neurology, 2003, 455, 249-259.	1.6	85
1486	JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. Journal of Neurochemistry, 2003, 85, 87-93.	3.9	60
1487	Increased p27, an essential component of cell cycle control, in Alzheimer's disease. Aging Cell, 2003, 2, 105-110.	6.7	88
1488	Association of phosphorylation site of tau protein with neuronal apoptosis in Alzheimer's disease. Journal of the Neurological Sciences, 2003, 208, 17-24.	0.6	55
1489	Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer's disease. Neurobiology of Disease, 2003, 14, 391-403.	4.4	86
1490	Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiology of Aging, 2003, 24, 1029-1046.	3.1	367
1491	Red wine micronutrients as protective agents in Alzheimer-like induced insult. Life Sciences, 2003, 72, 2369-2379.	4.3	52
1492	Immunohistochemical characterization of clathrin assembly protein AP180 and synaptophysin in human brain. Neurobiology of Aging, 2003, 24, 173-178.	3.1	12

#	Article	IF	CITATIONS
1493	Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiology of Aging, 2003, 24, 1-23.	3.1	232
1494	Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease. Neurobiology of Aging, 2003, 24, 655-662.	3.1	57
1495	Methylenetetrahydrofolate reductase and angiotensin converting enzyme gene polymorphisms in two genetically and diagnostically distinct cohort of Alzheimer patients. Neurobiology of Aging, 2003, 24, 933-939.	3.1	58
1496	Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Molecular Brain Research, 2003, 111, 148-154.	2.3	230
1497	Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases. Archives of Neurology, 2003, 60, 337.	4.5	854
1498	Diagnostic challenges of using CSF assay of tau and beta-amyloid42 in atypical degenerative dementias of the Alzheimer type. Archives of Clinical Neuropsychology, 2003, 18, 893-903.	0.5	0
1499	Defects in expression of genes related to synaptic vesicle traffickingin frontal cortex of Alzheimer's disease. Neurobiology of Disease, 2003, 12, 97-109.	4.4	200
1500	Dietary Lipids in the Aetiology of Alzheimer???s Disease. Drugs and Aging, 2003, 20, 399-418.	2.7	36
1501	APP processing is regulated by cytoplasmic phosphorylation. Journal of Cell Biology, 2003, 163, 83-95.	5.2	393
1502	A Collaborative Study of the Emergence and Clinical Features of the Major Depressive Syndrome of Alzheimer's Disease. American Journal of Psychiatry, 2003, 160, 857-866.	7.2	258
1503	Management of Alzheimer's Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2003, 58, M331-M353.	3.6	65
1504	Results of a high-resolution genome screen of 437 Alzheimer's Disease families. Human Molecular Genetics, 2003, 12, 23-32.	2.9	304
1505	<i>APOE</i> E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy. Neurology, 2003, 60, 240-245.	1.1	43
1506	Nonsteroidal Anti-inflammatory Drugs and Alzheimer Disease. JAMA - Journal of the American Medical Association, 2003, 289, 2865.	7.4	42
1507	Hippocampal volume deficits in alcoholic Korsakoff's syndrome. Neurology, 2003, 61, 1716-1719.	1.1	91
1508	Diagnostic challenges of using CSF assay of tau and beta-amyloid42 in atypical degenerative dementias of the Alzheimer type. Archives of Clinical Neuropsychology, 2003, 18, 893-903.	0.5	5
1509	Accidental Fatal Hypothermia in Elderly People with Alzheimer's Disease. Medicine, Science and the Law, 2003, 43, 127-131.	1.0	33
1510	Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology, 2003, 60, 1586-1590.	1.1	290

#	Article	IF	CITATIONS
1511	Characterization of an O-Glycosylated Plaque-Associated Protein from Alzheimer Disease Brain. Journal of Neuropathology and Experimental Neurology, 2003, 62, 34-41.	1.7	17
1512	Amyloid β Pathology in Alzheimer's Disease and Schizophrenia. American Journal of Psychiatry, 2003, 160, 867-872.	7.2	37
1513	Decreased nigral neuromelanin in Alzheimer's disease. Neurological Research, 2003, 25, 179-182.	1.3	17
1514	Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurological Research, 2003, 25, 665-674.	1.3	93
1515	Neuropathology of Cognitively Normal Elderly. Journal of Neuropathology and Experimental Neurology, 2003, 62, 1087-1095.	1.7	541
1516	Loss of Calbindin-D <sub>28K</sub> from Aging Human Cholinergic Basal Forebrain: Relation to Plaques and Tangles. Journal of Neuropathology and Experimental Neurology, 2003, 62, 605-616.	1.7	31
1517	Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future. Radiology, 2003, 226, 315-336.	7.3	372
1518	Early Olfactory Involvement in Alzheimer's Disease. Canadian Journal of Neurological Sciences, 2003, 30, 20-25.	0.5	166
1519	Stress protein expression in the Alzheimer-diseased choroid plexus. Journal of Alzheimer's Disease, 2003, 5, 171-177.	2.6	48
1520	Caractéristiques démographiques de sujets atteints de la maladie d'Alzheimer et de leurs familles. Cahiers Québécois De Démographie, 2003, 32, 177-200.	0.5	0
1521	Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: Correlation with Alzheimer's neuropathology. Journal of Alzheimer's Disease, 2003, 5, 39-48.	2.6	129
1522	Perceptual Organization Based Upon Spatial Relationships in Alzheimer's Disease. Behavioural Neurology, 2003, 14, 19-28.	2.1	19
1524	Alzheimer disease risk associated with <i>APOE4</i> is modified by <i>STH</i> gene polymorphism. Neurology, 2004, 62, 1631-1633.	1.1	13
1525	Personal Postscript. Wiley Series in Probability and Statistics, 2004, , 787-816.	0.0	0
1526	ApoE: Crossroads between Alzheimer's Disease and Atherosclerosis. Seminars in Vascular Medicine, 2004, 4, 279-285.	2.1	10
1527	The Effect of the ApoE ε4 Allele on Recognition Memory for Olfactory and Visual Stimuli in Patients with Pathologically Confirmed Alzheimer's Disease, Probable Alzheimer's Disease, and Healthy Elderly Controls. Journal of Clinical and Experimental Neuropsychology, 2004, 26, 779-794.	1.3	65
1528	The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease. Current Alzheimer Research, 2004, 1, 11-25.	1.4	32
1529	The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology, 2004, 62, 1984-1989.	1.1	403

		CITATION RE	PORT	
#	Article		IF	CITATIONS
1530	Alzheimer disease without neocortical neurofibrillary tangles. Neurology, 2004, 62, 114	1147.	1.1	54
1531	Combining Correlated Diagnostic Tests: Application to Neuropathologic Diagnosis of Alz Disease. Medical Decision Making, 2004, 24, 659-669.	heimer's	2.4	27
1532	Regional Analysis of Differently Phosphorylated Tau Proteins in Brains from Patients with Disease. Dementia and Geriatric Cognitive Disorders, 2004, 17, 122-131.	Alzheimer's	1.5	17
1533	Isolated Executive Impairment and Associated Frontal Neuropathology. Dementia and Ge Cognitive Disorders, 2004, 17, 360-367.	eriatric	1.5	27
1534	Apolipoprotein E ε4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopat Synucleinopathies, and Frontotemporal Degeneration. Archives of Neurology, 2004, 61,	hies, 1579.	4.5	64
1535	Neuropathologic Criteria for Diagnosing Alzheimer Disease in Persons with Pure Dement Alzheimer Type. Journal of Neuropathology and Experimental Neurology, 2004, 63, 1028	ia of -1037.	1.7	60
1536	Differences in olfactory and visual memory in patients with pathologically confirmed Alzl disease and the Lewy body variant of Alzheimer's disease. Journal of the International Neuropsychological Society, 2004, 10, 835-842.	neimer's	1.8	33
1537	Right prosubiculum amyloid plaque density correlates with anosognosia in Alzheimer's d Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1396-1400.	isease.	1.9	37
1538	Impact of <i>APOE</i> genotype on neuropathologic and neurochemical markers of Alzl Neurology, 2004, 62, 1977-1983.	reimer disease.	1.1	192
1539	Selective loss of NMDA receptor NR1 subunit isoforms in Alzheimer's disease. Journal of Neurochemistry, 2004, 89, 240-247.		3.9	45
1540	Neuroprotective properties of Bcl-w in Alzheimer disease. Journal of Neurochemistry, 200 1233-1240.	)4, 89,	3.9	54
1541	Differential expression of N-methyl-d-aspartate receptor NR2 isoforms in Alzheimer's disc of Neurochemistry, 2004, 90, 913-919.	ease. Journal	3.9	105
1542	(r)-, but not (s)-alpha lipoic acid stimulates deficient brain pyruvate dehydrogenase comp vascular dementia, but not in Alzheimer dementia. Journal of Neural Transmission, 2004,		2.8	24
1543	A new brain-derived neurotrophic factor transcript and decrease inbrain-derived neurotro factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. Journal of Neurochem 82, 1058-1064.	phic istry, 2004,	3.9	122
1544	Distribution, levels, and activation of MEK1 in Alzheimer's disease. Journal of Neurochem 86, 136-142.	istry, 2004,	3.9	55
1545	Retinal ganglion cells in Alzheimer's disease and aging. Annals of Neurology, 1993, 33, 2	48-257.	5.3	267
1546	Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-ass regulator of cyclin B, in Alzheimer's disease. Journal of Neuroscience Research, 2004, 75	sociated 698-703.	2.9	63
1547	Effect of long-term aluminum feeding on lipid/phospholipid profiles of rat brain myelin. L Health and Disease, 2004, 3, 13.	ipids in	3.0	29

	CITATION	CITATION REPORT	
Article		IF	Citations
Alzheimer's pathology in human temporal cortex surgically excised after severe brain in Experimental Neurology, 2004, 190, 192-203.	njury.	4.1	358
Stimulation of $\hat{l}^2$ -amyloid precursor protein $\hat{l}_{\pm}$ -processing by phorbol ester involves calactivation. Biochemical and Biophysical Research Communications, 2004, 316, 332-34	cium and calpain Ю.	2.1	32
Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease. Neuron, 20	04, 44, 181-193.	8.1	1,127
TBP, a polyglutamine tract containing protein, accumulates in Alzheimer's disease. Mo Research, 2004, 125, 120-128.	lecular Brain	2.3	21
Increased caveolin-1 expression in Alzheimer's disease brain. Neurobiology of Agin	g, 2004, 25, 753-759.	3.1	110
Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. Aging, 2004, 25, 977-989.	Neurobiology of	3.1	90
Evaluation of visual recognition memory in MCI patients. Neurology, 2004, 62, 1317-1	322.	1.1	208
Imaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brair	. Current	1.9	237

1552	Increased caveolin-1 expression in Alzheimer's disease brain. Neurobiology of Aging, 2004, 25, 753-759.	3.1	110
1553	Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. Neurobiology of Aging, 2004, 25, 977-989.	3.1	90
1554	Evaluation of visual recognition memory in MCI patients. Neurology, 2004, 62, 1317-1322.	1.1	208
1555	Imaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain. Current Pharmaceutical Design, 2004, 10, 1469-1492.	1.9	237
1556	Dissociation of remote and anterograde memory impairment and neural correlates in alcoholic Korsakoff syndrome. Journal of the International Neuropsychological Society, 2004, 10, 427-41.	1.8	49
1558	Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. Journal of Alzheimer's Disease, 2005, 6, 639-649.	2.6	117
1559	Differentiating Pathologic Delta From Healthy Physiologic Delta in Patients With Alzheimer Disease. Sleep, 2005, 28, 865-870.	1.1	37
1560	Pathology of the Insular Cortex in Alzheimer Disease Depends on Cortical Architecture. Journal of Neuropathology and Experimental Neurology, 2005, 64, 910-922.	1.7	87
1561	Complement Activation in Very Early Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 55-66.	1.3	99
1562	Brain aluminum, magnesium and phosphorus contents of control and Alzheimer-diseased patients. Journal of Alzheimer's Disease, 2005, 7, 273-284.	2.6	128
1563	Correlation between tau phosphorylation sites and tangle morphology in Alzheimer's disease. Psychogeriatrics, 2005, 5, 22-35.	1.2	2
1564	A 74-year-old woman presenting slowly progressive dementia and emotional instability. Neuropathology, 2005, 25, 107-109.	1.2	2
1565	Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Research, 2005, 1060, 144-152.	2.2	73
1566	A split-brain model of Alzheimer's disease?. Neuropsychologia, 2005, 43, 1307-1317.	1.6	20

#

1548

1549

#	Article	IF	Citations
1567	Linkage to chromosome 14q in Alzheimer's disease (AD) patients without psychotic symptoms. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 132B, 9-13.	1.7	26
1568	Characteristics of neuronal lipofuscin in the superior temporal gyrus in Alzheimer's disease do not differ from non-diseased controls: a comparison with disease-related changes in the superior frontal gyrus. Acta Neuropathologica, 2005, 109, 490-496.	7.7	6
1569	Three-dimensional reconstruction and analysis of structure characteristics on senile plaques of Alzheimer's disease. Science Bulletin, 2005, 50, 868-874.	1.7	0
1570	Associations of cortical astrogliosis with cognitive performance and dementia status. Journal of Alzheimer's Disease, 2005, 6, 595-604.	2.6	90
1571	What is aging? What is its role in Alzheimer's disease? What can we do about it?. Journal of Alzheimer's Disease, 2005, 7, 247-253.	2.6	21
1572	Cellular Changes in Alzheimer's Disease. , 0, , 1073-1081.		2
1573	Diagnosis of Alzheimer's disease: Two-decades of progress. Journal of Alzheimer's Disease, 2005, 9, 409-415.	2.6	29
1574	The Role of Aβ Peptides in Alzheimers Disease. Protein and Peptide Letters, 2005, 12, 513-519.	0.9	24
1575	Three-dimensional recon-struction and analysis of structure characteristics on senile plaques of Alzheimer's disease. Science Bulletin, 2005, 50, 868.	1.7	0
1576	Ribosomal RNA in Alzheimer Disease Is Oxidized by Bound Redox-active Iron. Journal of Biological Chemistry, 2005, 280, 20978-20986.	3.4	261
1577	Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology, 2005, 65, 397-403.	1.1	170
1578	Environmental reduplicative paramnesia in a case of atypical Alzheimer's disease. Neurocase, 2005, 11, 216-226.	0.6	13
1579	Large Meta-Analysis Establishes the ACE Insertion-Deletion Polymorphism as a Marker of Alzheimer's Disease. American Journal of Epidemiology, 2005, 162, 305-317.	3.4	190
1580	A Potent and Selective Tacrine Analog—Biomembrane Permeation and Physicochemical Characterization. Pharmaceutical Development and Technology, 2005, 10, 525-538.	2.4	12
1581	Changing Patient Characteristics and Survival Experience in an Alzheimer's Center Patient Cohort. Dementia and Geriatric Cognitive Disorders, 2005, 20, 198-208.	1.5	52
1582	Blood Cells Cholinesterase Activity in Early Stage Alzheimer's Disease and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2005, 19, 204-212.	1.5	29
1583	Loss of perineuronal net N-acetylgalactosamine in Alzheimer's disease. Acta Neuropathologica, 2005, 110, 393-401.	7.7	93
1584	Diagnosis of Alzheimer's disease: Two decades of progress. , 2005, 1, 93-98.		16

#	Article	IF	CITATIONS
1585	Commentary on "Diagnosis of Alzheimer's disease: Two decades of progress.―Alzheimer's Disease: Years of Progress, and an Army of Researchers Recruited; AD Remains an Elusive Adversary. , 2005, 1, 109-111.		1
1586	Commentary on "Diagnosis of Alzheimer's disease: Two decades of progress.―Symptomatology and biomolecular basis of Alzheimer's: A synthesis. , 2005, 1, 102-106.		0
1587	Evaluation of the Nucleolar Organizer Regions in Alzheimer's Disease. Gerontology, 2005, 51, 297-301.	2.8	30
1588	Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients. Neuroscience Letters, 2005, 388, 49-53.	2.1	55
1589	Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. Journal of Clinical Neuroscience, 2005, 12, 221-230.	1.5	51
1590	Lib, transcriptionally induced in senile plaque-associated astrocytes, promotes glial migration through extracellular matrix. Biochemical and Biophysical Research Communications, 2005, 335, 631-636.	2.1	18
1591	Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiology of Aging, 2005, 26, 455-464.	3.1	43
1592	Altered p59Fyn kinase expression accompanies disease progression in Alzheimer's disease: implications for its functional role. Neurobiology of Aging, 2005, 26, 625-635.	3.1	88
1593	Expression of somatostatin receptor subtypes (SSTR1–5) in Alzheimer's disease brain: An immunohistochemical analysis. Neuroscience, 2005, 134, 525-538.	2.3	90
1594	Reduced Density of Cholinergic Interneurons in the Ventral Striatum in Schizophrenia: An In Situ Hybridization Study. Biological Psychiatry, 2005, 58, 408-416.	1.3	71
1595	Dementia of Alzheimer's disease and other neurodegenerative disorders—memantine, a new hope. Pharmacological Research, 2005, 51, 1-17.	7.1	268
1596	Alzheimer's disease and vascular brain lesions. Journal of the Neurological Sciences, 2005, 231, 1-2.	0.6	5
1597	Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory. Journal of Neuroscience, 2005, 25, 7709-7717.	3.6	1,839
1598	Neuropathology of Alzheimer's Disease. Neuroimaging Clinics of North America, 2005, 15, 755-765.	1.0	64
1599	Comparison of clinical and neuropathologic diagnoses of Alzheimer's disease in 3 epidemiologic samples. Alzheimer's and Dementia, 2006, 2, 2-11.	0.8	42
1600	Statin use and the risk of Alzheimer's disease: The MIRAGE Study. , 2006, 2, 96-103.		48
1601	Phosphorylation of Neuronal Cytoskeletal Proteins in Alzheimer's Disease and Lewy Body Dementias <sup>a</sup> . Annals of the New York Academy of Sciences, 1994, 747, 92-109.	3.8	44
1602	Age-related neuropathology, cognitive decline, and Alzheimer's disease. Ageing Research Reviews, 2006, 5, 1-13.	10.9	134

#	Article	IF	CITATIONS
1603	Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiology of Aging, 2006, 27, 54-66.	3.1	184
1604	Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology. Neurobiology of Aging, 2006, 27, 199-210.	3.1	37
1605	White matter mapping in Alzheimer's disease: A neuropathological study. Neurobiology of Aging, 2006, 27, 673-680.	3.1	46
1606	The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiology of Aging, 2006, 27, 1644-1657.	3.1	129
1607	Cathepsin D-mediated proteolysis of apolipoprotein E: Possible role in Alzheimer's disease. Neuroscience, 2006, 143, 689-701.	2.3	67
1608	Ceruloplasmin (2-D PAGE) Pattern and Copper Content in Serum and Brain of Alzheimer Disease Patients. Biomarker Insights, 2006, 1, 117727190600100.	2.5	9
1609	Apolipoprotein A-V gene polymorphism –1131T>C and Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 10, 365-369.	2.6	5
1610	The essential lesion of Alzheimer disease: A surprise in retrospect. Journal of Alzheimer's Disease, 2006, 9, 29-33.	2.6	9
1611	Alzheimer's disease-related alterations in synaptic density: Neocortex and hippocampus. Journal of Alzheimer's Disease, 2006, 9, 101-115.	2.6	231
1612	Physiopathologie de la maladie d'Alzheimer. EMC - Traité De Médecine AKOS, 2006, 1, 1-11.	0.0	0
1613	La Lunga Attesa: Towards a Molecular Approach to Neuroimaging and Therapeutics in Alzheimer's Disease. Neuroradiology Journal, 2006, 19, 453-474.	1.2	12
1614	Laboratory Diagnosis of Dementia. Laboratory Medicine, 2006, 37, 362-365.	1.2	1
1615	Alzheimer Disease With Amygdala Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2006, 65, 685-697.	1.7	279
1616	Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2006, 65, 740-757.	1.7	95
1617	Argyrophilic Grain Disease in Demented Subjects Presenting Initially With Amnestic Mild Cognitive Impairment. Journal of Neuropathology and Experimental Neurology, 2006, 65, 602-609.	1.7	48
1618	Synaptic remodeling during aging and in Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 9, 91-99.	2.6	111
1619	The key role of mitochondria in Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 9, 101-110.	2.6	273
1620	A polymorphism in lipoprotein lipase affects the severity of Alzheimer's disease pathophysiology. European lournal of Neuroscience, 2006, 24, 1245-1251.	2.6	35

#	Article	IF	CITATIONS
1621	Dementia with Lewy Bodies. A Distinct Nonâ€Alzheimer Dementia Syndrome?. Brain Pathology, 1998, 8, 299-324.	4.1	96
1622	Senile Dementia with Tangles (Tangle Predominant Form of Senile Dementia). Brain Pathology, 1998, 8, 367-376.	4.1	124
1623	Micropurification of Two Human Cerebrospinal Fluid Proteins by High Performance Electrophoresis Chromatography. Journal of Neurochemistry, 1993, 61, 533-540.	3.9	18
1624	Distribution, levels and phosphorylation of Raf-1 in Alzheimer's disease. Journal of Neurochemistry, 2006, 99, 1377-1388.	3.9	28
1625	Alzheimer 100 – highlights in the history of Alzheimer research. Journal of Neural Transmission, 2006, 113, 1603-1623.	2.8	108
1626	Altered synaptic function in Alzheimer's disease. European Journal of Pharmacology, 2006, 545, 11-21.	3.5	95
1627	A novel membrane protein, encoded by the gene covering KIAA0233, is transcriptionally induced in senile plaque-associated astrocytes. Brain Research, 2006, 1108, 19-27.	2.2	55
1628	Neural substrates of cognitive and behavioral deficits in atypical Alzheimer's disease. Brain Research Reviews, 2006, 51, 176-211.	9.0	74
1629	Characterization of α1-antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma. Neurobiology of Disease, 2006, 24, 89-100.	4.4	54
1630	HDDD2 is a familial frontotemporal lobar degeneration with ubiquitinâ€positive, tauâ€negative inclusions caused by a missense mutation in the signal peptide of progranulin. Annals of Neurology, 2006, 60, 314-322.	5.3	186
1631	Change in circulating C-reactive protein is not associated with atorvastatin treatment in Alzheimer's disease. Neurological Research, 2006, 28, 621-624.	1.3	10
1632	Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia. Archives of Neurology, 2006, 63, 674.	4.5	377
1633	What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?. Brain, 2006, 129, 729-735.	7.6	235
1634	Alzheimer's Disease. Seminars in Neurology, 2006, 26, 499-506.	1.4	50
1635	Neuropathologic Features of Amnestic Mild Cognitive Impairment. Archives of Neurology, 2006, 63, 665.	4.5	562
1636	Human neurons express type I GnRH receptor and respond to GnRH I by increasing luteinizing hormone expression. Journal of Endocrinology, 2006, 191, 651-663.	2.6	64
1638	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. Expert Review of Neurotherapeutics, 2007, 7, 473-485.	2.8	41
1639	Memory changes with age. , 2007, , 483-518.		1

		CITATION RE	EPORT	
#	ARTICLE Idiopathic normal-pressure hydrocephalus: clinical comorbidity correlated with cerebral findings and outcome of cerebrospinal fluid shunting. Journal of Neurology, Neurosurg	l biopsy erv and	IF 1.9	CITATIONS
1641	Psychiatry, 2007, 78, 157-161. Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment. Current Top Chemistry, 2007, 7, 115-126.		2.1	161
1642	Education and Alzheimer disease without dementia. Neurology, 2007, 68, 223-228.		1.1	297
1643	Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias. Arc Neurology, 2007, 64, 535.	hives of	4.5	66
1644	Chapter 2 Alzheimer's Disease. Blue Books of Neurology, 2007, , 33-58.		0.1	2
1646	Atlas of Alzheimer's Disease. , 0, , .			7
1647	Chapter 3 Mild Cognitive Impairment. Blue Books of Neurology, 2007, , 59-87.		0.1	2
1648	Molecular Characterization and Measurement of Alzheimer's Disease Pathology: Implic Genetic and Environmental Aetiology. Novartis Foundation Symposium, 1992, 169, 26		1.1	3
1649	Ultrastructural Localization of Intraneuronal AÎ <sup>2</sup> -Peptide in Alzheimer Disease Brains. Jo Alzheimer's Disease, 2007, 11, 53-59.	urnal of	2.6	69
1651	Neuropathologic Heterogeneity in HDDD1: A Familial Frontotemporal Lobar Degenerat Ubiquitin-positive Inclusions and Progranulin Mutation. Alzheimer Disease and Associa 2007, 21, 1-7.		1.3	53
1652	Dementing Diseases Among Elderly Persons Who Suffered Fatal Accidents. American Ja Forensic Medicine and Pathology, 2007, 28, 73-79.	ournal of	0.8	13
1653	Autophagocytosis of Mitochondria Is Prominent in Alzheimer Disease. Journal of Neuro Experimental Neurology, 2007, 66, 525-532.	pathology and	1.7	138
1655	ls aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?. Neurobiolo 2007, 28, 1465-1480.	ogy of Aging,	3.1	124
1656	Disparate letter and semantic category fluency deficits in autopsy-confirmed frontoten dementia and Alzheimer's disease Neuropsychology, 2007, 21, 20-30.	nporal	1.3	143
1657	Racemization of the amyloidal $\hat{l}^2$ Asp1 residue blocks the acceleration of fibril formatio racemization of the Asp23 residue. Biochemical and Biophysical Research Communicat 464-469.		2.1	25
1658	Increased expression of the Nogo receptor in the hippocampus and its relation to the r in Alzheimer's disease. Human Pathology, 2007, 38, 426-434.	neuropathology	2.0	26
1659	The enigma of mixed dementia. Alzheimer's and Dementia, 2007, 3, 40-53.		0.8	111
1660	A chapter in the development of Alzheimer's disease research: A case study of public p development and funding of research programs. , 2007, 3, 243-258.	olicies on the		19

ARTICLE IF CITATIONS Morbo di Alzheimer. EMC - Neurologia, 2007, 7, 1-26. 0.0 0 1664 Neuropathological evaluation of mixed dementia. Journal of the Neurological Sciences, 2007, 257, 0.6 222 80-87 Continuous Fluorometric Assays for Acetylcholinesterase Activity and Inhibition with Conjugated 1667 13.8 151 Polyelectrolytes. Angewandte Chemie - International Edition, 2007, 46, 7882-7886. Creutzfeldtâ€Jakob disease with Alzheimerâ€type Al̂2â€reactive amyloid plaques. Histopathology, 1995, 26, 1669 2.9 445-450. Immunohistochemical localization of dopamine receptor subtypes (D1R–D5R) in Alzheimer's disease 1670 2.2 97 brain. Brain Research, 2007, 1131, 187-196. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics Journal, 2007, 7, 10-28. 1671 Increased Expression of p130 in Alzheimer Disease. Neurochemical Research, 2007, 32, 639-644. 1672 3.3 13 The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathologica, 2007, 113, 7.7 200 349-388. Evidence of DNA damage in Alzheimer disease: phosphorylation of histone H2AX in astrocytes. Age, 1674 3.0 133 2008, 30, 209-215. Phosphorylated tau in neuritic plaques of APPsw/Tauvlw transgenic mice and Alzheimer disease. Acta Neuropathologica, 2008, 116, 409-418. Activation of MKK6, an upstream activator of p38, in Alzheimer's disease. Journal of Neurochemistry, 1676 3.9 141 2008, 79, 311-318. Galaninâ€Like Immunoreactivity Is Increased in the Postmortem Cerebral Cortex from Patients with 3.9 Alzheimer's Disease. Journal of Neurochemistry, 1994, 62, 1516-1523. Diabetes and overweight associate with nonâ€APOE4 genotype in an alzheimer's disease population. 1678 1.7 35 American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 822-829. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. Journal of Neuroscience Methods, 1679 2.5 2008, 172, 277-282. Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe 1680 4.1 361 Consortium. Brain Pathology, 2008, 18, 484-496. Elevated levels of proâ€apoptotic p53 and its oxidative modification by the lipid peroxidation product, HNE, in brain from subjects with amnestic mild cognitive impairment and Alzheimer's disease. Journal 98 of Cellular and Molecular Medicine, 2008, 12, 987-994. Ageing, Alzheimer disease and mental retardation. Journal of Intellectual Disability Research, 1994, 38, 1682 2.0 28 233-239. Age and apoE associations with complex pathologic features in Alzheimer's disease. Journal of the Neurological Sciences, 2008, 273, 34-39

#	Article	IF	CITATIONS
1684	Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease. , 2008, , 93-157.		10
1685	Argyrophilic grains: A distinct disease or an additive pathology?. Neurobiology of Aging, 2008, 29, 566-573.	3.1	70
1686	Potential Role of Diffusion Tensor MRI in the Differential Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease. American Journal of Roentgenology, 2008, 190, 1369-1374.	2.2	71
1687	Alzheimer's disease and the eye. Ophthalmic and Physiological Optics, 1996, 16, S2.	2.0	8
1688	Neprilysin: An Enzyme Candidate to Slow the Progression of Alzheimer's Disease. American Journal of Pathology, 2008, 172, 1342-1354.	3.8	157
1689	Consortium to Establish a Registry for Alzheimer's Disease (CERAD): The first twenty years. Alzheimer's and Dementia, 2008, 4, 96-109.	0.8	333
1690	Interleukin-18 increases expression of kinases involved in tau phosphorylation in SH-SY5Y neuroblastoma cells. Journal of Neuroimmunology, 2008, 205, 86-93.	2.3	76
1691	Alzheimer Disease Pathology As a Host Response. Journal of Neuropathology and Experimental Neurology, 2008, 67, 523-531.	1.7	150
1692	Role of the Neuropathology of Alzheimer Disease in Dementia in the Oldest-Old. Archives of Neurology, 2008, 65, 1211-7.	4.5	142
1693	Structural Changes in Alzheimers Disease Brain Microvessels. Current Alzheimer Research, 2008, 5, 392-395.	1.4	44
1694	Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain, 2008, 131, 1630-1645.	7.6	837
1695	Human apolipoprotein C-I expression in mice impairs learning and memory functions. Journal of Lipid Research, 2008, 49, 856-869.	4.2	34
1696	Distinct cognitive profiles and rates of decline on the Mattis Dementia Rating Scale in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. Journal of the International Neuropsychological Society, 2008, 14, 373-383.	1.8	46
1697	Chronic Inflammation and Amyloidogenesis in Alzheimer's Disease Role of Spirochetes1. Journal of Alzheimer's Disease, 2008, 13, 381-391.	2.6	136
1698	Cholinergic Neuronal and Axonal Abnormalities Are Present Early in Aging and in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2008, 67, 309-318.	1.7	172
1699	Phosphorylated Tau: Toxic, Protective, or None of the Above. Journal of Alzheimer's Disease, 2008, 14, 377-383.	2.6	80
1700	Interaction of Neuritic Plaques and Education Predicts Dementia. Alzheimer Disease and Associated Disorders, 2008, 22, 188-193.	1.3	28
1702	Chromogranin B and Secretogranin II in Transgenic Mice Overexpressing Human APP751 with the London (V717I) and Swedish (K670M/N671L) Mutations and in Alzheimer Patients. Journal of Alzheimer's Disease, 2008, 13, 123-135.	2.6	11

#	Article	IF	CITATIONS
1704	Brain lodine and Other Halogens of Control and Alzheimer's Diseased Patients. , 2009, , 663-674.		0
1705	Genetic Regulatory Network Analysis for <i>App</i> Based on Genetical Genomics Approach. Experimental Aging Research, 2009, 36, 79-93.	1.2	14
1706	Large Vessel Cerebral Atherosclerosis Is Not in Direct Association with Neuropathological Lesions of Alzheimer's Disease. European Neurology, 2009, 62, 93-98.	1.4	34
1707	Clinical field-strength MRI of amyloid plaques induced by low-level cholesterol feeding in rabbits. Brain, 2009, 132, 1346-1354.	7.6	16
1708	Creutzfeldt-Jakob, Parkinson, Lewy Body Dementia and Alzheimer Diseases: From Diagnosis to Therapy. Central Nervous System Agents in Medicinal Chemistry, 2009, 9, 2-11.	1.1	11
1709	Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease. Archives of Neurology, 2009, 66, 1557-62.	4.5	188
1710	Chapter 6 Monitoring Autophagy in Alzheimer's Disease and Related Neurodegenerative Diseases. Methods in Enzymology, 2009, 453, 111-144.	1.0	26
1711	Vitamin A Deficiency in Rats Induces Anatomic and Metabolic Changes Comparable with Those of Neurodegenerative Disorders. Journal of Nutrition, 2009, 139, 696-702.	2.9	22
1712	Episodic simulation of future events is impaired in mild Alzheimer's disease. Neuropsychologia, 2009, 47, 2660-2671.	1.6	257
1713	Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurologica Scandinavica, 1993, 88, 16-21.	2.1	29
1714	Genomic convergence to identify candidate genes for Alzheimer Disease on chromosome 10. Human Mutation, 2009, 30, 463-471.	2.5	69
1715	TNF-related apoptosis-inducing ligand level in Alzheimer's disease. Neurological Sciences, 2009, 30, 263-267.	1.9	19
1716	Criteria for the neuropathological diagnosis of dementing disorders: routes out of the swamp?. Acta Neuropathologica, 2009, 117, 101-110.	7.7	47
1717	A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathologica, 2009, 118, 505-517.	7.7	41
1718	Classification and basic pathology of Alzheimer disease. Acta Neuropathologica, 2009, 118, 5-36.	7.7	805
1719	TARDBP 3′-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathologica, 2009, 118, 633-645.	7.7	139
1720	Antiamnesic potential of <i> Murraya koenigii</i> leaves. Phytotherapy Research, 2009, 23, 308-316.	5.8	42
1721	Alzheimer's disease: synaptic dysfunction and Aβ. Molecular Neurodegeneration, 2009, 4, 48.	10.8	388

#	Article	IF	CITATIONS
1722	The dorsal raphe nucleus shows phosphoâ€ŧau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?. Neuropathology and Applied Neurobiology, 2009, 35, 406-416.	3.2	186
1723	Does Alzheimer's disease begin in the brainstem?. Neuropathology and Applied Neurobiology, 2009, 35, 532-554.	3.2	170
1724	Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature, 2009, 461, 916-922.	27.8	567
1725	Analysis of the nicastrin promoter rs10752637 polymorphism and its association with Alzheimer's disease. European Journal of Neuroscience, 2009, 30, 1831-1836.	2.6	11
1726	Involvement of paraoxonase 1 genetic variants in Alzheimer's disease neuropathology. European Journal of Neuroscience, 2009, 30, 1823-1830.	2.6	30
1727	Current Hypotheses and Research Milestones in Alzheimer's Disease. , 2009, , .		4
1728	Expression of interleukin-18 is increased in the brains of Alzheimer's disease patients. Neurobiology of Aging, 2009, 30, 198-209.	3.1	186
1729	Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. Neurobiology of Aging, 2009, 30, 561-573.	3.1	77
1730	Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease. Neurobiology of Aging, 2009, 30, 1026-1036.	3.1	558
1731	Expression, purification, and characterization of recombinant human β-amyloid42 peptide in Escherichia coli. Protein Expression and Purification, 2009, 64, 55-62.	1.3	25
1732	Assessing neuronal networks: Understanding Alzheimer's disease. Progress in Neurobiology, 2009, 89, 125-133.	5.7	109
1733	Heme-a, the heme prosthetic group of cytochrome c oxidase, is increased in Alzheimer's disease. Neuroscience Letters, 2009, 461, 302-305.	2.1	8
1734	Alzheimer's Disease and the Eyeâ~†. Journal of Optometry, 2009, 2, 103-111.	1.3	65
1735	Alzheimer's Disease: An Overview. , 2009, , 259-263.		3
1736	Changing perspectives regarding late-life dementia. Nature Reviews Neurology, 2009, 5, 649-658.	10.1	259
1737	Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1-14.	1.7	492
1738	Reexamining Alzheimer's Disease: Evidence for a Protective Role for Amyloid-β Protein Precursor and Amyloid-β. Journal of Alzheimer's Disease, 2009, 18, 447-452.	2.6	139
1739	Neuroimaging Studies in Alzheimer's Disease. Neuroradiology Journal, 2009, 22, 525-533.	1.2	0

#	Article	IF	CITATIONS
1740	Transgenic Alzheimer Mice Have a Larger Minimum Alveolar Anesthetic Concentration of Isoflurane than Their Nontransgenic Littermates. Anesthesia and Analgesia, 2010, 110, 438-441.	2.2	18
1741	Reduced Homocysteine-Thiolactonase Activity in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 1177-1183.	2.6	37
1742	Endothelin-1 is Elevated in Alzheimer's Disease Brain Microvessels and is Neuroprotective. Journal of Alzheimer's Disease, 2010, 21, 887-896.	2.6	42
1743	Ascertainment Bias in the Clinical Diagnosis of Alzheimer Disease. Archives of Neurology, 2010, 67, 1364-9.	4.5	35
1744	Neuropathologic Alterations in Mild Cognitive Impairment: A Review. Journal of Alzheimer's Disease, 2010, 19, 221-228.	2.6	202
1745	Alzheimer Disease. Disease-a-Month, 2010, 56, 484-546.	1.1	391
1747	Intraneuronal amyloid $\hat{\rm l}^2$ accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiology of Disease, 2010, 37, 731-737.	4.4	88
1748	Callosal microstructural abnormalities in Alzheimer's disease and alcoholism: same phenotype, different mechanisms. Psychiatry Research - Neuroimaging, 2010, 184, 49-56.	1.8	17
1750	D10S1423 identifies a susceptibility locus for Alzheimer's disease ( <i>AD7</i> ) in a prospective, longitudinal, doubleâ€blind study of asymptomatic individuals: Results at 14 years. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 359-364.	1.7	9
1751	Synthesis of physostigmine analogues and evaluation of their anticholinesterase activities. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1532-1534.	2.2	34
1752	Profile of Cognitive Impairment in Parkinson's Disease. Brain Pathology, 2010, 20, 640-645.	4.1	156
1753	Demented Patients. , 2010, , 105-118.		1
1754	Neocortical Variation of AÎ <sup>2</sup> Load in Fully Expressed, Pure Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 57-68.	2.6	19
1755	Diagnostic Tests for Alzheimer's Disease: Rationale, Methodology, and Challenges. International Journal of Alzheimer's Disease, 2010, 2010, 1-6.	2.0	13
1756	Biopsy Pathology of Neurodegenerative Disorders in Adults. , 2010, , 551-571.		0
1757	Pharmacological evidences for antiamnesic potentials of Phyllanthus amarus in mice. African Journal Biomedical Research, 2010, 10, .	0.4	9
1758	Morphological Changes of the Human Purkinje Cells and Deposition of Neuritic Plaques and Neurofibrillary Tangles on the Cerebellar Cortex of Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 585-591.	1.9	54
1759	Aging-Related Memory Disorders—Alzheimer's Disease. , 2010, , 292-319.		2

#	Article	IF	CITATIONS
1760	Which Presidents Are Most Memorable?. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 32-36.	1.9	1
1761	Brain Aging in the Oldest-Old. Current Gerontology and Geriatrics Research, 2010, 2010, 1-10.	1.6	37
1762	Can enzyme kinetics of prooxidants teach us a lesson about the treatment of Alzheimer's disease: A pilot post-mortem study. World Journal of Biological Psychiatry, 2010, 11, 677-681.	2.6	5
1763	Biochemical and Histochemical Comparison of Cholinesterases in Normal and Alzheimer Brain Tissues. Current Alzheimer Research, 2010, 7, 386-400.	1.4	35
1764	Functional, Global and Cognitive Decline Correlates to Accumulation of Alzheimers Pathology in MCI and AD. Current Alzheimer Research, 2010, 7, 280-286.	1.4	68
1765	Genetic regulatory network analysis for Myoc based on genetical genomics approach. , 2010, , .		0
1766	In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology, 2010, 74, 77-84.	1.1	165
1767	Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomarkers in Medicine, 2010, 4, 51-63.	1.4	65
1768	Toward a pathological definition of vascular dementia. Journal of the Neurological Sciences, 2010, 299, 136-138.	0.6	64
1769	Neuroprotective effects of salidroside against beta-amyloid-induced oxidative stress in SH-SY5Y human neuroblastoma cells. Neurochemistry International, 2010, 57, 547-555.	3.8	186
1770	RANTES upregulation in the Alzheimer's disease brain: A possible neuroprotective role. Neurobiology of Aging, 2010, 31, 8-16.	3.1	132
1771	Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiology of Aging, 2010, 31, 1805-1813.	3.1	93
1772	Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: The essential role of the Neuropathology Core. Alzheimer's and Dementia, 2010, 6, 274-279.	0.8	31
1773	Brain Endothelial Cells Synthesize Neurotoxic Thrombin in Alzheimer's Disease. American Journal of Pathology, 2010, 176, 1600-1606.	3.8	95
1774	A theoretical artificial approach on reducing mitochondrial abnormalities in Alzheimer's disease. , 2010, , .		2
1775	Neuropathological Alterations in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2011, 1, a006189-a006189.	6.2	2,365
1776	Positron Emission Tomography Radiopharmaceuticals for Imaging Brain Beta-Amyloid. Seminars in Nuclear Medicine, 2011, 41, 283-299.	4.6	76
1777	An electrochemical platform for acetylcholinesterase activity assay and inhibitors screening based on Michael addition reaction between thiocholine and catechol-terminated SAMs. Analyst, The, 2011, 136, 5084.	3.5	9

		CHATION R	EPORI	
#	Article		IF	CITATIONS
1778	Coenzyme Q10 and cognition in atorvastatin treated dogs. Neuroscience Letters, 201	1, 501, 92-95.	2.1	15
1779	Revision of the criteria for Alzheimer's disease: A symposium. Alzheimer's and Dementi	a, 2011, 7, e1-12.	0.8	33
1780	Introduction to the recommendations from the National Institute on Agingâ€Alzheime workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementi 257-262.	r's Association a, 2011, 7,	0.8	1,547
1781	Assessment of cognition in mild cognitive impairment: A comparative study. Alzheimer 2011, 7, 338-355.	's and Dementia,	0.8	85
1782	Revised criteria for diagnosis of Alzheimer's disease: National Institute on Agingâ€Alzh Association diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2		0.8	58
1783	Prospective memory in Alzheimer's disease and Mild Cognitive Impairment. Dementia B Neuropsychologia, 2011, 5, 64-68.	:	0.8	19
1784	When mild cognitive impairment really is Alzheimer's disease. , 0, , 18-25.			0
1785	Biomarkers Predicting Alzheimer's Disease in Cognitively Normal Aging. Journal of Clini	cal Neurology		

#	Article	IF	CITATIONS
1796	Blocking the Apolipoprotein E/Amyloid-β Interaction Reduces Fibrillar Vascular Amyloid Deposition and Cerebral Microhemorrhages in TgSwDI Mice. Journal of Alzheimer's Disease, 2011, 24, 269-285.	2.6	47
1797	A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brainâ€derived synaptic plasticityâ€disrupting Aβ. Journal of Neurochemistry, 2011, 119, 189-201.	3.9	28
1798	Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype. Molecular Psychiatry, 2011, 16, 836-847.	7.9	47
1799	Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurology, The, 2011, 10, 785-796.	10.2	733
1800	Loss of motor function in preclinical Alzheimer's disease. Expert Review of Neurotherapeutics, 2011, 11, 665-676.	2.8	200
1801	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathologica, 2011, 122, 673-690.	7.7	277
1802	Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. Journal of Neuroinflammation, 2011, 8, 90.	7.2	273
1803	Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is â€~too big to fail'. Journal of Pathology, 2011, 224, 147-152.	4.5	110
1804	Normalization of gene expression using SYBR green qPCR: A case for paraoxonase 1 and 2 in Alzheimer's disease brains. Journal of Neuroscience Methods, 2011, 200, 14-19.	2.5	31
1805	Stem Cell Therapy for Alzheimers Disease. CNS and Neurological Disorders - Drug Targets, 2011, 10, 459-485.	1.4	43
1806	A multi-task learning formulation for predicting disease progression. , 2011, , .		171
1807	Therapeutic Interventions Targeting Beta Amyloid Pathogenesis in an Aging Dog Model. Current Neuropharmacology, 2011, 9, 651-661.	2.9	17
1808	The search for neuroimaging biomarkers of Alzheimer's disease with advanced MRI techniques. Acta Radiologica, 2011, 52, 211-222.	1.1	33
1809	Emerging roles of pathogens in Alzheimer disease. Expert Reviews in Molecular Medicine, 2011, 13, e30.	3.9	162
1810	Overview and Findings from the Rush Memory and Aging Project. Current Alzheimer Research, 2012, 9, 646-663.	1.4	733
1811	Differences between Early and Late-Onset Alzheimer's Disease in Neuropsychological Tests. Frontiers in Neurology, 2012, 3, 81.	2.4	51
1812	Is the Amyloid Hypothesis of Alzheimer's disease therapeutically relevant?. Biochemical Journal, 2012, 446, 165-177.	3.7	89
1813	Overview and Findings from the Religious Orders Study. Current Alzheimer Research, 2012, 9, 628-645.	1.4	582

#	Article	IF	Citations
	Editorial (Hot Topic: Epidemiology & Risk Factors for Alzheimer's Disease). Current Alzheimer		
1814	Research, 2012, 9, 617-620.	1.4	23
1815	Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. Advances in Pharmacology, 2012, 64, 27-81.	2.0	78
1816	Pathologic Lesions in Neurodegenerative Diseases. Progress in Molecular Biology and Translational Science, 2012, 107, 1-40.	1.7	22
1817	Resting state brain networks and their implications in neurodegenerative disease. Proceedings of SPIE, 2012, , .	0.8	0
1818	Modeling disease progression via fused sparse group lasso. , 2012, 2012, 1095-1103.		121
1819	Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. Immunotherapy, 2012, 4, 213-238.	2.0	121
1820	An evaluation of the impact of <i>MAPT</i> , <i>SNCA</i> and <i>APOE</i> on the burden of Alzheimer's and Lewy body pathology. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 424-429.	1.9	50
1821	Understanding Dementia Prevalence Among Centenarians. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2012, 67A, 358-365.	3.6	52
1822	Vascular dementia: why pathology is still important. Reviews in Clinical Gerontology, 2012, 22, 35-51.	0.5	2
1823	Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. Journal of Neuropathology and Experimental Neurology, 2012, 71, 266-273.	1.7	797
1824	Pathologic Accumulation of α-Synuclein and Aβ in Parkinson Disease Patients With Dementia. Archives of Neurology, 2012, 69, 1326.	4.5	173
1825	p38 MAPK: A Mediator of Hypoxia-Induced Cerebrovascular Inflammation. Journal of Alzheimer's Disease, 2012, 32, 587-597.	2.6	34
1826	Neuropathological Basis of AlzheimerÂ's Disease and AlzheimerÂ's Disease Diagnosis. Advances in Biological Psychiatry, 2012, , 49-70.	0.2	1
1827	Gene Expression Profiling in Alzheimer's Disease Brain Microvessels. Journal of Alzheimer's Disease, 2012, 31, 193-205.	2.6	22
1828	Modeling the Dementia Epidemic. CNS Neuroscience and Therapeutics, 2012, 18, 175-181.	3.9	9
1829	Metabolic Alterations Induced by Sucrose Intake and Alzheimer's Disease Promote Similar Brain Mitochondrial Abnormalities. Diabetes, 2012, 61, 1234-1242.	0.6	129
1830	Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathologica, 2012, 124, 681-692.	7.7	103
1831	Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiology of Aging, 2012, 33, 622.e1-622.e16.	3.1	62

#	Article	IF	CITATIONS
1832	Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Progress in Neurobiology, 2012, 97, 38-51.	5.7	153
1833	Molecular imaging of dementia. Psychogeriatrics, 2012, 12, 106-114.	1.2	22
1834	The challenges of tau imaging. Future Neurology, 2012, 7, 409-421.	0.5	82
1835	Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients. Journal of Proteomics, 2012, 75, 2080-2092.	2.4	48
1836	Mitochondria and Cell Bioenergetics: Increasingly Recognized Components and a Possible Etiologic Cause of Alzheimer's Disease. Antioxidants and Redox Signaling, 2012, 16, 1434-1455.	5.4	169
1837	Potential of a γ-Glutamyl-Transpeptidase-Stable Glutathione Analogue against Amyloid-β Toxicity. ACS Chemical Neuroscience, 2012, 3, 204-210.	3.5	19
1838	Hippocampal atrophy in Alzheimer's disease. Neurodegenerative Disease Management, 2012, 2, 197-209.	2.2	2
1839	Erythrocyte antioxidants in aging and dementia. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2012, 6, 273-277.	0.4	5
1840	Reversal of memory deficits by ethanolic extract of Mimusops elengi Linn. in mice. Pharmacognosy Journal, 2012, 4, 30-39.	0.8	2
1841	Long Night's Journey into the Day: Amyloid-β Imaging in Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S349-S359.	2.6	21
1842	A Cultural Algorithm for the Representation of Mitochondrial Population. Advances in Artificial Intelligence, 2012, 2012, 1-7.	0.9	8
1843	Isolation, Identification and Characterization of a Antidementia Acetylcholinesterase Inhibitor-Producing <i>Yarrowia lipolytica</i> S-3. Mycobiology, 2012, 40, 42-46.	1.7	0
1844	CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathologica, 2012, 124, 23-35.	7.7	161
1845	Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. Journal of Neurochemistry, 2012, 120, 419-429.	3.9	422
1846	Mitsugumin 29 is transcriptionally induced in senile plaque-associated astrocytes. Brain Research, 2012, 1441, 9-16.	2.2	5
1847	Association of interleukin $1\hat{l}^2$ polymorphisms and haplotypes with Alzheimer's disease. Journal of Neuroimmunology, 2012, 247, 59-62.	2.3	28
1848	A meta-analysis of voxel-based morphometry studies of white matter volume alterations in Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2012, 36, 757-763.	6.1	85
1849	Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 202-208.	6.4	40

#	Article	IF	CITATIONS
1850	Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	6.4	55
1851	Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathologica, 2012, 123, 433-447.	7.7	78
1852	Is AD a homogeneous nosologic entity? Yes. Journal of Neural Transmission, 2013, 120, 1467-1473.	2.8	0
1853	Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease. Drug Discovery Today, 2013, 18, 1185-1199.	6.4	107
1854	Synthesis and anticholinesterase activity of (â^')-physostigmine analogues with modifications at C3a and C5. Chemical Research in Chinese Universities, 2013, 29, 888-893.	2.6	1
1855	Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathologica, 2013, 125, 289-302.	7.7	87
1856	Clinicopathologic Study of Alzheimer's Disease: Alzheimer Mimics. Journal of Alzheimer's Disease, 2013, 35, 799-811.	2.6	43
1857	Neuropsychiatric Features of Frontal LobeÂDysfunction in Autopsy-Confirmed Patients with Lewy Bodies and "Pure―Alzheimer Disease. American Journal of Geriatric Psychiatry, 2013, 21, 509-519.	1.2	22
1858	Modeling disease progression via multi-task learning. NeuroImage, 2013, 78, 233-248.	4.2	174
1859	Hemispheric asymmetry of primary auditory cortex and Heschl's gyrus in schizophrenia and nonpsychiatric brains. Psychiatry Research - Neuroimaging, 2013, 214, 435-443.	1.8	13
1860	Computational Assembly of Polymorphic Amyloid Fibrils Reveals Stable Aggregates. Biophysical Journal, 2013, 104, 683-693.	0.5	36
1861	The molecular mechanism for human metallothionein-3 to protect against the neuronal cytotoxicity of Aβ1–42 with Cu ions. Journal of Biological Inorganic Chemistry, 2013, 18, 39-47.	2.6	19
1862	Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis. Medical Clinics of North America, 2013, 97, 377-398.	2.5	52
1863	Diagnostic opportunities based on skin biomarkers. European Journal of Pharmaceutical Sciences, 2013, 50, 546-556.	4.0	64
1864	Exploring the differences between mouse mAβ1–42 and human hAβ1–42 for Alzheimer's disease related properties and neuronal cytotoxicity. Chemical Communications, 2013, 49, 5865.	4.1	27
1865	Predicting Cognitive Decline in Subjects at Risk for Alzheimer Disease by Using Combined Cerebrospinal Fluid, MR Imaging, and PET Biomarkers. Radiology, 2013, 266, 583-591.	7.3	212
1866	Neurovascular Unit and the Effects of Dosage in VEGF Toxicity: Role for Oxidative Stress and Thrombin. Journal of Alzheimer's Disease, 2013, 34, 281-291.	2.6	36
1867	Molecular Pathology of Alzheimer's Disease. Colloquium Series on Neurobiology of Alzheimer S Disease, 2013, 1, 1-91.	0.0	4

#	Article	IF	CITATIONS
1868	The Prion Protein Ligand, Stress-Inducible Phosphoprotein 1, Regulates Amyloid-β Oligomer Toxicity. Journal of Neuroscience, 2013, 33, 16552-16564.	3.6	70
1869	Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI. PLoS ONE, 2013, 8, e55531.	2.5	41
1870	Dementia: An Evidence-Based Review of Common Presentations and Family-Based Interventions. Journal of Osteopathic Medicine, 2013, 113, 768-775.	0.8	12
1871	Age-dependent effect of Alzheimer's risk variant of CLU on EEG alpha rhythm in non-demented adults. Frontiers in Aging Neuroscience, 2013, 5, 86.	3.4	27
1872	Review article What causes alzheimer's disease?. Folia Neuropathologica, 2013, 3, 169-188.	1.2	141
1873	Neuropathology of Alzheimer's Disease. , 2014, , 2014-2020.		3
1874	CSF Biomarkers of Alzheimer's Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. Advances in Geriatrics, 2014, 2014, 1-14.	1.6	15
1875	Thioredoxin System Regulation in the Central Nervous System: Experimental Models and Clinical Evidence. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-13.	4.0	60
1876	Can a Bacterial Endotoxin be a Key Factor in the Kinetics of Amyloid Fibril Formation?. Journal of Alzheimer's Disease, 2014, 39, 169-179.	2.6	149
1877	Factors Determining Disease Duration in Alzheimer's Disease: A Postmortem Study of 103 Cases Using the Kaplan-Meier Estimator and Cox Regression. BioMed Research International, 2014, 2014, 1-7.	1.9	15
1878	Solving Reality Problems by Using Mutual Information Analysis. Mathematical Problems in Engineering, 2014, 2014, 1-4.	1.1	1
1879	Computer-Based Assessment of Alzheimer's Disease Employing fMRI and/or EEG: A Comprehensive Review. Neuromethods, 2014, , 351-383.	0.3	1
1880	A Candidate Plasma Protein Classifier to Identify Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 549-563.	2.6	37
1881	The dark sides of amyloid in Alzheimer's disease pathogenesis. FEBS Letters, 2014, 588, 641-652.	2.8	53
1882	The complexities of the pathology–pathogenesis relationship in Alzheimer disease. Biochemical Pharmacology, 2014, 88, 671-676.	4.4	77
1883	Glutamatergic Dysfunctioning in Alzheimer's Disease and Related Therapeutic Targets. Journal of Alzheimer's Disease, 2014, 42, S177-S187.	2.6	64
1884	A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson disease. Journal of Neural Transmission, 2014, 121, 171-181.	2.8	37
1885	LED-based interferometric reflectance imaging sensor for the detection of amyloid-β aggregation. Analyst, The, 2014, 139, 59-65.	3.5	5

#	Article	IF	CITATIONS
1886	Golgi Apparatus and Protein Trafficking in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, S153-S162.	2.6	37
1887	Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer's disease?. Alzheimer's Research and Therapy, 2014, 6, 24.	6.2	35
1888	The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 372-380.	0.8	189
1889	Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 777-788.	2.6	32
1890	Brain stem hemorrhage due to cerebral amyloid angiopathy: The autopsy of a patient with Alzheimer's disease at a young age. Legal Medicine, 2014, 16, 98-101.	1.3	3
1891	Parkinsonism and distinct dementia patterns in a family with the MAPT R406W mutation. , 2014, 10, 360-365.		17
1892	Memory Deficits in Aging and Neurological Diseases. Progress in Molecular Biology and Translational Science, 2014, 122, 1-29.	1.7	29
1893	A comparison of Al <sup>2</sup> amyloid pathology staging systems and correlation with clinical diagnosis. Acta Neuropathologica, 2014, 128, 543-550.	7.7	26
1894	Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathologica, 2014, 128, 411-421.	7.7	119
1896	A critical analysis of the â€~amyloid cascade hypothesis'. Folia Neuropathologica, 2014, 3, 211-225.	1.2	87
1897	Type-1 Cannabinoid Receptor Activity During Alzheimer's Disease Progression. Journal of Alzheimer's Disease, 2014, 42, 761-766.	2.6	54
1898	Forensic Aspects of Adult and General Neuropathology. , 2014, , 89-262.		0
1899	Oculoâ€visual changes and clinical considerations affecting older patients with dementia. Ophthalmic and Physiological Optics, 2015, 35, 352-376.	2.0	54
1900	Neuropathologic assessment of participants in two multiâ€center longitudinal observational studies: The <scp>A</scp> lzheimer <scp>D</scp> isease <scp>N</scp> euroimaging <scp>I</scp> nitiative ( <scp>ADNI</scp> ) and the <scp>D</scp> ominantly <scp>I</scp> nherited <scp>A</scp> lzheimer <scp>N</scp> etwork ( <scp>DIAN</scp> ). Neuropathology, 2015, 35, 390-400.	1.2	68
1902	Cognitive reserve and Aβ1-42 in mild cognitive impairment (Argentina-Alzheimer's) Tj ETQc	10.0.0 rgB <sup>-</sup>	T /Qverlock 1
1903	Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. , 2015, 6, 282.		101
1904	Alternative neural circuitry that might be impaired in the development of Alzheimer disease. Frontiers in Neuroscience, 2015, 9, 145.	2.8	7
1905	Cortical Transcriptional Profiles in APOE4 Carriers with Alzheimer's Disease: Patterns of Protection and Degeneration. Journal of Alzheimer's Disease. 2015. 48. 969-978.	2.6	10

ARTICLE IF CITATIONS Eyeblink Classical Conditioning., 2015, , 635-641. 1906 0 Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. Journal of Medicinal 6.4 88 Chemistry, 2015, 58, 4365-4382. Clinicopathologic and<sup>11</sup>C-Pittsburgh compound B implications of Thal amyloid phase 1908 270 7.6 across the Alzheimer's disease spectrum. Brain, 2015, 138, 1370-1381. A decade from discovery to therapy: Lingo-1, the dark horse in neurological and psychiatric disorders. 1909 6.1 Neuroscience and Biobéhavioral Réviews, 2015, 56, 97-114. Amyloid-Î<sup>2</sup> as a biomarker for Alzheimer's disease: quantification methods in body fluids. Expert Review 1910 3.0 27 of Proteomics, 2015, 12, 343-354. Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants. Alzheimer's and Dementia, 2015, 11, 815-822. 0.8 46 Historic evidence to support a causal relationship between spirochetal infections and Alzheimer's 1912 3.4 142 disease. Frontiers in Aging Neuroscience, 2015, 7, 46. Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review. Movement 159 Disorders, 2015, 30, 928-935. Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease. Neuroscience, 1914 2.3 265 2015, 309, 29-50. Modern Electroencephalographic Assessment Techniques. Neuromethods, 2015, , . Emerging Concepts in Alzheimer's Disease. Annual Review of Pathology: Mechanisms of Disease, 2015, 1917 22.4 211 10, 291-319. HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study. Molecular Psychiatry, 2015, 20, 867-873. New Perspectives in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease: Novel Uses of 1919 0 Biomarkers., 2016, , . ADAMTS4, 5, 9, and 15 Expressions in the Autopsied Brain of Patients with Alzheimer's Disease: A 1920 2.1 Preliminary Immunohistochemistry Study. Journal of Microbiology and Biotechnology, 2016, 26, 7-14. Bacterial Amyloid and DNA are Important Constituents of Senile Plaques: Further Evidence of the 1921 120 2.6 Spirochetal and Biofilm Nature of Senile Plaques. Journal of Alzheimer's Disease, 2016, 53, 1459-1473. Role of Striatal-Enriched Tyrosine Phosphatase in Neuronal Function. Neural Plasticity, 2016, 2016, 1-9. 2.2 28 The Influence of Na+, K+-ATPase on Glutamate Signaling in Neurodegenerative Diseases and Senescence. 1923 2.8 49 Frontiers in Physiology, 2016, 7, 195. New Hydroxyquinolineâ€Based Derivatives as Potent Modulators of Amyloidâ€Î<sup>2</sup> Aggregations. Archiv Der 1924 4.1 Pharmazie, 2016, 349, 327-341.

## # ARTICLE

IF CITATIONS

Andrographolide recovers cognitive impairment in a natural model of Alzheimer's disease (Octodon) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5

1926	Handbook of Gerontology Research Methods. , 0, , .		1
1927	Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology. Journal of Molecular Neuroscience, 2016, 58, 109-119.	2.3	10
1929	Optical Detection of Enzymatic Activity and Inhibitors on Non-Covalently Functionalized Fluorescent Graphene Oxide. ACS Nano, 2016, 10, 5346-5353.	14.6	33
1930	Quantification of immunohistochemical findings of neurofibrillary tangles and senile plaques for a diagnosis of dementia in forensic autopsy cases. Legal Medicine, 2016, 22, 82-89.	1.3	3
1931	Butyrylcholinesterase K and Apolipoprotein E-É>4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects. Journal of Alzheimer's Disease, 2016, 54, 913-922.	2.6	33
1932	Tenascin-C Is Associated with Cored Amyloid-β Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly. Journal of Neuropathology and Experimental Neurology, 2016, 75, 868-876.	1.7	31
1933	β-Amyloid-acetylcholine molecular interaction: new role of cholinergic mediators in anti-Alzheimer therapy?. Future Medicinal Chemistry, 2016, 8, 1179-1189.	2.3	32
1934	Design, Synthesis and Bioassays of 3â€Substitutedâ€3â€Hydroxyoxindoles for Cholinesterase Inhibition. ChemistrySelect, 2016, 1, 3580-3588.	1.5	16
1935	Kinematic Analyses of Graphomotor Functions in Individuals with Alzheimer's Disease and Amnestic Mild Cognitive Impairment. Journal of Medical and Biological Engineering, 2016, 36, 334-343.	1.8	20
1936	On cognitive ecology and the environmental factors that promote Alzheimer disease: lessons from Octodon degus (Rodentia: Octodontidae). Biological Research, 2016, 49, 10.	3.4	25
1937	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.8	1,318
1938	Amyloid imaging: Past, present and future perspectives. Ageing Research Reviews, 2016, 30, 95-106.	10.9	43
1939	Changes in Neurotransmitter Profiles during Early Zebrafish ( <i>Danio rerio</i> ) Development and after Pesticide Exposure. Environmental Science & Technology, 2016, 50, 3222-3230.	10.0	84
1940	Neuroimaging biomarkers in Alzheimer's disease and other dementias. Ageing Research Reviews, 2016, 30, 4-16.	10.9	32
1941	Modeling and predicting AD progression by regression analysis of sequential clinical data. Neurocomputing, 2016, 195, 50-55.	5.9	7
1942	Discovery of <i>N</i> -(Pyridin-4-yl)-1,5-naphthyridin-2-amines as Potential Tau Pathology PET Tracers for Alzheimer's Disease. Journal of Medicinal Chemistry, 2017, 60, 1272-1291.	6.4	31
1943	Vascular protective effects of KLF2 on Aβ-induced toxicity: Implications for Alzheimer's disease. Brain Research, 2017, 1663, 174-183.	2.2	16

	Сітат	ION REPOR	:T	
#	Article	IF		CITATIONS
1944	Research in Computational Molecular Biology. Lecture Notes in Computer Science, 2017, 10229, 389-39	0. 1.3	5	1
1945	Spinal Alterations of Reil Insula in Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2017, 32, 222-229.	1.9	)	4
1946	Alzheimer Disease. Mayo Clinic Proceedings, 2017, 92, 978-994.	3.0	)	57
1947	Tau Positron Emission Tomography Imaging. Cold Spring Harbor Perspectives in Biology, 2017, 9, a023721.	5.5	5	24
1948	Nonlinearity-aware based dimensionality reduction and over-sampling for AD/MCI classification from MRI measures. Computers in Biology and Medicine, 2017, 91, 21-37.	7.0	)	41
1949	Advanced Drug Discovery for Alzheimer's Disease: Challenges and Strategies. , 2017, , 9-29.			0
1950	Applications for Treatment of Neurodegenerative Diseases. Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques, 2017, , 99-134.	0.6	5	5
1951	Monitoring disease progression in mild cognitive impairment: Associations between atrophy patterns, cognition, APOE and amyloid. NeuroImage: Clinical, 2017, 16, 418-428.	2.7	,	23
1952	Sparse shared structure based multi-task learning for MRI based cognitive performance prediction of Alzheimer's disease. Pattern Recognition, 2017, 72, 219-235.	8.1	L	42
1953	Drug Design: Principles and Applications. , 2017, , .			5
1954	Four Decades of Research in Alzheimer's Disease (1975–2014): A Bibliometric and Scientometric Analysis. Journal of Alzheimer's Disease, 2017, 59, 763-783.	2.6	5	33
1955	Centella asiatica, an Ayurvedic Medicinal Plant, Prevents the Major Neurodegenerative and Neurotoxic Mechanisms Associated with Cognitive Impairment. Medicinal and Aromatic Plants of the World, 2017, , 3-48.	0.2	2	3
1956	Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 341-358.	7.4	Ļ	42
1958	Aβ-amyloid and Tau Imaging in Dementia. Seminars in Nuclear Medicine, 2017, 47, 75-88.	4.6	5	96
1959	The Differential Effects of Alzheimer's Disease and Lewy Body Pathology on Cognitive Performance: a Meta-analysis. Neuropsychology Review, 2017, 27, 1-17.	4.9	)	34
1960	DNA methylation alterations in Alzheimer's disease. Environmental Epigenetics, 2017, 3, dvx008.	1.8		54
1962	Diagnosis of Alzheimer's—Standard-of-Care. , 2017, , 52-77.			2
1963	Neuroinflammation and Infection: Molecular Mechanisms Associated with Dysfunction of Neurovascular Unit. Frontiers in Cellular and Infection Microbiology, 2017, 7, 276.	3.9	)	112

#	Article	IF	CITATIONS
1964	Identification of Cerebral Metal Ion Imbalance in the Brain of Aging Octodon degus. Frontiers in Aging Neuroscience, 2017, 9, 66.	3.4	26
1965	MicroRNA-322 attenuates aluminum maltolate-induced apoptosis in the human SH-SY5Y neuroblastoma cell line. Molecular Medicine Reports, 2017, 16, 2199-2204.	2.4	13
1966	Lower Serum Levels of miR-29c-3p and miR-19b-3p as Biomarkers for Alzheimer's Disease. Tohoku Journal of Experimental Medicine, 2017, 242, 129-136.	1.2	76
1967	Maternal Vitamin B Deficiency and Epigenetic Changes of Genes Involved in the Alzheimer' s Disease Pathogenesis. Biology and Medicine (Aligarh), 2017, 09, .	0.3	1
1968	Neuroinflammation in Alzheimer's disease: Pleiotropic roles for cytokines and neuronal pentraxins. Behavioural Brain Research, 2018, 347, 49-56.	2.2	39
1969	Amyloid-β with isomerized Asp7 cytotoxicity is coupled to protein phosphorylation. Scientific Reports, 2018, 8, 3518.	3.3	24
1970	<i>CDK5RAP2</i> gene and tau pathophysiology in lateâ€onset sporadic Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 787-796.	0.8	15
1971	Isoprenoids and tau pathology in sporadic Alzheimer's disease. Neurobiology of Aging, 2018, 65, 132-139.	3.1	24
1972	lmaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions. Nature Reviews Neurology, 2018, 14, 225-236.	10.1	321
1973	Alterations in cholesterol metabolism–related genes in sporadic Alzheimer's disease. Neurobiology of Aging, 2018, 66, 180.e1-180.e9.	3.1	39
1974	Alzheimer's Disease Assessment: A Review and Illustrations Focusing on Item Response Theory Techniques. Assessment, 2018, 25, 360-373.	3.1	16
1975	Emergence of breath testing as a new non-invasive diagnostic modality for neurodegenerative diseases. Brain Research, 2018, 1691, 75-86.	2.2	12
1976	Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 2018, 31, 90-96.	2.3	21
1977	Modeling Alzheimer's disease cognitive scores using multi-task sparse group lasso. Computerized Medical Imaging and Graphics, 2018, 66, 100-114.	5.8	31
1978	Analysis of Structure and Cost in an American Longitudinal Study of Alzheimer's Disease. , 2018, 08, .		4
1979	Diverse Protein Profiles in CNS Myeloid Cells and CNS Tissue From Lipopolysaccharide- and Vehicle-Injected APPSWE/PS1ΔE9 Transgenic Mice Implicate Cathepsin Z in Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2018, 12, 397.	3.7	26
1980	Multimodal neuroimaging study of cerebrovascular disease, amyloid deposition, and neurodegeneration in Alzheimer's disease progression. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 638-646.	2.4	10
1981	Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease. Acta Neuropathologica, 2018, 136, 663-689.	7.7	151

#	Article	IF	CITATIONS
1982	Sex and age interact to determine clinicopathologic differences in Alzheimer's disease. Acta Neuropathologica, 2018, 136, 873-885.	7.7	69
1983	Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer's Disease: Present Status and Future Opportunities. Frontiers in Aging Neuroscience, 2018, 10, 284.	3.4	99
1984	TLR4 Gene Expression and Pro-Inflammatory Cytokines in Alzheimer's Disease and in Response to Hippocampal Deafferentation in Rodents. Journal of Alzheimer's Disease, 2018, 63, 1547-1556.	2.6	36
1985	Linearized and Kernelized Sparse Multitask Learning for Predicting Cognitive Outcomes in Alzheimer's Disease. Computational and Mathematical Methods in Medicine, 2018, 2018, 1-13.	1.3	6
1986	In Vivo MRI of Amyloid Plaques in a Cholesterol-Fed Rabbit Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 911-923.	2.6	9
1987	Longitudinal Genotype–Phenotype Association Study through Temporal Structure Auto-Learning Predictive Model. Journal of Computational Biology, 2018, 25, 809-824.	1.6	6
1988	Novel botanical drug DA-9803 prevents deficits in Alzheimer's mouse models. Alzheimer's Research and Therapy, 2018, 10, 11.	6.2	14
1989	<i>APOE</i> ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 2018, 91, e1182-e1195.	1.1	122
1990	Exploring the selective vulnerability in Alzheimer disease using tissue specific variant analysis. Genomics, 2019, 111, 936-949.	2.9	19
1991	Primary Care Mental Health in Older People. , 2019, , .		2
1991 1992	Primary Care Mental Health in Older People. , 2019, , . Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases. , 2019, , 251-298.		2
	Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with	10.8	
1992	Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases. , 2019, , 251-298.	10.8	2
1992 1993	Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases. , 2019, , 251-298. The neuropathological diagnosis of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 32. Association of PPP2R1A with Alzheimer's disease and specific cognitive domains. Neurobiology of		2 1,497
1992 1993 1994	Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases. , 2019, , 251-298. The neuropathological diagnosis of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 32. Association of PPP2R1A with Alzheimer's disease and specific cognitive domains. Neurobiology of Aging, 2019, 81, 234-243. Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National	3.1	2 1,497 12
1992 1993 1994 1995	Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with Lewy Bodies, and Prion and Infectious Diseases. , 2019, , 251-298.         The neuropathological diagnosis of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 32.         Association of PPP2R1A with Alzheimer's disease and specific cognitive domains. Neurobiology of Aging, 2019, 81, 234-243.         Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer's Association Research Framework. JAMA Neurology, 2019, 76, 1174.	3.1	2 1,497 12 182
1992 1993 1994 1995 1996	Neurocognitive Disorders in Old Age: Alzheimer's Disease, Frontotemporal Dementia, Dementia with         Lewy Bodies, and Prion and Infectious Diseases. , 2019, , 251-298.         The neuropathological diagnosis of Alzheimer's disease. Molecular Neurodegeneration, 2019, 14, 32.         Association of PPP2R1A with Alzheimer's disease and specific cognitive domains. Neurobiology of         Aging, 2019, 81, 234-243.         Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National         Institute on Aging–Alzheimer's Association Research Framework. JAMA Neurology, 2019, 76, 1174.         Biological Psychiatry and Psychopharmacology. , 2019, , 397-458.         Purkinje Cells Pathology in Alzheimer's Disease. American Journal of Alzheimer's Disease and Other	<b>3.1</b> 9.0	2 1,497 12 182 0

#	Article	IF	CITATIONS
2001	Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone�. Alzheimer's and Dementia, 2019, 15, 1348-1356.	0.8	20
2002	Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 183, 111707.	5.5	46
2003	Close Association of Myeloperoxidase-Producing Activated Microglia with Amyloid Plaques in Hypercholesterolemic Rabbits. Journal of Alzheimer's Disease, 2019, 67, 1221-1234.	2.6	3
2004	A Luminescence Turn-On Assay for Acetylcholinesterase Activity and Inhibitor Screening Based on Supramolecular Self-Assembly of Alkynylplatinum(II) Complexes on Coordination Polymer. ACS Applied Materials & Interfaces, 2019, 11, 4799-4808.	8.0	35
2005	Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3Î <sup>2</sup> inhibitors. Journal of Molecular Modeling, 2019, 25, 171.	1.8	22
2006	Basal Implantology. , 2019, , .		5
2007	Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation. Alzheimer's and Dementia, 2019, 15, 951-960.	0.8	27
2008	A brief history of "Alzheimer disease― Neurology, 2019, 92, 1053-1059.	1.1	52
2009	Augmented Reality for Early Alzheimer's Disease Diagnosis. , 2019, , .		7
2010	A Novel PEGylated Block Copolymer in New Age Therapeutics for Alzheimer's Disease. Molecular Neurobiology, 2019, 56, 6551-6565.	4.0	16
2011	The Neuropathological and Clinical Diagnostic Criteria of Chronic Traumatic Encephalopathy: A Critical Examination in Relation to Other Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2019, 68, 591-608.	2.6	7
2012	Late Effects. , 2019, , 496-554.		0
2013	Flexible fiber-based optoelectronics for neural interfaces. Chemical Society Reviews, 2019, 48, 1826-1852.	38.1	100
2014	A Survey of Disease Progression Modeling Techniques for Alzheimer's Diseases. , 2019, , .		12
2015	Alzheimer's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 231-255.	1.8	415
2016	An Overview of the Intrinsic Role of Citrullination in Autoimmune Disorders. Journal of Immunology Research, 2019, 2019, 1-39.	2.2	65
2017	An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nature Neuroscience, 2019, 22, 1903-1912.	14.8	242
2018	A Comparative Analysis to Visualize the Behavior of Different Machine Learning Algorithms for Normalized and Un-Normalized Data in Predicting Alzheimer's Disease. Journal of Computational and Theoretical Nanoscience, 2019, 16, 3840-3848.	0.4	1

#	Article	IF	CITATIONS
2019	Temporal association of neuropsychological test performance using unsupervised learning reveals a distinct signature of Alzheimer's disease status. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 964-973.	3.7	6
2020	Coexistence of Multiple Sclerosis and Alzheimer's disease: A review. Multiple Sclerosis and Related Disorders, 2019, 27, 232-238.	2.0	32
2021	Role of GTPases in the Regulation of Mitochondrial Dynamics in Alzheimer's Disease and CNS-Related Disorders. Molecular Neurobiology, 2019, 56, 4530-4538.	4.0	26
2022	Human Plasma Protein Corona of Aβ Amyloid and Its Impact on Islet Amyloid Polypeptide Cross-Seeding. Biomacromolecules, 2020, 21, 988-998.	5.4	15
2023	MicroRNA-425-5p promotes tau phosphorylation and cell apoptosis in Alzheimer's disease by targeting heat shock protein B8. Journal of Neural Transmission, 2020, 127, 339-346.	2.8	23
2024	A Machine Learning Approach to Identify a Circulating MicroRNA Signature for Alzheimer Disease. journal of applied laboratory medicine, The, 2020, 5, 15-28.	1.3	17
2025	A multiscale study on photophysical properties of a novel fluorescent probe for imaging amyloid―β in Alzheimer's disease. International Journal of Quantum Chemistry, 2020, 120, e26344.	2.0	4
2026	Functional genomic analyses uncover APOE-mediated regulationÂofÂbrain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. Acta Neuropathologica Communications, 2020, 8, 196.	5.2	8
2027	Late-onset vs nonmendelian early-onset Alzheimer disease. Neurology: Genetics, 2020, 6, e512.	1.9	82
2028	Chemometric Modeling of Structurally Diverse Carbamates for the Inhibition of Acetylcholinesterase (AChE) Enzyme in Alzheimer's Disease. International Journal of Quantitative Structure-Property Relationships, 2020, 5, 6-60.	0.5	2
2029	MicroRNA-138 promotes neuroblastoma SH-SY5Y cell apoptosis by directly targeting DEK in Alzheimer's disease cell model. BMC Neuroscience, 2020, 21, 33.	1.9	14
2030	Significance of cytosolic cathepsin D in Alzheimer's disease pathology: Protective cellular effects of PLGA nanoparticles against βâ€amyloidâ€toxicity. Neuropathology and Applied Neurobiology, 2020, 46, 686-706.	3.2	14
2031	Sensitivity–Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022.	5.3	32
2032	Protein Biomarkers for the Diagnosis of Alzheimer's Disease at Different Stages of Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 6749.	4.1	4
2033	PyrPeg, a Blood–Brain-Barrier-Penetrating Two-Photon Imaging Probe, Selectively Detects Neuritic Plaques, Not Tau Aggregates. ACS Chemical Neuroscience, 2020, 11, 1801-1810.	3.5	9
2034	A Role of Low-Density Lipoprotein Receptor-Related Protein 4 (LRP4) in Astrocytic Aβ Clearance. Journal of Neuroscience, 2020, 40, 5347-5361.	3.6	35
2035	Modelling neurodegenerative diseases with <scp>3D</scp> brain organoids. Biological Reviews, 2020, 95, 1497-1509.	10.4	30
2036	Healthcare predictive analytics for disease progression: a longitudinal data fusion approach. Journal of Intelligent Information Systems, 2020, 55, 351-369.	3.9	9

#	Article	IF	CITATIONS
2037	NDRG4 Alleviates Aβ1–40 Induction of SH-SY5Y Cell Injury via Activation of BDNF-Inducing Signalling Pathways. Neurochemical Research, 2020, 45, 1492-1499.	3.3	5
2038	Alzheimer's disease and automatic speech analysis: A review. Expert Systems With Applications, 2020, 150, 113213.	7.6	64
2039	Cortical laminar distribution of β-amyloid deposits in five neurodegenerative disorders. Folia Neuropathologica, 2020, 58, 1-9.	1.2	7
2040	Characterization of neurotransmitters and related metabolites in Daphnia magna juveniles deficient in serotonin and exposed to neuroactive chemicals that affect its behavior: A targeted LC-MS/MS method. Chemosphere, 2021, 263, 127814.	8.2	19
2041	A Multilevel View of the Development of Alzheimer's Disease. Neuroscience, 2021, 457, 283-293.	2.3	43
2042	Synthesis and Evaluation of Fluorine-18 Labeled 2-Phenylquinoxaline Derivatives as Potential Tau Imaging Agents. Molecular Pharmaceutics, 2021, 18, 1176-1195.	4.6	16
2043	Alzheimer's Disease Prediction via the Association of Single Nucleotide Polymorphism with Brain Regions. Lecture Notes in Computer Science, 2021, , 102-111.	1.3	0
2044	A Novel Channel Selection Method for BCI Classification Using Dynamic Channel Relevance. IEEE Access, 2021, 9, 126698-126716.	4.2	22
2045	Dual-phase 18F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer's disease. NeuroImage: Clinical, 2021, 31, 102773.	2.7	8
2046	Biomedical Computer Aided Design Systems: Application to Alzheimer Disease. Smart Sensors, Measurement and Instrumentation, 2021, , 285-303.	0.6	2
2047	Betahydroxybutyrate Consumption in Autopsy Brain Tissue from Alzheimer's Disease Subjects. Journal of Alzheimer's Disease Reports, 2021, 5, 135-141.	2.2	2
2048	Molecular Factors Mediating Neural Cell Plasticity Changes in Dementia Brain Diseases. Neural Plasticity, 2021, 2021, 1-20.	2.2	13
2049	Asymmetric Amyloid Deposition as an Early Sign of Progression in Mild Cognitive Impairment Due to Alzheimer Disease. Clinical Nuclear Medicine, 2021, 46, 527-531.	1.3	6
2050	Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. Alzheimer's and Dementia, 2021, 17, 1554-1574.	0.8	114
2051	Brain [F-18]FDG PET for Clinical Dementia Workup: Differential Diagnosis of Alzheimer's Disease and Other Types of Dementing Disorders. Seminars in Nuclear Medicine, 2021, 51, 230-240.	4.6	44
2052	Role of Neuron and Glia in Alzheimer's Disease and Associated Vascular Dysfunction. Frontiers in Aging Neuroscience, 2021, 13, 653334.	3.4	28
2053	Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nature Neuroscience, 2021, 24, 1302-1312.	14.8	105
2054	The complexity of Alzheimer's disease: an evolving puzzle. Physiological Reviews, 2021, 101, 1047-1081.	28.8	110

#	Article	IF	CITATIONS
2055	The potential role of mesenchymal stem cells in modulating antiageing process. Cell Biology International, 2021, 45, 1999-2016.	3.0	5
2056	Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance. Journal of Neurochemistry, 2021, 158, 1394-1411.	3.9	42
2057	Detection of Amyloid β Oligomers by a Fluorescence Ratio Strategy Based on Optically Trapped Highly Doped Upconversion Nanoparticles-SiO <sub>2</sub> @Metal–Organic Framework Microspheres. Analytical Chemistry, 2021, 93, 12447-12455.	6.5	22
2058	Identification of the Neural Circuit Underlying Episodic Memory Deficit in Amnestic Mild Cognitive Impairment via Machine Learning on Gray Matter Volume. Journal of Alzheimer's Disease, 2021, 84, 959-964.	2.6	3
2059	Alzheimer's disease diagnosis framework from incomplete multimodal data using convolutional neural networks. Journal of Biomedical Informatics, 2021, 121, 103863.	4.3	26
2060	METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer's disease through aberrant cell cycle events. Molecular Neurodegeneration, 2021, 16, 70.	10.8	87
2061	A pilot clinical study of low-intensity transcranial focused ultrasound in Alzheimer's disease. Ultrasonography, 2021, 40, 512-519.	2.3	29
2062	Functional bioprobe for responsive imaging and inhibition of amyloid-β oligomer based on curcuminoid scaffold. Journal of Luminescence, 2021, 238, 118218.	3.1	8
2063	New Neuropathological Criteria for Alzheimer Disease. Archives of Neurology, 1998, 55, 1174-1176.	4.5	78
2064	Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease. Archives of Neurology, 1998, 55, 1185-1191.	4.5	275
2065	Biologic Markers, Genetics, and Alzheimer's Disease. Archives of General Psychiatry, 1988, 45, 945.	12.3	9
2067	Relationship of Down's Syndrome to Alzheimer's Disease. , 1990, , 325-340.		14
2068	Alzheimer's Disease: Theories of Causation. Advances in Experimental Medicine and Biology, 1990, 282, 31-38.	1.6	3
2069	The Neuropsychology of Aging and Dementia: Clinical Issues. Springer Series in Neuropsychology, 1988, , 1-60.	0.3	7
2070	Neuropathological Correlates of Dementia in Alzheimer's Disease. Cerebral Cortex, 1999, , 513-551.	0.6	3
2071	Vascular-Related and Mediated Alterations in Alzheimer's Disease. Cerebral Cortex, 1999, , 733-772.	0.6	6
2073	The Neuropathology of Alzheimer's Disease. , 1994, , 185-207.		11
2074	Molecular Pathobiology of Alzheimer's Disease. , 1994, , 209-238.		3

#	Article	IF	Citations
2075	The Clinical Diagnosis of Alzheimer's Disease. , 1994, , 309-326.		1
2076	Neuropathological Bases of Alzheimer Disease, Implications for Treatment. , 1994, , 17-22.		2
2077	Development of a Pyrrolidinone Derivative (Cyclic GABA) for Modulating Brain Glutamate Transmission. Advances in Behavioral Biology, 1989, , 185-196.	0.2	1
2079	The Human Primary Visual Cortex. Cerebral Cortex, 1994, , 469-503.	0.6	6
2080	Alzheimer Neuropathology and Limbic Circuits. , 1993, , 606-626.		14
2081	Early Diagnosis of Alzheimer's Disease. , 2000, , 1-27.		11
2082	Pathological Diagnosis of Alzheimer's Disease. , 2000, , 65-82.		5
2083	Genetic Testing in the Early Diagnosis of Alzheimer's Disease. , 2000, , 105-125.		1
2084	Neuropsychological Detection of Early Probable Alzheimer's Disease. , 2000, , 169-189.		13
2085	Pick Disease. , 1997, , 253-269.		3
2086	The Aβcentric Pathway of Alzheimer's Disease. , 2007, , 5-36.		1
2087	Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. , 2006, , 39-43.		36
2088	Longitudinal Genotype-Phenotype Association Study via Temporal Structure Auto-learning Predictive Model. Lecture Notes in Computer Science, 2017, 10229, 287-302.	1.3	8
2089	The Limbic System. , 2011, , 633-710.		2
2090	Alzheimer's Disease and Age-Related Pathology in Diffuse Lewy Body Disease. , 1992, , 168-186.		6
2091	Heterogeneity in Familial Alzheimer's Disease. Research and Perspectives in Alzheimer's Disease, 1992, , 81-87.	0.1	2
2092	Klinische Aspekte der Alzheimer-Krankheit. , 1999, , 71-103.		4
2093	Aspects of Cortical Destruction in Alzheimer's Disease. , 1997, , 1-16.		9

#	Article	IF	CITATIONS
2094	Connections and Cognitive Impairment in Alzheimer's Disease. , 1997, , 149-166.		11
2095	Monoaminerge Läion bei seniler Demenz vom Alzheimer-Typ (SDAT): Vorläfige Befunde. , 1988, , 151-157.		5
2096	Pathology of Parkinson's Syndrome. Handbook of Experimental Pharmacology, 1989, , 47-112.	1.8	31
2097	Neurodegenerative Diseases: Alzheimer Disease (AD). , 2019, , 897-931.		2
2098	Morphology of Alzheimer's disease and related disorders. Key Topics in Brain Research, 1990, , 61-77.	0.2	36
2099	Measuring cognition in advanced Alzheimer's disease for clinical trials. Journal of Neural Transmission Supplementum, 2002, , 135-148.	0.5	40
2100	The neuropathological diagnosis of Alzheimer disease. Journal of Neural Transmission Supplementum, 1998, 53, 97-118.	0.5	76
2101	Morphological substrates of mental dysfunction in Lewy body disease: an update. , 2000, 59, 185-212.		45
2102	Possible role of the cholinergic system and disease models. , 1997, 49, 93-102.		22
2103	Pathology of familial Alzheimer's disease with Lewy bodies. Journal of Neural Transmission Supplementum, 1997, 51, 121-135.	0.5	22
2104	Morphological substrates of dementia in parkinsonism A critical update. Journal of Neural Transmission Supplementum, 1997, 51, 57-82.	0.5	61
2105	The Lewy body variant of Alzheimer disease. Journal of Neural Transmission Supplementum, 1997, 51, 83-93.	0.5	51
2106	Structural basis of dementia in neurodegenerative disorders. Journal of Neural Transmission Supplementum, 1996, 47, 1-29.	0.5	45
2107	Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: impact on non Alzheimer's dementia?. Journal of Neural Transmission Supplementum, 1996, 47, 259-266.	0.5	10
2108	Neuropathology of Alzheimer's disease: a critical update. Journal of Neural Transmission Supplementum, 1998, 54, 77-95.	0.5	196
2109	Classification of dementias based on functional morphology. Key Topics in Brain Research, 1994, , 9-39.	0.2	7
2110	Pathologic Lesions in Alzheimer Disease and Other Neurodegenerative Diseases—Cellular and Molecular Components. , 2012, , 37-60.		1
2111	The Role of Al̂² and Tau Oligomers in the Pathogenesis of Alzheimer's Disease. , 2012, , 135-188.		5

		CITATION RE	PORT	
#	Article		IF	Citations
2112	Tau proteins and their significance in the pathobiology of Alzheimer's disease. , 1995, , $\cdot$	41-58.		6
2113	Types of Age-Related Brain Lesions and Relationship to Neuropathologic Diagnostic Sys Alzheimer's Disease. , 2001, , 65-76.	tems of		2
2114	Neurobiology of Disorders with Lewy Bodies. , 2001, , 173-182.			2
2115	Aging-Related Memory Disorders. , 2003, , 337-366.			2
2116	The Association of Aluminum and Neurofibrillary Degeneration in Alzheimer's Diseas Perspective. , 2001, , 133-146.	se, a Personal		3
2118	Secretion of the beta/A4 amyloid precursor protein. Identification of a cleavage site in c mammalian cells Journal of Biological Chemistry, 1991, 266, 16960-16964.	ultured	3.4	155
2119	Immunochemical and biochemical characterization of tau proteins in normal and Alzhein brains with Alz 50 and Tau-1 Journal of Biological Chemistry, 1988, 263, 7948-7953.	mer's disease	3.4	84
2120	Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid dep Alzheimer disease. Journal of Biological Chemistry, 1994, 269, 10987-10990.	osits of	3.4	189
2122	Evidence for a dissociation between perceptual and conceptual priming in Alzheimer's c Behavioral Neuroscience, 1991, 105, 326-342.	lisease	1.2	114
2123	Intact acquisition and long-term retention of mirror-tracing skill in Alzheimer's disease a amnesia Behavioral Neuroscience, 1993, 107, 899-910.	nd in global	1.2	84
2124	Assessment of behavioral problems in dementia: The Revised Memory and Behavior Prol Psychology and Aging, 1992, 7, 622-631.	olems Checklist	1.6	457
2126	14 Amyloid Imaging and (What is "Normal�) Aging. , 2009, , 191-244.			2
2127	Aging and mental retardation. Current Opinion in Psychiatry, 1995, 8, 301-307.		6.3	2
2128	Densitometric Analysis of Gαo Protein Subunit Levels from Postmortem Alzheimer Dise and Prefrontal Cortical Membranes. Alzheimer Disease and Associated Disorders, 2000,		1.3	5
2129	Interpretation Variability of 18FDG-Positron Emission Tomography Studies in Dementia. Radiology, 1996, 31, 316-322.	Investigative	6.2	28
2130	Medium-chain fatty acids in nutritional therapy: A review. Malaysian Journal of Fundame Applied Sciences, 2020, 16, 318-323.	ntal and	0.8	2
2131	Neuropathological changes in scrapie and Alzheimer's disease are associated with incre- expression of apolipoprotein E and cathepsin D in astrocytes. Journal of Virology, 1991,		3.4	280
2132	Inverse relation between Braak stage and cerebrovascular pathology in Alzheimer predo dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 799a-800.	minant	1.9	5

#	Article	IF	CITATIONS
2133	Leukoencephalopathy-Related Cerebral Amyloid Angiopathy With Cystatin C Deposition. Stroke, 1996, 27, 1417-1419.	2.0	19
2134	Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid Journal of Clinical Investigation, 1997, 100, 3093-3104.	8.2	98
2135	Forensic Aspects of Adult General Neuropathology. , 2008, , 79-246.		1
2136	The Neuropathology of Alzheimer's Disease. , 1996, , .		5
2137	Polio and ALS. Neurology, 1990, 40, 1150-1150.	1.1	3
2138	Auditory function in Alzheimer's disease. Neurology, 1993, 43, 1893-1893.	1.1	64
2139	Interrater agreement for diagnosis of Alzheimer's disease. Neurology, 1994, 44, 652-652.	1.1	40
2140	Neurobiological correlates of a putative risk allele for Alzheimer's disease on chromosome 12q. Neurology, 1999, 52, 725-725.	1.1	15
2141	Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study. PLoS ONE, 2017, 12, e0171524.	2.5	29
2142	Coexistence of reactive plasticity and neurodegeneration in Alzheimer diseased brains. Histology and Histopathology, 2004, 19, 1075-84.	0.7	13
2143	5-HIAA as a Potential Biological Marker for Neurological and Psychiatric Disorders. Advanced Pharmaceutical Bulletin, 2019, 9, 374-381.	1.4	39
2144	Mitochondrial Abnormalities in Alzheimer's Disease. Journal of Neuroscience, 2001, 21, 3017-3023.	3.6	1,179
2145	Pathophysiology and management of alzheimer's disease: an overview. Journal of Analytical & Pharmaceutical Research, 2018, 7, .	1.0	30
2146	Association Discovery and Diagnosis of AlzheimerÂ's Disease with Bayesian Multiview Learning. Journal of Artificial Intelligence Research, 0, 56, 247-268.	7.0	9
2147	Antioxidant Capacity in the Lipophilic Fraction of Alzheimer's Brain Tissues. Bosnian Journal of Basic Medical Sciences, 2008, 7, 317-321.	1.0	4
2149	Beta-amyloid induces apoptosis of neuronal cells by inhibition of the Arg/N-end rule pathway proteolytic activity. Aging, 2019, 11, 6134-6152.	3.1	10
2151	The Influence of Vitamin D on Neurodegeneration and Neurological Disorders: A Rationale for its Physio-pathological Actions. Current Pharmaceutical Design, 2020, 26, 2475-2491.	1.9	10
2152	Key Peptides and Proteins in Alzheimer's Disease. Current Protein and Peptide Science, 2019, 20, 577-599.	1.4	30

#	Article	IF	CITATIONS
2153	Cognition and memory function of Taraxacum coreanum in an in vivo amyloid-β-induced mouse model of Alzheimer's disease. Archives of Biological Sciences, 2014, 66, 1357-1366.	0.5	7
2154	The Alzheimer s plaques tangles and memory deficits may have a common origin part V why is Ca sup 2 sup signal lower in the disease. Frontiers in Bioscience - Landmark, 1999, 4, a9-15.	3.0	16
2155	Where do Alzheimer's plaques and tangles come from? aging-induced protein degradation inefficiency. Frontiers in Bioscience - Landmark, 2001, 6, e1.	3.0	18
2156	Primary age-related tauopathy and the amyloid cascade hypothesis: the exception that proves the rule?. Journal of Neurology and Neuromedicine, 2016, 1, 53-57.	0.9	43
2158	Age-related mild cognitive deficit: a ready-to-use concept?. Dialogues in Clinical Neuroscience, 2003, 5, 61-76.	3.7	6
2159	Is there a neuropathology difference between mild cognitive impairment and dementia?. Dialogues in Clinical Neuroscience, 2009, 11, 171-179.	3.7	38
2160	Metal and complementary molecular bioimaging in Alzheimer's disease. Frontiers in Aging Neuroscience, 2014, 6, 138.	3.4	44
2161	The Pathology of Alzheimer Disease Elicits an In Vivo Immunological Response. American Journal of Immunology, 2007, 3, 10-14.	0.1	2
2162	Diagnosis of Alzheimer's Disease. Psychiatric Annals, 1996, 26, 262-268.	0.1	9
2163	Effects of exposure to aluminum on long-term potentiation and AMPA receptor subunits in rats in vivo. Biomedical and Environmental Sciences, 2014, 27, 77-84.	0.2	16
2164	Brain imaging of mild cognitive impairment and Alzheimer's disease. Neural Regeneration Research, 2013, 8, 435-44.	3.0	20
2165	Alzheimer's Disease A Century Later. Journal of Clinical Psychiatry, 2006, 67, 1784-1800.	2.2	99
2166	CXB-909 Attenuates Cognitive Deficits in the Mu-P-75 Saporin Mouse Model of Alzheimer's Disease. Neuroscience and Medicine, 2012, 03, 65-68.	0.2	1
2167	Environmental Effects on the Assessment of People With Dementia: A Pilot Study. American Journal of Occupational Therapy, 2003, 57, 396-402.	0.3	19
2168	Characterization of Black Ginseng Extract with Acetyl- and Butyrylcholinesterase Inhibitory and Antioxidant Activities. Journal of Ginseng Research, 2010, 34, 348-354.	5.7	11
2169	Modeling the mitochondrial dysfunction in neurogenerative diseases due to high H+ concentration. Bioinformation, 2011, 6, 173-175.	0.5	12
2170	Prevalence of dementia subtypes in a developing country: a clinicopathological study. Clinics, 2013, 68, 1140-1145.	1.5	42
2171	Brain Amyloid and Alzheimer Disease. Annals of Internal Medicine, 1988, 109, 41.	3.9	54

# 2172	ARTICLE A Method for Predicting Alzheimer's Disease Based on the Fusion of Single Nucleotide Polymorphisms and Magnetic Resonance Feature Extraction. Lecture Notes in Computer Science, 2021, , 105-115.	IF 1.3	CITATIONS 0
2173	Tensor Multi-Task Learning for Predicting Alzheimer's Disease Progression using MRI data with Spatio-temporal Similarity Measurement. , 2021, , .		6
2174	Editorial: Machine Learning for Non/Less-Invasive Methods in Health Informatics. Frontiers in Digital Health, 2021, 3, 763109.	2.8	0
2176	Clinical Aspects of Alzheimer's Disease. , 2001, , 1157-1177.		0
2177	Physiologisches und pathologisches Altern des Gehirns. , 2002, , 91-112.		0
2178	Neurodegenerative Disease. , 2002, , .		0
2179	Dementias. , 2003, , 199-242.		0
2181	Alzheimer's Disease and Vascular Dementia. , 2004, , 103-130.		0
2183	The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics. , 2007, , 194-211.		0
2184	Resonancia magnética IIEspectroscopia. , 2008, , 65-98.		0
2186	Evidence-Based Practice with Alzheimerâ $\in$ Ms Disease and Dementia. , 2009, , 321-341.		0
2187	Strategies for Alzheimer's Disease Diagnosis. , 2009, , 217-226.		0
2188	Control of Fatty Acid Intake and the Role of Essential Fatty Acids in Cognitive Function and Neurological Disorders. Frontiers in Neuroscience, 2009, , 463-484.	0.0	1
2189	Introduction: Still More Questions than Answers. , 2009, , 3-10.		0
2190	10 Imaging Cognitive Decline in Aging: Predicting Decline with Structural Imaging. , 2009, , 135-150.		0
2195	Aβ Imaging in Aging, Alzheimer's Disease and Other Neurodegenerative Conditions. , 2014, , 213-254.		2
2196	Correspondence amongst the PENO Test Battery Cognitive Results and Hippocampal Lesions in Alzheimer's Disease. Advances in Aging Research, 2014, 03, 239-251.	0.4	0
2197	Perfusion SPECT: Its Role in the Diagnosis and Differential Diagnosis of Alzheimer's Disease, with Particular Emphasis on Guidelines. , 2014, , 323-337.		0

#	Article	IF	CITATIONS
2198	Alzheimer's Disease: An Overviewâ~†. , 2014, , .		0
2199	Studies of the Beta-Amyloid Precursor Protein in Brain and the Pathological Transformation of Tau into the Neurofibrillary Tangle. , 1988, , 164-173.		0
2200	Potential Diagnostic Markers for Alzheimer's Disease. , 1989, , 17-22.		1
2202	Die Alzheimer-Krankheit. Verhandlungen Der Deutschen Gesellschaft Für Neurologie, 1989, , 39-51.	0.0	3
2203	Biological Markers of Alzheimer's Disease: A View from the Perspective of Phospholipids in Membrane Function. , 1990, , 205-211.		0
2204	Abnormal Phospholipid Metabolism in Neurodegenerative Diseases: Elevations in Glycerophosphocholine and Glycerophospho-Ethanolamine Levels in Brain of Alzheimer's Disease But Not in Down Syndrome Patients. Advances in Behavioral Biology, 1990, , 133-138.	0.2	0
2205	Reflection of changes in membrane constituents in various regions of Alzheimer brains to differential scanning thermograms. , 1990, 32, 259-267.		1
2206	Alzheimer's Disease and Animal Models. , 1990, , 195-204.		0
2208	Protease Nexin I Immunostaining in Alzheimer's Disease. , 1990, , 329-336.		0
2209	Brain Phospholipids and their Metabolites in Alzheimer's Disease: Possible Role of "Auto-Cannibalism― and Implications for Drug Development. , 1991, , 183-189.		0
2210	ELECTRON MICROSCOPIC STUDIES OF DIFFUSE PLAQUES IN ALZHEIMER-TYPE DEMENTIA. The KITAKANTO Medical Journal, 1991, 41, 807-819.	0.0	0
2211	Typische hÃ <b>¤</b> fige Krankheitssyndrome. , 1991, , 385-489.		1
2212	Phospholipide und Pathophysiologie bei der Alzheimer-Krankheit. , 1992, , 58-66.		0
2213	Development and Aging in Down's Syndrome. , 1992, , 141-156.		1
2214	DEMONSTRATION OF SERINE PROTEASE INHIBITORS IN THE ALZHEIMER-TYPE DEMENTIA BRAINS. The KITAKANTO Medical Journal, 1993, 43, 473-484.	0.0	0
2215	Dementia and Neurodegenerative Diseases. Oklahoma Notes, 1993, , 64-71.	0.0	0
2217	Olfactory Bulb Involvement in AD: An Early Change. , 1994, , 34-40.		0
2218	Heterogeneity in Alzheimer's Disease: A European View. , 1994, , 115-125.		3

#	Article	IF	Citations
2219	Dementia in Parkinson's Disease and Lewy Body Disease. , 1994, , 719-737.		2
2220	Genetic Evidence for a Novel Familial Alzheimer's Disease Locus on Chromosome 14: Analysis of Candidate Genes. , 1994, , 3-18.		0
2221	Relationship of plaques and tangles to Alzheimer's disease phenotype. , 1995, , 193-223.		3
2223	Neurodegenerative Diseases and Dementia. Oklahoma Notes, 1995, , 78-89.	0.0	1
2224	Complement Components and GFAP Immunoreactivity within Alzheimer and Pathologic Aged Cortex. Advances in Behavioral Biology, 1995, , 217-222.	0.2	0
2225	Physiologische Hirnalterung und Altersdemenzen. , 1995, , 55-61.		Ο
2226	Cellular and animal models of amyloid $\hat{l}^2$ -protein amyloidosis. , 1995, , 183-192.		0
2228	Die organisch bedingten Psychosen. , 1996, , 156-201.		2
2229	Positron Emission Tomography Neuroimaging in Dementia. , 1996, , 185-222.		0
2230	Pathology, Neurobiology, and Animal Models of Alzheimer's Disease. , 1996, , .		1
2231	The Metabolism of Apolipoprotein E and the Alzheimer's Diseases. , 1996, , .		0
2232	Pathological Changes in the Elderly Human Brain. , 1997, , 5-114.		0
2233	Possible Anti-ApoptoticActivity of Carnitines on Excitatory Amino Acid-Induced Neurotoxicity. , 1997, , 247-257.		0
2234	Is Alzheimer's Disease Accelerated Aging? Different Patterns of Age and Alzheimer's Disease-Related Neuronal Losses in the Hippocampus. , 1997, , 141-147.		0
2235	Aging and Mental Retardation. Critical Issues in Neuropsychology, 1997, , 331-347.	0.4	2
2236	Phenserine: A Selective, Long-Acting and Brain-Directed Acetylcholinesterase Inhibitor Affecting Cognition and $\hat{I}^2$ -APP Processing. , 1997, , 231-237.		1
2237	The Neuropsychology of Alzheimer's Disease. Critical Issues in Neuropsychology, 1997, , 141-158.	0.4	12
2238	The relationship of Alzheimer-type pathology to dementia in Parkinson's disease. , 1997, 49, 23-31.		6

#	Article	IF	CITATIONS
2239	Neuropathology of Alzheimer's Disease and the Lewy Body Variant of Alzheimer's Disease: Synapse Density and Pathological Staging: New Pieces of the Puzzle. Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders, 1997, 7, 11-15.	0.3	0
2240	Glial Changes in Aging and Alzheimer's Disease. , 1998, , 385-404.		0
2242	Alzheimer%#x2019;s Disease and Genetically Engineered Animal Models. , 1999, , 187-214.		0
2243	Alzheimer's Disease Dementia, Amyloid Imaging and Underpinning Fibrillar Aβ Plaque Associated Pathology: Are They Aligned?. Journal of Neurology & Stroke, 0, , .	0.1	0
2245	Tracks in the Snow. Indiana University Journal of Undergraduate Research, 2016, 2, 29-33.	0.1	0
2246	Gini Based Learning for the Classification of Alzheimer's Disease and Features Identification with Automatic RGB Segmentation Algorithm. Lecture Notes in Computer Science, 2018, , 92-106.	1.3	1
2248	A Comparative Study of [F-18] Florbetaben (FBB) PET Imaging, Pathology, and Cognition between Normal and Alzheimer Transgenic Mice. Biomedical Science Letters, 2019, 25, 7-14.	0.3	1
2249	Alteration in the Expression of Alzheimer's-Related Genes in Rat Hippocampus by Exercise and Morphine Treatments. The Neuroscience Journal of Shefaye Khatam, 2019, 7, 23-29.	0.4	0
2250	Unraveling the Gordian knot: genetics and the troubled road to effective therapeutics for Alzheimer's disease. Genetics, 2021, , .	2.9	2
2251	Interoperable Multi-Modal Data Analysis Platform for Alzheimer's Disease Management. , 2020, , .		2
2252	Herpes Simplex Virus Type 1 in the Brain, Apolipoprotein E Genotype and Alzheimer's Disease. McGill Journal of Medicine, 1998, 4, .	0.1	1
2253	Visual Analysis of Biomarkers Selected via Multi-Task Learning for Modeling Alzheimer's Disease Progression. , 2020, , .		2
2254	The Limbic System. , 2020, , 745-830.		3
2257	Role of Advanced Glycated End Products (AGEs) in Predicting Diabetic Complications Using Machine Learning Tools: A Review from Biological Perspective. Lecture Notes in Electrical Engineering, 2021, , 1535-1548.	0.4	1
2258	Aβ Imaging in Aging, Alzheimer's Disease, and Other Neurodegenerative Conditions. , 2021, , 283-343.		0
2259	Perfusion SPECT: Its Role in the Diagnosis and Differential Diagnosis of Alzheimer's Disease, with Particular Emphasis on Guidelines. , 2021, , 453-468.		0
2260	Effects of Modeling of Hypercalcemia and β-Amyloid on Cultured Hippocampal Neurons of Rats. Neurophysiology, 2020, 52, 348-357.	0.3	1
2261	Extent, pattern, and correlates of remote memory impairment in Alzheimer's disease and Parkinson's disease Neuropsychology, 2000, 14, 265-276.	1.3	15

#	Article	IF	CITATIONS
2263	Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release. Journal of Psychiatry and Neuroscience, 1993, 18, 226-34.	2.4	39
2264	Clinico-pathological correlation in dementias. Journal of Psychiatry and Neuroscience, 1995, 20, 276-82.	2.4	4
2265	Segregation analysis reveals evidence of a major gene for Alzheimer disease. American Journal of Human Genetics, 1991, 48, 1026-33.	6.2	65
2266	Interleukin-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer's disease. American Journal of Pathology, 1997, 150, 1267-74.	3.8	95
2267	Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. American Journal of Pathology, 1997, 150, 437-43.	3.8	163
2268	Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. American Journal of Pathology, 1997, 150, 1933-9.	3.8	300
2269	Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. American Journal of Pathology, 1997, 150, 119-31.	3.8	195
2270	Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques. American Journal of Pathology, 1996, 148, 259-65.	3.8	89
2271	Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. American Journal of Pathology, 1996, 148, 2083-95.	3.8	261
2272	Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. American Journal of Pathology, 1996, 148, 399-403.	3.8	120
2273	Expression and distribution of amyloid precursor protein-like protein-2 in Alzheimer's disease and in normal brain. American Journal of Pathology, 1996, 149, 1087-95.	3.8	17
2274	Evidence of neuronal oxidative damage in Alzheimer's disease. American Journal of Pathology, 1996, 149, 21-8.	3.8	446
2275	Ultrastructural instability of paired helical filaments from corticobasal degeneration as examined by scanning transmission electron microscopy. American Journal of Pathology, 1996, 149, 639-51.	3.8	36
2276	Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. American Journal of Pathology, 1995, 147, 503-15.	3.8	44
2277	Widespread cytoskeletal pathology characterizes corticobasal degeneration. American Journal of Pathology, 1995, 146, 1388-96.	3.8	215
2278	Aberrant GAP-43 gene expression in Alzheimer's disease. American Journal of Pathology, 1995, 147, 934-46.	3.8	46
2279	Detection of HLA-DR on microglia in the human brain is a function of both clinical and technical factors. American Journal of Pathology, 1990, 136, 1101-14.	3.8	160
2280	Relative abundance of tau and neurofilament epitopes in hippocampal neurofibrillary tangles. American Journal of Pathology, 1990, 136, 1069-75.	3.8	47

#	Article	IF	CITATIONS
2281	Increased tau messenger RNA in Alzheimer's disease hippocampus. American Journal of Pathology, 1990, 137, 497-502.	3.8	37
2282	Immunochemical demonstration of tropomyosin in the neurofibrillary pathology of Alzheimer's disease. American Journal of Pathology, 1990, 137, 291-300.	3.8	37
2283	Neuronal and microglial involvement in beta-amyloid protein deposition in Alzheimer's disease. American Journal of Pathology, 1990, 137, 241-6.	3.8	139
2284	Immunoreactive A4 and gamma-trace peptide colocalization in amyloidotic arteriolar lesions in brains of patients with Alzheimer's disease. American Journal of Pathology, 1990, 137, 233-40.	3.8	86
2285	The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. American Journal of Pathology, 1990, 137, 1435-46.	3.8	105
2286	Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. American Journal of Pathology, 1989, 135, 309-19.	3.8	248
2287	Electron micrograph of diffuse plaques. Initial stage of senile plaque formation in the Alzheimer brain. American Journal of Pathology, 1989, 135, 593-7.	3.8	117
2288	Astrocytes in Alzheimer's disease gray matter express alpha 1-antichymotrypsin mRNA. American Journal of Pathology, 1989, 135, 827-34.	3.8	108
2289	Negative correlations between parenchymal amyloid and vascular amyloid in hippocampus. American Journal of Pathology, 1988, 130, 532-6.	3.8	10
2290	Alpha 1-antichymotrypsin is present in diffuse senile plaques. A comparative study of beta-protein and alpha 1-antichymotrypsin immunostaining in the Alzheimer brain. American Journal of Pathology, 1991, 138, 247-57.	3.8	55
2291	Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. American Journal of Pathology, 1991, 139, 53-65.	3.8	130
2292	Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. American Journal of Pathology, 1992, 140, 621-8.	3.8	279
2293	Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques. American Journal of Pathology, 1991, 138, 373-84.	3.8	74
2294	Tissue factor antigen in senile plaques of Alzheimer's disease. American Journal of Pathology, 1991, 139, 491-4.	3.8	35
2295	Molecular features of hypothalamic plaques in Alzheimer's disease. American Journal of Pathology, 1991, 139, 681-91.	3.8	52
2296	A comparative immunohistochemical study of Kuru and senile plaques with a special reference to glial reactions at various stages of amyloid plaque formation. American Journal of Pathology, 1991, 139, 589-98.	3.8	62
2297	Image analysis microspectroscopy shows that neurons participate in the genesis of a subset of early primitive (diffuse) senile plaques. American Journal of Pathology, 1991, 139, 599-607.	3.8	31
2298	Immunohistochemical colocalization of amyloid precursor protein with cerebrovascular amyloid of Alzheimer's disease. American Journal of Pathology, 1991, 139, 523-33.	3.8	17

#	Article	IF	CITATIONS
2299	Aberrant accumulation of phospholipase C-delta in Alzheimer brains. American Journal of Pathology, 1991, 139, 737-42.	3.8	57
2300	Massive accumulation of modified tau and severe depletion of normal tau characterize the cerebral cortex and white matter of Alzheimer's disease. Demonstration using the hydrated autoclaving method. American Journal of Pathology, 1992, 140, 937-45.	3.8	28
2301	Subcellular localization of amyloid precursor protein in senile plaques of Alzheimer's disease. American Journal of Pathology, 1992, 140, 947-58.	3.8	43
2302	Lack of ubiquitin immunoreactivities at both ends of neuropil threads. Possible bidirectional growth of neuropil threads. American Journal of Pathology, 1992, 140, 277-82.	3.8	36
2303	Beta protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease. American Journal of Pathology, 1992, 140, 283-90.	3.8	54
2304	The N terminal region of human tau is present in Alzheimer's disease protein A68 and is incorporated into paired helical filaments. American Journal of Pathology, 1991, 139, 1463-70.	3.8	23
2305	Alzheimer's amyloid precursor protein-positive degenerative neurites exist even within kuru plaques not specific to Alzheimer's disease. American Journal of Pathology, 1991, 139, 1245-50.	3.8	19
2306	Immune electron microscopic characterization of monoclonal antibodies to Alzheimer neurofibrillary tangles. American Journal of Pathology, 1992, 141, 343-55.	3.8	3
2307	Alzheimer's disease. Beta-amyloid precursor protein expression in the nucleus basalis of Meynert. American Journal of Pathology, 1992, 141, 357-61.	3.8	8
2308	Heterogeneity of tau proteins in Alzheimer's disease. Evidence for increased expression of an isoform and preferential distribution of a phosphorylated isoform in neurites. American Journal of Pathology, 1993, 142, 387-94.	3.8	38
2309	Immunohistochemical and histopathologic correlates of Alzheimer's disease-associated Alz-50 immunoreactivity quantified in homogenates of cerebral tissue. American Journal of Pathology, 1992, 141, 1459-69.	3.8	1
2310	Biochemical and anatomical redistribution of tau protein in Alzheimer's disease. American Journal of Pathology, 1993, 143, 565-78.	3.8	85
2311	Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. American Journal of Pathology, 1994, 144, 104-16.	3.8	74
2312	High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. American Journal of Pathology, 1994, 145, 452-60.	3.8	159
2313	Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration. American Journal of Pathology, 1994, 145, 1496-508.	3.8	145
2314	Alterations of annexin expression in pathological neuronal and glial reactions. Immunohistochemical localization of annexins I, II (p36 and p11 subunits), IV, and VI in the human hippocampus. American Journal of Pathology, 1994, 145, 640-9.	3.8	94
2315	Evidence for major gene inheritance of Alzheimer disease in families of patients with and without apolipoprotein E epsilon 4. American Journal of Human Genetics, 1996, 59, 664-75.	6.2	28
2316	Apolipoprotein E: risk factor for Alzheimer disease. American Journal of Human Genetics, 1994, 54, 643-9.	6.2	193

#	Article	IF	CITATIONS
2317	Estimating the probability for major gene Alzheimer disease. American Journal of Human Genetics, 1994, 54, 374-83.	6.2	9
2318	Multiple etiologies for Alzheimer disease are revealed by segregation analysis. American Journal of Human Genetics, 1994, 55, 991-1000.	6.2	28
2319	Diagnosis of dementia and treatment of Alzheimer's disease. Pharmacologic management of disease progression and cognitive impairment. Canadian Family Physician, 1999, 45, 945-52.	0.4	5
2320	Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease. International Journal of Clinical and Experimental Pathology, 2008, 1, 134-46.	0.5	24
2321	Cortical Alzheimer type pathology does not influence tau pathology in progressive supranuclear palsy. International Journal of Clinical and Experimental Pathology, 2009, 2, 399-406.	0.5	11
2322	Racial differences in the etiology of dementia and frequency of Alzheimer lesions in the brain. Journal of the National Medical Association, 1989, 81, 644-52.	0.8	29
2323	Pathogenesis of Alzheimer's disease. Clinical Interventions in Aging, 2007, 2, 347-59.	2.9	162
2324	Ceruloplasmin (2-D PAGE) Pattern and Copper Content in Serum and Brain of Alzheimer Disease Patients. Biomarker Insights, 2007, 1, 205-13.	2.5	17
2332	Polyadenylated messenger RNA in paired helical filament-immunoreactive neurons in Alzheimer disease. Alzheimer Disease and Associated Disorders, 1990, 4, 69-78.	1.3	6
2334	Computational design of new tacrine analogs: an in silico prediction of their cholinesterase inhibitory, antioxidant, and hepatotoxic activities. Journal of Biomolecular Structure and Dynamics, 2021, , 1-15.	3.5	2
2335	α-Synuclein-mediated neurodegeneration in Dementia with Lewy bodies: the pathobiology of a paradox. Cell and Bioscience, 2021, 11, 196.	4.8	8
2336	A deep learning framework with an embedded-based feature selection approach for the early detection of the Alzheimer's disease. Computers in Biology and Medicine, 2022, 141, 105056.	7.0	49
2337	Speech- and Language-Based Classification of Alzheimer's Disease: A Systematic Review. Bioengineering, 2022, 9, 27.	3.5	22
2338	Multi-view prediction of Alzheimer's disease progression with end-to-end integrated framework. Journal of Biomedical Informatics, 2022, 125, 103978.	4.3	6
2339	Ursolic acid ameliorates amyloid β-induced pathological symptoms in Caenorhabditis elegans by activating the proteasome. NeuroToxicology, 2022, 88, 231-240.	3.0	11
2340	Quantifying regional α â€synuclein, amyloid β, and tau accumulation in lewy body dementia. Annals of Clinical and Translational Neurology, 2022, 9, 106-121.	3.7	21
2341	The Role of ERK1/2 Pathway in the Pathophysiology of Alzheimer's Disease: An Overview and Update on New Developments. Cellular and Molecular Neurobiology, 2023, 43, 177-191.	3.3	22
2342	Advances in Deep Neuropathological Phenotyping of Alzheimer Disease: Past, Present, and Future. Journal of Neuropathology and Experimental Neurology, 2022, 81, 2-15.	1.7	26

#	Article	IF	CITATIONS
2343	Asymmetric Multi-Task Learning with Local Transference. ACM Transactions on Knowledge Discovery From Data, 0, , .	3.5	1
2344	Nutritional factors relevant to Alzheimer's disease. Journal of the American Dietetic Association, 1989, 89, 392-396.	1.1	35
2345	A Review of the Current Mammalian Models of Alzheimer's Disease and Challenges That Need to Be Overcome. International Journal of Molecular Sciences, 2021, 22, 13168.	4.1	31
2346	Iron Dysregulation in Mitochondrial Dysfunction and Alzheimer's Disease. Antioxidants, 2022, 11, 692.	5.1	30
2347	Dementia analysis from functional connectivity network with graph neural networks. Information Processing and Management, 2022, 59, 102901.	8.6	7
2348	Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2022, 61, 116742.	3.0	37
2349	Thammasat-NECTEC-Chula's Thai Language and Cognition Assessment (TLCA): The Thai Alzheimer's and Mild Cognitive Impairment Screening Test. , 2021, 2021, 690-694.		0
2350	Development of Thai Picture Description Task for Alzheimer's Screening using Part-of-Speech Tagging. , 2021, 2021, 2104-2109.		0
2351	A Multi-modal Data Platform for Diagnosis and Prediction of Alzheimer's Disease Using Machine Learning Methods. Mobile Networks and Applications, 2021, 26, 2341-2352.	3.3	6
2352	Modeling Disease Progression Flexibly with Nonlinear Disease Structure via Multi-task Learning. , 2021, , .		4
2355	Dorsolateral Prefrontal Cortex. , 2008, , 999-999.		11
2369	Alzheimer's disease with asymmetric atrophy of the cerebral hemispheres: morphometric analysis of four cases. Acta Neuropathologica, 1994, 88, 440-447.	7.7	0
2370	Alzheimer's disease: Current congressional response American Psychologist, 1985, 40, 1256-1261.	4.2	5
2371	Inhibition of aluminum chloride-induced amyloid AÎ <sup>2</sup> peptide accumulation and brain neurodegeneration by flower decoction Iranian Journal of Basic Medical Sciences, 2021, 24, 1437-1445.	1.0	1
2372	Autobiographical memory in normal ageing and dementia. Behavioural Neurology, 1991, 4, 235-48.	2.1	3
2373	Fusing Multimodal and Anatomical Volumes of Interest Features Using Convolutional Auto-Encoder and Convolutional Neural Networks for Alzheimer's Disease Diagnosis. Frontiers in Aging Neuroscience, 2022, 14, 812870.	3.4	1
2374	The olfactory bulb in Alzheimer's disease. Acta Biologica Hungarica, 1998, 49, 29-42.	0.7	2
2375	Investigation of the Relationship Between Polymorphism in miR-34b/c and Risk of Alzheimer's Disease. Journal of Human Genetics and Genomics, 2022, 4, .	0.0	О

#	Article	IF	CITATIONS
2376	A History of Senile Plaques: From Alzheimer to Amyloid Imaging. Journal of Neuropathology and Experimental Neurology, 2022, 81, 387-413.	1.7	6
2377	Multimodal Data Fusion for Automatic Detection of Alzheimer's Disease. Lecture Notes in Computer Science, 2022, , 79-94.	1.3	1
2378	A comprehensive computational perspective in drug discovery for Alzheimer's disease Combinatorial Chemistry and High Throughput Screening, 2022, 25, .	1.1	0
2379	Gene expression data analysis using Hellinger correlation in weighted gene co-expression networks (WGCNA). Computational and Structural Biotechnology Journal, 2022, 20, 3851-3863.	4.1	21
2380	Sparse Bayesian Multiview Learning for Simultaneous Association Discovery and Diagnosis of Alzheimer's Disease. Proceedings of the AAAI Conference on Artificial Intelligence, 2015, 29, .	4.9	7
2381	Microstate feature fusion for distinguishing AD from MCI. Health Information Science and Systems, 2022, 10, .	5.2	5
2382	Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes. Brain, 2022, 145, 4506-4518.	7.6	15
2383	Individualized diagnosis of preclinical Alzheimer's Disease using deep neural networks. Expert Systems With Applications, 2022, 210, 118511.	7.6	4
2384	A Multi-scale Attention-based Convolutional Network for Identification of Alzheimer's Disease based on Hippocampal Subfields. , 2022, , .		1
2385	Spatio-temporal Tensor Multi-Task Learning for Predicting Alzheimer's Disease in a Longitudinal study. , 2022, , .		1
2386	Pharmacological importance of Bacopa monnieri on Neurological disease (Alzheimer's Disease) and Diabetic neuropathy - A Concise Review. Research Journal of Pharmacy and Technology, 2022, , 3790-3795.	0.8	0
2387	Insomnia and subjective cognitive decline in older adults: avenues for continued investigation and potential intervention. Sleep, 0, , .	1.1	Ο
2388	Dementia and neurodegenerative disorder: An introduction. , 2023, , 1-36.		0
2391	Explainable Tensor Multi-Task Ensemble Learning Based on Brain Structure Variation for Alzheimer's Disease Dynamic Prediction. IEEE Journal of Translational Engineering in Health and Medicine, 2023, 11, 1-12.	3.7	3
2392	The Control Center of Anger. , 2022, , 51-77.		0
2393	Classification of Schizophrenia and Alzheimer's Disease using Resting-State Functional Network Connectivity. , 2022, , .		2
2394	PET molecular imaging for pathophysiological visualization in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 765-783.	6.4	18
2395	Vascular endothelialâ€cadherin as a marker of endothelial injury in preclinical Alzheimer disease. Annals of Clinical and Translational Neurology, 2022, 9, 1926-1940.	3.7	9

#	Article	IF	CITATIONS
2397	Obesity and Alzheimer's: An attempt to decipher the role of obesity in blood–brain barrier degradation. Chaos, Solitons and Fractals, 2023, 166, 112902.	5.1	1
2398	Evaluation of natural xanthones for the development of new drugs to treat Alzheimer's disease by computational chemistry. , 2022, , .		0
2399	Phytochemical Compounds and Nanoparticles as Phytochemical Delivery Systems for Alzheimer's Disease Management. Molecules, 2022, 27, 9043.	3.8	3
2400	Is It Schizophrenia or Not? Different Biological Characterization. , 2023, , 71-81.		0
2401	Transfer Learning for Classification of Alzheimer's Disease Based on Genome Wide Data. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2023, 20, 2700-2711.	3.0	4
2402	Modeling Alzheimer's Disease Progression via Amalgamated Magnitude-Direction Brain Structure Variation Quantification and Tensor Multi-task Learning. , 2022, , .		6
2403	Early Diagnosis of Alzheimer Disease using GA optimized Transfer Learning Techniques. , 2022, , .		0
2404	Noncanonical regulation of imprinted gene lgf2 by amyloid-beta 1–42 in Alzheimer's disease. Scientific Reports, 2023, 13, .	3.3	3
2405	Synthesis of benzylidene-indandione derivatives as quantification of amyloid fibrils. Biophysical Chemistry, 2023, 296, 106982.	2.8	0
2407	Role of hippocampal subfields in neurodegenerative disease progression analyzed with a multi-scale attention-based network. NeuroImage: Clinical, 2023, 38, 103370.	2.7	3
2408	Alzheimer's Disease and Cognitively Impaired Elderly: Providing Dental Care. Journal of the California Dental Association, 1999, 27, 709-715.	0.1	12
2409	Stem cells in the treatment of Alzheimer's disease – Promises and pitfalls. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166712.	3.8	1
2410	Fuzzy-VGG: A fast deep learning method for predicting the staging of Alzheimer's disease based on brain MRI. Information Sciences, 2023, 642, 119129.	6.9	1
2411	Bioactive chemicals in Helianthus tuberosus L may reduce beta-amyloid cytotoxicity as a potential novel treatment for Alzheimer's disease. Studies in Natural Products Chemistry, 2023, , 111-134.	1.8	0
2412	Longitudinal Patterns of Brain Changes in a Community Sample in Relation to Aging and Cognitive Status. Journal of Alzheimer's Disease, 2023, , 1-10.	2.6	0
2413	Early-onset Alzheimer's disease with depression as the first symptom: a case report with literature review. Frontiers in Psychiatry, 0, 14, .	2.6	8
2414	Alzheimer's Disease Management in Developing Countries. , 2023, , 1-15.		0
2415	Gut microbiota and circadian rhythm in Alzheimer's disease pathophysiology: a review and hypothesis on their association _ 2023_9		0

#	Article	IF	CITATIONS
2416	An extensible hierarchical graph convolutional network for early Alzheimer's disease identification. Computer Methods and Programs in Biomedicine, 2023, 238, 107597.	4.7	3
2417	Cognitive Enhancers and Treatments for Alzheimer's Disease. , 2023, , 1-42.		Ο
2418	Capsaicin, The Vanilloid Receptor TRPV1 Agonist in Neuroprotection: Mechanisms Involved and Significance. Neurochemical Research, 2023, 48, 3296-3315.	3.3	9
2419	Fibroblast growth factor 10 ameliorates neurodegeneration in mouse and cellular models of Alzheimer's disease via reducing tau hyperphosphorylation and neuronal apoptosis. Aging Cell, 2023, 22, .	6.7	0
2420	Rhombomere 1 r1. , 2023, , 391-436.		0
2421	Alzheimer's Disease Diagnosis Using Machine Learning: A Survey. Applied Sciences (Switzerland), 2023, 13, 8298.	2.5	2
2422	Implication of the cooking oil-peroxidation product "hydroxynonenal―for Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 15, .	3.4	3
2423	Neuropathological substrate of incident dementia in older patients with schizophrenia: A clinicopathological study. Psychiatry and Clinical Neurosciences, 2024, 78, 29-40.	1.8	1
2424	Early Detection of Alzheimerâ $\in$ ™s Disease using CNN with PSO for parameter optimization. , 2023, , .		0
2426	Therapeutic Frontiers in Alzheimer's Disease. Pharmacotherapy, 1992, 12, 217-231.	2.6	1
2427	Postmortem Brain Imaging in Alzheimer's Disease and Related Dementias: The South Texas Alzheimer's Disease Research Center Repository. Journal of Alzheimer's Disease, 2023, 96, 1267-1283.	2.6	0
2428	High-throughput digital quantification of Alzheimer disease pathology and associated infrastructure in large autopsy studies. Journal of Neuropathology and Experimental Neurology, 2023, 82, 976-986.	1.7	2
2429	Prospects of Developing Interventions to Prevent Alzheimer's Disease. Pharmacotherapy, 1998, 18, 74-78.	2.6	1
2430	Introduction to Alzheimer's Disease. , 2023, , 1-26.		0
2431	Early Detection of Alzheimer's Disease using Feed Forward Neural Network. , 2023, , .		0
2432	Diagnosis of Alzheimer Disease Progression Stage from Cross Sectional Cognitive Data by Deep Neural Network. Lecture Notes in Computer Science, 2024, , 273-284.	1.3	0
2433	Simultaneously Measured Kinetics of Two Amyloid Polymorphs Using Cross Peak Specific 2D IR Spectroscopy. Journal of Physical Chemistry Letters, 0, , 11750-11757.	4.6	0
2434	Conjugated Polyelectrolytes: Illuminating the Path to Neurodegenerative Disorders Detection and Treatment. ACS Applied Materials & Interfaces, 0, , .	8.0	0

#	Article	IF	CITATIONS
2435	Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History. Journal of Clinical Medicine, 2024, 13, 536.	2.4	0
2436	Roles of nano medicine in diagnosis of Alzheimer's disease. , 2024, , 115-138.		0
2437	Randomized Multi-task Feature Learning Approach forÂModelling andÂPredicting Alzheimer's Disease Progression. Communications in Computer and Information Science, 2024, , 52-68.	0.5	0
2438	IoT Assistant-Based Secured System for Alzheimer's Disease. International Journal of Advanced Research in Science, Communication and Technology, 0, , 341-346.	0.0	Ο